

CITATION REPORT

List of articles citing

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

DOI: 10.1093/eurheartj/ehs253

European Heart Journal, 2012, 33, 2719-47.

Source: <https://exaly.com/paper-pdf/53979263/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2268	Cys-tRNACys formation and cysteine biosynthesis in methanogenic archaea: two faces of the same problem?. 2004 , 61, 2437-45		9
2267	Biological functions of the ING family tumor suppressors. 2004 , 61, 2597-613		97
2266	Biochemistry and biology of mammalian DNA methyltransferases. 2004 , 61, 2571-87		414
2265	Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease. 2005 , 62, 281-92		34
2264	Compensatory caspase activation in MPP+-induced cell death in dopaminergic neurons. 2005 , 62, 227-38		23
2263	Association, mutual stabilization, and transcriptional activity of the STRA13 and MSP58 proteins. 2005 , 62, 471-84		32
2262	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. 2012 , 10, 1471-80		37
2261	Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. 2012 , 2,		40
2260	[Cardiac computed tomography and ablation of atrial fibrillation]. 2012 , 23, 281-8		3
2259	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the E. 2012 , 9, 632-696.e21		1314
2258	Catheter ablation for atrial fibrillation - Single center experience. 2012 , 54, e369-e374		3
2257	Summary of the 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Prepared by the Czech Society of Cardiology. 2012 , 54, e341-e351		4
2256	Catheter ablation for atrial fibrillation - Update focused on the Czech Republic. 2012 , 54, e352-e360		
2255	Editorial special issue Atrial fibrillation. 2012 , 54, e339-e340		
2254	Robot-assisted navigation in atrial fibrillation ablation - of any benefits?. 2012 , 54, e408-e413		5
2253	Impact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedarone. 2012 , 3, 95-103		
2252	New and old anti-thrombotic treatments for patients with atrial fibrillation. 2013 , 35, 297-302		8

2251	Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. 2013 , 168, 1832-6		31
2250	[Surgical closure of the left atrial appendage in patients with atrial fibrillation. Indications, techniques and results]. 2013 , 24, 53-7		5
2249	Epidemiology of atrial fibrillation in Spain in the past 20 years. 2013 , 66, 561-5		2
2248	Conduction recovery in patients with recurrent atrial fibrillation after pulmonary vein isolation using multi-electrode duty cycled radiofrequency ablation. 2013 , 37, 197-204		7
2247	An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. 2013 , 13, 31		13
2246	Oral anticoagulation during atrial fibrillation ablation: Facts and controversies. 2013 , 55, e101-e106		2
2245	Appropriate and inappropriate use of dronedarone in 2013. 2013 , 15, 467-75		3
2244	Novel oral anticoagulants for atrial fibrillation. 2013 , 15, 344		13
2243	Katheterablation des Vorhofflimmerns. 2013 , 7, 115-121		0
2242	Perkutaner Vorhoffohrverschluss. 2013 , 7, 122-129		
2241	The dronedarone shared-care clinical model and database: a coordinated paradigm to optimize management of evolving clinical recommendations. 2013 , 30, 623-9		
2240	Prediction of symptomatic embolism in infective endocarditis: construction and validation of a risk calculator in a multicenter cohort. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1384-92	15.1	89
2239	Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2255-6	15.1	44
2238	Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemia. 2013 , 102, 875-84		14
2237	[Diagnosis of atrial fibrillation. From the standard ECG to analysis of electrograms]. 2013 , 24, 97-102		
2236	[Catheter ablation of paroxysmal atrial fibrillation. Optimal approach and result]. 2013 , 24, 7-14		1
2235	Implantation of the AMPLATZER® Cardiac Plug: tips and tricks. 2013 , 24, 33-8		3
2234	Stroke Prevention in Atrial Fibrillation. 2013 , 1, 98-104		

2233	[Heart or brain? Problem patients at the interface between cardiology and neurology]. 2013 , 38, 395-401; quiz 402-3	
2232	Catheter ablation of atrial fibrillation to reduce stroke risk. 2013 , 38, 247-50	2
2231	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. 2013 , 67, 516-26	16
2230	Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). 2013 , 111, 1159-64	91
2229	Features and costs of patients admitted for cardiac arrhythmias in Spain. 2013 , 213, 235-239	
2228	Heart failure, atrial fibrillation, and catheter ablation: are we there yet?. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1904-5	15.1 3
2227	Phrenic nerve paralysis during cryoballoon ablation for atrial fibrillation: a comparison between the first- and second-generation balloon. 2013 , 10, 1318-24	102
2226	Predictors of regional variations in hospitalizations following emergency department visits for atrial fibrillation. 2013 , 112, 1410-6	24
2225	Preclinical evaluation of a new left atrial appendage occluder (Lifetech LAMBERT device) in a canine model. 2013 , 168, 3996-4001	35
2224	Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. 2013 , 168, 904-9	54
2223	Actualité sur la prévention secondaire après un AIT ou un infarctus cérébral. 2013 , 4, 97-101	
2222	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). 2013 , 30, 4-91	7
2221	Atrial fibrillation: food for thought in 2013. 2013 , 126, 937-8	4
2220	Almanac 2013: novel non-coronary cardiac interventions. 2013 , 99, 1309-16	2
2219	Mechanical antithrombotic intervention by LAA occlusion in atrial fibrillation. 2013 , 10, 707-22	29
2218	The new oral anticoagulants in atrial fibrillation: once daily or twice daily?. 2013 , 59, 53-62	20
2217	Flecainide acetate for the treatment of atrial and ventricular arrhythmias. 2013 , 14, 347-57	17
2216	Novel percutaneous left atrial appendage closure. 2013 , 14, 164-7	13

2215	Balancing thromboembolic risk against vitamin K antagonist-related bleeding and accelerated calcification: is fondaparinux the Holy Grail for end-stage renal disease patients with atrial fibrillation?. 2013 , 28, 2923-8		4
2214	Nonpharmacologic approaches to stroke prevention in atrial fibrillation. 2013 , 29, S79-86		8
2213	Periprocedural management of oral anticoagulation in patients with atrial fibrillation: approach in the era of new oral anticoagulants. 2013 , 29, S54-9		11
2212	Fibrillation atriale et infarctus du myocarde : un risque accru de mortalité. 2013 , 5, 114-118		
2211	La fibrillation atriale chez la personne âgée : actualités de la prise en charge thérapeutique selon les dernières recommandations (2012) de la Société européenne de cardiologie : focus sur le traitement anticoagulant. 2013 , 5, 245-256		1
2210	Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. 2013 , 168, 4228-33		88
2209	Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. <i>European Heart Journal</i> , 2013, 34, 1471-4	9.5	51
2208	The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2199-204	15.1	144
2207	Polycystic ovary syndrome is associated with P-wave prolongation and increased P-wave dispersion. 2013 , 29, 830-3		3
2206	Iron therapy in patients with heart failure. A straight shot. 2013 , 168, 5071-2		1
2205	Neue orale Antikoagulanzen. 2013 , 18, 665-674		2
2204	Atrial fibrillation: to map or not to map?. 2014 , 22, 259-66		21
2203	La fibrillation atriale chez la personne âgée: déterminants de la prescription d'anticoagulants. Étude originale réalisée chez 170 résidents de l'HPAD. 2013 , 5, 268-273		
2202	New oral anticoagulants in non-valvular atrial fibrillation. 2013 , 20, 53-60		3
2201	[Atrial fibrillation: current recommendations for diagnosis and treatment]. 2013 , 54, 583-95		1
2200	[Current treatment of tachycardia]. 2013 , 54, 1459-67		1
2199	Almanac 2013: novel non-coronary cardiac interventions. 2013 , 125, 766-75		
2198	Patient perspective on the management of atrial fibrillation in five European countries. 2013 , 13, 108		14

2197	[Joy and sorrow with guidelines 2013]. 2013 , 38, 809-11	0
2196	Management of dabigatran-induced bleeding: expert statement. 2013 , 125, 721-9	11
2195	Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG). 2013 , 30, 1019-28	12
2194	Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. 2013 , 31, 909-18	33
2193	Personalizing oral anticoagulant treatment in patients with atrial fibrillation. 2013 , 11, 959-73	10
2192	Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease. 2013 , 11, 817-28	
2191	The Metabolic Syndrome. 2013 ,	6
2190	Management of cardiovascular disease in haemophilia. 2013 , 132, 8-14	18
2189	Antiarrhythmic drugs in atrial fibrillation: do they have a future?. 2013 , 29, 1158-64	2
2188	Which oral anticoagulant for which atrial fibrillation patient: recent clinical trials and evidence-based choices. 2013 , 29, 1165-72	13
2187	Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management. 2013 , 17, 239	5
2186	Analisi di impatto sul budget di WatchmanTM, dispositivo per la prevenzione tromboembolica nei pazienti con fibrillazione atriale. 2013 , 15, 45-63	2
2185	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: ready for the prime time?. 2013 , 11, 1587-9	4
2184	Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. 2013 , 3, e003343	54
2183	The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis. 2013 , 19, 619-31	34
2182	Atrial fibrillation through the years: contemporary evaluation and management. 2013 , 127, 408-16	10
2181	Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. 2013 , 27, 23-35	24
2180	Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. 2013 , 127, 930-7	171

2179	Aspectos epidemiológicos y diagnósticos de la fibrilación auricular. 2013 , 39, 3-9		0
2178	New Oral Anticoagulants. 2013 , 2, e456-e471		
2177	Stroke prevention in atrial fibrillation in heart failure. 2013 , 9, 427-35, viii		2
2176	[Stroke prevention in patients with nonvalvular atrial fibrillation.What's new?]. 2013 , 45 Suppl 1, 1-4		2
2175	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. 2013 , 166, 442-8		102
2174	Transcatheter aortic valve implantation in nonagenarians: effective and safe. 2013 , 24, 750-5		29
2173	Les nouveaux anticoagulants oraux dans le traitement de la fibrillation atriale. 2013 , 2013, 9-12		
2172	Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2079-87	15.1	83
2171	Tratamiento antiarrítmico farmacológico en fase crítica de la fibrilación auricular. 2013 , 13, 21-26		
2170	First-in-man randomized clinical trial of renal denervation for atrial arrhythmia raises concern. <i>Journal of the American College of Cardiology</i> , 2013 , 62, e445-e446	15.1	10
2169	Impact of atrial fibrillation on outcomes in heart failure. 2013 , 9, 437-49, viii		0
2168	Indicaciones actuales del cierre percutáneo de la orejuela auricular izquierda en la fibrilación auricular no valvular. 2013 , 48, 91-92		1
2167	Anticoagulation for emergency department patients with atrial fibrillation: is our duty to inform or prescribe?. 2013 , 62, 566-8		15
2166	Percutaneous left atrial appendage occlusion. 2013 , 66, 919-22		
2165	Defining the role of left atrial appendage closure in atrial fibrillation. 2013 , 66, 79-82		1
2164	"Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan. 2013 , 62, 366-73		12
2163	[Interventional prevention of ischemic stroke]. 2013 , 62, 411-8		
2162	Treatment failure of low molecular weight heparin in diabetic patient. 2013 , 168, e63-4		24

2161	Atrial fibrillation in heart failure in the older population. 2013 , 9, 451-9, viii-ix		3
2160	Indicaciones de rivaroxab� en diferentes situaciones cl�nicas. 2013 , 39, 24-29		0
2159	Fine tuning risk stratification for atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2285-7	15.1	5
2158	Effect of percutaneous closure of patent foramen ovale on post-procedural arrhythmias. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2449-2450	15.1	11
2157	Very long-term results of surgical and transcatheter ablation of long-standing persistent atrial fibrillation. 2013 , 96, 1273-1278		20
2156	Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. 2013 , 170, 208-14		60
2155	Fibrillation atriale non valvulaire : traitement antithrombotique conventionnel (antivitamines K et antiagr�gants plaquettaires). 2013 , 5, 132-140		
2154	Receptor for advanced glycation end products (RAGE) in atrial fibrillation. 2013 , 168, 5072-3		4
2153	Actualizaci� en insuficiencia cardiaca, trasplante cardiaco, cardiopat�s cong�nitas y cardiolog� cl�nica. 2013 , 66, 290-297		3
2152	Tiempo en rango terap�utico de los pacientes que siguen tratamiento con derivados cumar�nicos en la pr�ctica cl�nica diaria. 2013 , 48, 158-161		
2151	Treatment failure of low molecular weight heparin in post-surgery orthopedic case. 2013 , 169, e36-7		2
2150	Treatment failure of low molecular weight heparin bridging therapy. 2013 , 167, e106-7		8
2149	Fibrilaci� auricular. 2013 , 17, 1-7		
2148	Mise � jour des recommandations europ�ennes et comparaison avec les recommandations nord-am�ricaines. 2013 , 5, 161-167		
2147	Epidemiolog� de la fibrilaci� auricular en Espa� en los �timos 20 a�s. 2013 , 66, 561-565		27
2146	Effects of dronedarone and amiodarone on atrial fibrillatory rate in patients with persistent atrial fibrillation. 2013 , 167, 2354-6		5
2145	What is the future for left atrial appendage closure?. 2013 , 32, 473-5		1
2144	Cierre percut�neo de la orejuela izquierda. 2013 , 66, 919-922		6

2143	Cost analysis of radiofrequency catheter ablation for atrial fibrillation. 2013 , 167, 2462-7	7
2142	Features and costs of patients admitted for cardiac arrhythmias in Spain. 2013 , 213, 235-9	9
2141	Questions pratiques dans le traitement de la fibrillation atriale. 2013 , 5, 148-160	
2140	Guà de pràctica clínic de la ESH/ESC para el manejo de la hipertensió arterial (2013). 2013 , 66, 880.e1-880.e64	13
2139	Editorial. 2013 , 5, 111-113	
2138	Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. 2013 , 10, 1792-9	55
2137	What is the future for left atrial appendage closure?. 2013 , 32, 473-475	1
2136	¿Què dicen las guàs sobre la anticoagulació en la fibrilació auricular no valvular?. 2013 , 39, 17-23	1
2135	Definició del paper de la oclusió de la orejuela auricular izquierda en la fibrilació auricular. 2013 , 66, 79-82	5
2134	The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. 2013 , 29, 190-200	60
2133	Complications thromboemboliques de la fibrillation atriale. 2013 , 5, 125-131	
2132	Stroke prophylaxis in high-risk patients with atrial fibrillation: rhythm vs. rate control strategy. 2013 , 24, 314-7	1
2131	Stress echocardiography for risk assessment in octogenarians. 2013 , 167, 2356-8	5
2130	[Improvements in oral anticoagulant therapy for atrial fibrillation]. 2013 , 141, 487-93	2
2129	The prognostic role of the adiponectin levels in atrial fibrillation. 2013 , 43, 168-73	16
2128	Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. 2013 , 11, 129-41	29
2127	The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. 2013 , 109, 431-9	26
2126	A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant. 2013 , 31, e55-62	9

2125	Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2551-6	15.1	482
2124	Improving the use of direct oral anticoagulants in atrial fibrillation. 2013 , 24, 288-94		11
2123	Atrial fibrillation: Anticoagulation for AF: can we GRASP-AF patients?. 2013 , 10, 241-2		1
2122	Antithrombotic therapy and bleeding risk in atrial fibrillation. Fewer unanswered questions. 2013 , 109, 363-5		0
2121	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. 2013 , 69, 1617-33		71
2120	The Indication for Antithrombotic Primary Prophylaxis and Treatment in Case of Thromboembolic Complications in Patients with Metabolic Syndrome. 2013 , 155-164		
2119	Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. 2013 , 67, 647-55		3
2118	Atrial fibrillation in the elderly. 2013 , 30, 593-601		23
2117	Update on heart failure, heart transplant, congenital heart disease, and clinical cardiology. 2013 , 66, 290-7		2
2116	Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease. 2013 , 29, S60-70		9
2115	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. 2013 , 22, 193-278		286
2114	Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. 2013 , 29, S4-S13		23
2113	Stroke prevention in patients with atrial fibrillation - anticoagulation strategy 2012. 2013 , 55, e95-e100		
2112	Practice implications of the Atrial Fibrillation Guidelines. 2013 , 111, 1660-70		10
2111	Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. 2013 , 106, 303-23		40
2110	Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. 2013 , 102, 399-412		155
2109	Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 2013 , 73, 825-43		14
2108	Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. 2013 , 73, 715-39		13

2107	Management of unruptured intracranial aneurysms. 2013 , 3, 99-108		51
2106	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219	9.5	3400
2105	Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. <i>Stroke</i> , 2013 , 44, 3357-64	6.7	152
2104	Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 â) channels. 2013 , 721, 237-48		24
2103	Kommentar zu den neuen Leitlinien (2012) der Europ�ischen Gesellschaft f�r.Kardiologie zur kardiovaskul�ren Pr�vention. 2013 , 7, 251-260		2
2102	Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?. 2013 , 126, 233-43		7
2101	Gender differences in patients with atrial fibrillation. 2013 , 24, 176-83		9
2100	Deep sedation during catheter ablation for atrial fibrillation in elderly patients. 2013 , 38, 115-21		16
2099	Integrated approach to treatment-resistant atrial fibrillation: additional value of acupuncture. 2013 , 31, 327-30		4
2098	Current management of atrial fibrillation: an observational study in NHS primary care. 2013 , 3, e003004		4
2097	Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. <i>Stroke</i> , 2013 , 44, 1329-36	6.7	77
2096	Estimation of left atrial blood stasis using diastolic late mitral annular velocity. 2013 , 14, 752-7		8
2095	The unbearable futility of deriving the left atrial size from a single-linear dimension. 2013 , 14, 711-3		1
2094	The Year in Cardiology 2012: arrhythmia and pacing. <i>European Heart Journal</i> , 2013 , 34, 333-7	9.5	
2093	CardioPulse Articles: peripartum cardiomyopathy registry: a new ESC initiative. <i>European Heart Journal</i> , 2013 , 34, 549-55a	9.5	1
2092	A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. <i>European Heart Journal</i> , 2013 , 34, 2725-30	9.5	58
2091	Atrial fibrillation and the 'other drug problem': reducing non-adherence with technology. <i>European Heart Journal</i> , 2013 , 34, 2031-3	9.5	7
2090	Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation. 2013 , 41, 49-60		

2089	Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. 2013 , 3,		130
2088	ESC core curriculum for the general cardiologist (2013). <i>European Heart Journal</i> , 2013 , 34, 2381-411	9.5	56
2087	Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers. 2013 , 16, 1190-2		
2086	Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. <i>European Heart Journal</i> , 2013 , 34, 3572-9	9.5	66
2085	Diabetes mellitus und Herz. 2013 , 8, S128-S132		
2084	Catheter ablation versus rate control for atrial fibrillation: what have we learnt from the ARC-HF trial?. 2013 , 9, 599-602		1
2083	Antiplatelet therapy strategies after percutaneous coronary intervention in patients needing oral anticoagulation. 2013 , 9, 759-62		
2082	Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. 2013 , 41, 37-48		1
2081	Atrial fibrillation. 2013 , 2013, 142673		
2080	Paroxysmal atrial fibrillation after ischemic stroke: how should we hunt for it?. 2013 , 11, 485-94		8
2079	Stroke prevention in older adults with atrial fibrillation. 2013 , 185, 1479-80		4
2078	New orally active anticoagulants in critical care and anesthesia practice: the good, the bad and the ugly. 2013 , 16, 193-200		9
2077	Factors that influence awareness and treatment of atrial fibrillation in older adults. 2013 , 106, 415-24		35
2076	A new piece of puzzle: inflammation in the prediction of recurrence after successful electrical cardioversion in patients with nonvalvular atrial fibrillation. 2013 , 13, 403-4		1
2075	Vorhofflimmern. 2013 , 102, 1199-1202		
2074	Anticoagulation therapy for atrial fibrillation. 2013 , 39, 147-52		11
2073	Practical management of patients on apixaban: a consensus guide. 2013 , 11, 27		24
2072	Importance of multislice computed tomography angiography for the diagnosis and evaluation of silent coronary ischemia and asymptomatic acute myocardial infarction: long-term follow-up of three cases. 2013 , 13, 405-7		

2071 News and views. **2013**, 19, 3-5

2070 European Perspectives. **2013**, 127,

2069 The real decoy: an antidote for factor Xa-directed anticoagulants. **2013**, 113, 954-7

17

2068 Letter by Marf et al regarding article, "Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study". **2013**, 127, e584

2067 Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. **2013**, 6, 740-7

82

2066 Geographic variations in the quality of oral anticoagulation with vitamin k antagonists in the era of new anticoagulants. **2013**, 2, e000088

4

2065 Recent advances in management of atrial fibrillation in patients with heart failure. **2013**, 28, 197-208

5

2064 The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. **2013**, 31, 2109-17; discussion 2117

14

2063 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). **2013**, 31, 1281-357

3363

2062 Guideline for the surgical treatment of atrial fibrillation. **2013**, 44, 777-91

42

2061 Response to letter regarding article, "Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study". **2013**, 127, e585

1

2060 Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2013**, 34, 2636-48, 2648a-2648d

9.5 1552

2059 The epidemiology of atrial fibrillation in end-stage renal disease. **2013**, 26, 617-23

6

2058 Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. **2013**, 125, 34-44

10

2057 Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants. **2013**, 125, 155-61

0

2056 Managing atrial fibrillation in the global community: The European perspective. **2013**, 2013, 173-84

6

2055 ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation. **2013**, 2013, 354-6

4

2054 Predicting the future in patients with atrial fibrillation: who develops heart failure?. **2013**, 15, 366-7

2

2053	Updated national multicenter registry on procedural safety of catheter ablation for atrial fibrillation. 2013 , 24, 1069-74	27
2052	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. 2013 , 15, 1053-61	65
2051	Warfarin for stroke prevention in atrial fibrillation: time to switch?. 2013 , 67, 603-5	3
2050	New oral anticoagulants in heart failure. 2013 , 15, 966-73	6
2049	Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillation. 2013 , 11, 1069-77	9
2048	The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. 2013 , 11, 975-87	34
2047	Atrial fibrillation and stroke - reading list. 2013 , 1, 26-26	
2046	Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting. 2013 , 36, 585-94	16
2045	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. 2013 , 11, 1619-29	12
2044	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. 2013 , 11, 77-90	7
2043	Apixaban: new anticoagulant for stroke prevention. 2013 , 24, 32-35	3
2042	Atrial fibrillation: inflammation in disguise?. 2013 , 78, 112-9	14
2041	Care with clonidine in atrial fibrillation. 2013 , 68, 545-6	
2040	EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. <i>European Heart Journal</i> , 2013 , 34, 2094-106	9.5 281
2039	Alcohol intake and prognosis of atrial fibrillation. 2013 , 99, 1093-9	45
2038	Renal insufficiency should be included in stroke risk scores. 2013 , 83, 1204-5	6
2037	Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range. 2013 , 127, 2163-5	9
2036	[Novel oral anticoagulants and atrial fibrillation in the elderly]. 2013 , 11, 34-40	1

2035	Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. 2013 , 77, 2264-70	93
2034	Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on the elderly. 2013 , 77, 1380-8	31
2033	The management of arrhythmias after AF ablation. 2013 , 8, 338-344	
2032	Visual impairment. 2013 , 346, f2163	
2031	Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. 2013 , 110, 1189-98	139
2030	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. 2013 , 110, 1087-107	278
2029	Transcatheter left atrial appendage closure for stroke prevention in atrial fibrillation with Amplatzer cardiac plug: the Belgian Registry. 2013 , 68, 551-8	42
2028	Organizing patient-centred anticoagulant therapy. 2013 , 68, 413-5	1
2027	Evaluation of the cost of atrial fibrillation during emergency hospitalization. 2013 , 68, 469-74	2
2026	Catheter ablation for atrial fibrillation in the elderly. 2013 , 10, 493-502	
2025	Antikoagulation bei chronisch Herzkranken. 2013 , 10, 53-62	
2024	Fibrillation atriale. 2013 , 8, 1-7	
2023	Medikamentöse Therapie supraventrikulärer und ventrikulärer Arrhythmien. 2013 , 2, 379-388	
2022	WITHDRAWN: Dabigatran in clinical trials and clinical praxis. 2013 ,	
2021	Response to letter regarding article, "Atrial fibrillation and the risk of ischemic stroke--does it still matter in patients with a CHA2DS2-VASc score of 0 or 1?". <i>Stroke</i> , 2013 , 44, e39	6.7 1
2020	New atrial fibrillation guidelines: implementation in the clinic. 2013 , 10, 31-38	
2019	Current world literature. 2013 , 28, 259-68	
2018	[Expert consensus of the French society of geriatrics and gerontology and the French society of cardiology on the management of atrial fibrillation in elderly people]. 2013 , 11, 117-43	2

2017	Dabigatran monitoring made simple?. 2013 , 110, 393-5		9
2016	The perioperative management of new direct oral anticoagulants: a question without answers. 2013 , 110, 515-22		59
2015	Device-related thrombus overlying a left-atrial occlusion device implanted for persistent spontaneous echo contrast despite prolonged oral anticoagulation therapy. 2013 , 125, 78-81		2
2014	Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression. 2014 , 10, 1-12		19
2013	Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. <i>PLoS ONE</i> , 2013 , 8, e63479	3.7	297
2012	Patient preferences at ten years following initial diagnosis of atrial fibrillation: the Belgrade Atrial Fibrillation Study. 2013 , 7, 835-42		3
2011	Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation". 2013 , 110, 496-500		8
2010	Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation. 2013 , 43, 151-8		3
2009	New oral anticoagulants - will they be used with antiplatelet drugs in patients with atrial fibrillation after acute coronary syndrome?. 2013 , 9, 348-52		1
2008	[Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part II: Hemorrhagic risk and guidelines recommendations]. 2013 , 80, 111-7		
2007	Is there really misuse and abuse of dabigatran?. 2013 , 198, 358-9		3
2006	Warfarin in non-valvular atrial fibrillation. 2013 , 103, 901-4		3
2005	[Critical issues in megatrials on new oral anticoagulants. Rocket AF: applying results to low risk patients]. 2013 , 80, 3-6		1
2004	Simultaneously Presented Acute Ischemic Stroke and Non-ST Elevation Myocardial Infarction in a Patient with Paroxysmal Atrial Fibrillation. 2013 , 43, 766-9		11
2003	New oral anticoagulants. 2013 , 56, 57		1
2002	PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION. 2013 , 9, 551-556		
2001	Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy. 2013 , 110, 623-5		11
2000	Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. <i>PLoS ONE</i> , 2013 , 8, e71675	3.7	20

1999	Frequent periodic leg movement during sleep is an unrecognized risk factor for progression of atrial fibrillation. <i>PLoS ONE</i> , 2013 , 8, e78359	3.7	21
1998	Anticoagulation for Atrial Fibrillation: Is This the End of Warfarin? Not Just Yet. 2013 , 2013, 1-7		4
1997	The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors. 2013 , 110, 525-32		37
1996	The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. 2013 , 9, 341-52		13
1995	COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE. 2013 , 9, 398-403		
1994	New oral anticoagulants in the prevention of stroke. 2013 , 3, 264-266		
1993	Direct oral anticoagulants in real practice: which doses for which patients. Limitations and bleeding risk compared to vitamin K antagonists. 2013 , 7, 41		
1992	Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation. 2013 , 7, 8		2
1991	Dabigatran etexilate in non-valvular atrial fibrillation. 2013 , 11, 130-138		
1990	Pharmacological treatments for stroke prevention in AF. 2013 , 8, 580-587		1
1989	COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS. 2013 , 9, 433-438		4
1988	Clinical trials update: recent and ongoing studies in anticoagulation for atrial fibrillation. 2013 , 101		
1987	Early screening is important for managing atrial fibrillation. 2013 , 8, 164-165		
1986	[Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by new oral anticoagulants, to be cautiously used]. 2013 , 80, 151-60		
1985	The nurse prescriber's role in management of post-operative atrial fibrillation. 2014 , 9, 273-279		
1984	Blood stasis secondary to heart failure forms warfarin-resistant left atrial thrombus. 2014 , 55, 506-11		15
1983	[Efficacy and safety of apixaban compared with warfarin regarding time within the therapeutic range]. 2014 , 155, 177-81		
1982	Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. 2014 , 10, 197-205		6

1981	Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. 2014 , 10, 101-14		16
1980	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. 2014 , 10, 425-34		23
1979	Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2014 , 9, e95354	3.7	6
1978	Likelihood and predictors of ST-elevation in patients hospitalized for myocardial infarction. <i>PLoS ONE</i> , 2014 , 9, e108440	3.7	5
1977	Defining disease phenotypes using national linked electronic health records: a case study of atrial fibrillation. <i>PLoS ONE</i> , 2014 , 9, e110900	3.7	53
1976	Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice. 2014 , 111, 607-14		15
1975	Left atrium by echocardiography in clinical practice: from conventional methods to new echocardiographic techniques. 2014 , 2014, 451042		41
1974	Burden of disease from atrial fibrillation in adults from seven countries in Latin America. 2014 , 7, 441-8		19
1973	Calcium dysregulation in atrial fibrillation: the role of CaMKII. 2014 , 5, 30		35
1972	Predicting adverse drug reactions in older adults; a systematic review of the risk prediction models. 2014 , 9, 1581-93		39
1971	A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation—full speed ahead or proceed with caution?. 2014 , 10, 507-22		14
1970	Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation?. 2014 , 111, 14-8		44
1969	Serum potassium levels inversely correlate with D-dimer in patients with acute-onset atrial fibrillation. 2015 , 104, 181-4		2
1968	Who will benefit from anticoagulant therapy? Use of the CHADS2 score and its variants. 2014 , 83		
1967	Novel oral anticoagulants in non-valvular atrial fibrillation. 2014 , 12, 3-8		17
1966	Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation. 2014 , 14, 79-86		1
1965	Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation. 2014 , 9, 1335-42		7
1964	Contact force mapping during catheter ablation for atrial fibrillation: procedural data and one-year follow-up. 2014 , 10, 266-72		27

1963	A survey on the treatment of atrial fibrillation in South Africa. 2014 , 104, 623-7	8
1962	Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study. 2014 , 112, 789-95	10
1961	COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION. 2014 , 10, 275-282	2
1960	THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER. 2014 , 10, 625-630	6
1959	Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. 2014 , 111, 833-41	77
1958	'Lone' atrial fibrillation: no longer lone or even alone. 2015 , 21, 531-2	2
1957	MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION. 2014 , 10, 432-437	
1956	NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY. 2014 , 10, 444-447	
1955	Diving to the foot of an iceberg: the SEARCH for undiagnosed atrial fibrillation. 2014 , 112, 1-3	93
1954	Eight challenges faced by general practitioners caring for patients after an acute coronary syndrome. 2014 , 201, S110-4	1
1953	Incidence and anatomical locations of catheter instability during circumferential pulmonary vein isolation using contact force. 2014 , 55, 249-55	13
1952	Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with non-valvular paroxysmal atrial fibrillation not receiving anticoagulant therapy. 2014 , 55, 119-25	18
1951	Patient care on the agenda at BANCC study day. 2014 , 9, 204-205	
1950	Huge right atrial thrombus after discontinuation of anticoagulant therapy in atrial fibrillation. 2014 , 2014,	
1949	Massive haemoptysis following dabigatran administration in a patient with bronchiectasis. 2014 , 2014,	1
1948	Practical Management of Stroke Prevention in Patients with Atrial Fibrillation and Renal Impairment Receiving Newer Oral Anticoagulants: Focus on Rivaroxaban. 2014 , 02,	
1947	Other Interventional Techniques. 2014 ,	
1946	Multielectrode Pulmonary Vein Ablation Catheter (PVAC(□)): current data on results and risks. 2014 , 25, 236-40	2

1945	Acute hospital, community, and indirect costs of stroke associated with atrial fibrillation: population-based study. <i>Stroke</i> , 2014 , 45, 3670-4	6.7	27
1944	Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. 2014 , 107, 955-67		97
1943	Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway pressure therapy: follow-up of 4.5 million Danish adults. 2014 , 276, 659-66		32
1942	Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). <i>European Heart Journal</i> , 2014 , 35, 508-16	9.5	278
1941	Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. <i>European Heart Journal</i> , 2014 , 35, 1897-906	9.5	64
1940	Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. <i>Stroke</i> , 2014 , 45, 2983-8	6.7	24
1939	Is there association between changes in eGFR value and the risk of permanent type of atrial fibrillation? Analysis of valvular and non-valvular atrial fibrillation population. 2014 , 39, 600-8		3
1938	LAA-Verschluß nicht gleichberechtigt mit oraler Antikoagulation. 2014 , 14, 47-49		
1937	Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. 2014 , 12, 29		14
1936	Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. 2014 , 70, 1477-85		39
1935	Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt). 2014 , 14, 199		9
1934	EMBRACE- und CRYSTAL-AF-Studien belegen Bedeutung einer prolongierten Rhythmusüberwachung bei Patienten nach kryptogenem Schlaganfall. 2014 , 8, 366-368		
1933	Computer Simulation of Cathode Ablation for Atrial Fibrillation. 2014 ,		1
1932	Optimale Schlaganfallprävention bei geriatrischen Patienten mit Vorhofflimmern. 2014 , 156, 84-88		4
1931	Three-dimensional Echocardiographic Analysis of left Atrial size and Volumetric Function â€”Clinical Implications and Comparison with Other Imaging Modalities. 2014 , 7, 1		
1930	Vorhofohrverschluss einer Antikoagulation berlegen. 2014 , 14, 46-47		
1929	Katheterablation bei Vorhofflimmern. 2014 , 156, 62-64		
1928	Comparison of end-diastolic versus end-systolic cardiac-computed tomography reconstruction interval in patient's prior to pulmonary vein isolation. 2014 , 3, 218		3

1927	Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. <i>Stroke</i> , 2014 , 45, 696-701	6.7	32
1926	Atrial fibrillation and retinal vein or artery occlusion: looking beyond the eye. 2014 , 98, 1141-3		10
1925	Cost-utility analysis of oral anticoagulants for nonvalvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand. 2014 , 36, 1389-94.e4		10
1924	The EHJ: the first years and the future. <i>European Heart Journal</i> , 2014 , 35, 3399-407	9.5	2
1923	Management des Vorhofflimmerns. 2014 , 8, 374-384		1
1922	[Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants]. 2014 , 126, 792-808		2
1921	Amiodarone-related thyroid dysfunction. 2014 , 9, 829-39		5
1920	Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis. 2014 , 12, 1067-75		7
1919	Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. 2014 , 4, 619-639		1
1918	Interventional treatment of atrial fibrillation - contemporary methods and perspectives. 2014 , 11, 595-603		
1917	Prediction of postoperative atrial fibrillation after coronary artery bypass grafting surgery: is CHA ₂ DS ₂ -VASc score useful?. 2014 , 17, 182-7		21
1916	Characterization of patients with atrial fibrillation not treated with oral anticoagulants. 2014 , 32, 226-31		14
1915	Total adiponectin is inversely associated with platelet activation and CHA ₂ DS ₂ -VASc score in anticoagulated patients with atrial fibrillation. 2014 , 2014, 908901		13
1914	Feasibility of a cardiologist-only approach to sedation for electrical cardioversion of atrial fibrillation: a randomized, open-blinded, prospective study. 2014 , 176, 930-5		17
1913	Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. 2014 , 177, 91-9		50
1912	Left Atrial Appendage Closure With the Watchman [®] Device. 2014 , 22, 56-63		
1911	An automated system using spatial oversampling for optical mapping in murine atria. Development and validation with monophasic and transmembrane action potentials. 2014 , 115, 340-8		17
1910	A clinical dilemma about a new oral anticoagulant treatment. 2014 , 14, 748-9		

1909 Anticoagulation in Pregnancy. **2014**, 79-105

1908 Direct oral anticoagulants: integration into clinical practice. **2014**, 90, 529-39

13

1907 Angioedema due to the new oral anticoagulant rivaroxaban. **2014**, 17, 173-4

7

1906 Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. **2014**, 121 Suppl, 1-20

36

1905 In response to "Anaphylaxis during intravenous administration of amiodarone": is amiodarone the best choice for management of atrial fibrillation?. **2014**, 17, 70-1

1

1904 Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). *European Heart Journal*, **2014**, 35, 501-7

9.5 198

1903 Cardiovascular imaging. *European Heart Journal*, **2014**, 35, 1161-2

9.5 3

1902 Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. *European Heart Journal*, **2014**, 35, 3377-85

9.5 127

1901 The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. *European Heart Journal*, **2014**, 35, 3250-7

9.5 66

1900 Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors. **2014**, 4, e004565

75

1899 Development of an anatomic heart model for the minimally-invasive closure of the left atrial appendage. **2014**,

1

1898 Application of a Conceptual Framework for the Modelling and Execution of Clinical Guidelines as Networks of Concurrent Processes. **2014**, 35, 671-680

3

1897 Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. **2014**, 33, 535-44

21

1896 Twiddler syndrome causing an inappropriate implantable cardioverter-defibrillator shock. *European Heart Journal*, **2014**, 35, 516

9.5 4

1895 Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. **2014**, 161, 690-8

58

1894 Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. *European Heart Journal*, **2014**, 35, 1864-72

9.5 237

1893 Diabetes und kardiovaskuläre Erkrankungen, Zusammenfassung der ESC-Leitlinien 2013. **2014**, 09, 323-335

1892 Ablation von Rotoren bei Vorhofflimmern – eine neue Ära der Ablationstechnik?. **2014**, 10, 135-145

1891	Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage. 2014 , 82, 135-8		49
1890	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?. 2014 , 42, 153-62		1
1889	Effects of human atrial ionic remodelling by β -blocker therapy on mechanisms of atrial fibrillation: a computer simulation. 2014 , 16, 1524-33		16
1888	Antikoagulation bei Herzinsuffizienz. 2014 , 10, 47-59		
1887	[Prophylaxis and therapy for atrial fibrillation after general thoracic surgery]. 2014 , 139 Suppl 1, S39-42		1
1886	Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. <i>European Heart Journal</i> , 2014 , 35, 1327-34	9.5	19
1885	Measurement of left and right atrial volume in patients undergoing ablation for atrial arrhythmias: comparison of a manual versus semiautomatic algorithm of real time 3D echocardiography. 2014 , 31, 499-507		13
1884	Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention. <i>European Heart Journal</i> , 2014 , 35, 3323-5	9.5	6
1883	Predictors of long-term maintenance of normal sinus rhythm after successful electrical cardioversion. 2014 , 37, 381-5		18
1882	An unusual case of flecainide-induced QT prolongation leading to cardiac arrest. 2014 , 34, e30-3		7
1881	The prevalence of oral anticoagulation in patients with atrial fibrillation in Portugal: Systematic review and meta-analysis of observational studies. 2014 , 33, 555-60		14
1880	Antithrombotics in atrial fibrillation and coronary disease. 2014 , 12, 977-86		4
1879	Quantitative assessment of synchronization during atrial fibrillation based on a novel index. 2014 , 2014, 998-1001		
1878	A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. 2014 , 78, 599-609		21
1877	Vernakalant hydrochloride to treat atrial fibrillation. 2014 , 15, 865-72		1
1876	Fluoroscopy of spontaneous breathing is more sensitive than phrenic nerve stimulation for detection of right phrenic nerve injury during cryoballoon ablation of atrial fibrillation. 2014 , 25, 859-865		16
1875	Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence. 2014 , 12, 933-47		5
1874	Three-dimensional echocardiography and structural heart interventions. 2014 , 75, 378-83		1

1873	What is 'valvular' atrial fibrillation? A reappraisal. <i>European Heart Journal</i> , 2014 , 35, 3328-35	9.5	123
1872	Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study. 2014 , 12, 1413-8		18
1871	Atrial fibrillation, stroke, and mortality rates after transcatheter aortic valve implantation. 2014 , 114, 1861-6		35
1870	Atrial fibrillation is associated with impaired mobility in community-dwelling older adults. 2014 , 15, 929-33		17
1869	Experiencia inicial con un nuevo catéter balón de ablación con energía láser para el aislamiento eléctrico de las venas pulmonares. 2014 , 67, 1061-1062		4
1868	Prediabetes, diabetes and left heart deformation. 2014 , 67, 1062-4		2
1867	Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry. 2014 , 37, 277-84		19
1866	Grupo de Trabajo Conjunto sobre cirugía no cardíaca: Evaluación y manejo cardiovascular de la Sociedad Europea de Cardiología (ESC) y la European Society of Anesthesiology (ESA). 2014 , 67, 1052.e1-1052.e43		3
1865	Initial experience with a new ablation catheter using laser energy for electrical pulmonary vein isolation. 2014 , 67, 1061-2		
1864	Percutaneous left atrial appendage closure with a novel self-modeling device: a pre-clinical feasibility study. 2014 , 177, 957-63		11
1863	An explanation of recommendation differences: illustrations from recent atrial fibrillation guidelines. 2014 , 37, 116-27		4
1862	Antiarrhythmic drug therapy for maintaining sinus rhythm early after pulmonary vein ablation in patients with symptomatic atrial fibrillation. 2014 , 32, 7-12		6
1861	Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation. 2014 , 83, 796-802		16
1860	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). <i>European Heart Journal</i> , 2014 , 35, 2323-134	9.5	849
1859	Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. 2014 , 12, 1636-46		113
1858	Atrial fibrillation: current approaches to management. 2014 , 25, 15-21		
1857	Fluoroscopy-free recrossing of the interatrial septum during left atrial ablation procedures. 2014 , 41, 261-6		5
1856	Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens. 2014 , 30, 1541-6		22

1855	Anticoagulants oraux directs, fibrillation atriale et accidents vasculaires cŕbraux. 2014 , 5, 269-276		
1854	ŒPor quŕdebemos estratificar el riesgo hemorrŕgico junto con el isquŕmico en el sŕndrome coronario agudo?. 2014 , 14, 10-17		
1853	[Antithrombotic therapy and atrial fibrillation. Dual or triple therapy after acute coronary syndrome and stent?]. 2014 , 39, 814-8		2
1852	Baseline characteristics and management of patients with atrial fibrillation/flutter in the emergency department: results of a prospective, multicentre registry in China. 2014 , 44, 742-8		9
1851	Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2471-82	15.1	205
1850	Haemorrhagic stroke due to rivaroxaban and use of prothrombin complex concentrate as a reversal agent. 2014 , 44, 129-131		0
1849	Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation. 2014 , 311, 1150-1		7
1848	Electrophysiological study 6 months after Epicorŕhigh-intensity focused ultrasound atrial fibrillation ablation. 2014 , 41, 245-51		6
1847	The atrial fibrillation epidemic is approaching the physician's door: will mobile technology improve detection?. 2014 , 12, 180		6
1846	Peripheral pulse measurement after ischemic stroke: A feasibility study. 2014 , 83, 598-603		14
1845	Which drug should we use for stroke prevention in atrial fibrillation?. 2014 , 29, 293-300		6
1844	Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter. 2014 , 64, 247-55		4
1843	2014 Oman Heart Association protocol for the management of acute atrial fibrillation. 2014 , 13, 117-27		2
1842	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). 2014 , 31, 517-73		242
1841	Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: a long-term analysis of risk versus benefit. 2014 , 76, 642-9; discussion 649-50		52
1840	The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects. 2014 , 63, 152-7		3
1839	Research progress of warfarin-associated vascular calcification and its possible therapy. 2014 , 63, 76-82		13
1838	Increased risk of myocardial infarction with dabigatran: fact or fiction?. 2014 , 15, 19-26		7

1837	Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial fibrillation: a cohort study. 2014 , 15, 189-93	2
1836	Radiotherapy beyond cancer: target localization in real-time MRI and treatment planning for cardiac radiosurgery. 2014 , 41, 120702	29
1835	Relation of red cell distribution width with CHA2DS2-VASc score in patients with nonvalvular atrial fibrillation. 2014 , 20, 687-92	19
1834	Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. 2014 , 311, 692-700	391
1833	Integrating real-time clinical information to provide estimates of net clinical benefit of antithrombotic therapy for patients with atrial fibrillation. 2014 , 7, 680-6	17
1832	Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. 2014 , 111, 933-42	82
1831	New Antiarrhythmic Drugs and New Concepts for Old Drugs. 2014 , 1111-1119	
1830	Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines. 2014 , 174, 625-9	6
1829	Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. 2014 , 36, 1160-8	45
1828	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , 2014 , 35, 1856-63	9.5 20
1827	Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. 2014 , 34, 709-21	11
1826	Atrial fibrillation in severe aortic valve stenosis – Association with left ventricular left atrial remodeling. 2014 , 4, 102-107	8
1825	Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. 2014 , 7, 281-7	73
1824	Self-detection of atrial fibrillation in an aged population: the LietoAF Study. 2014 , 21, 1437-42	20
1823	Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. 2014 , 311, 919-28	104
1822	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. 2014 , 111, 798-807	38
1821	Management of atrial fibrillation in critically ill patients. 2014 , 2014, 840615	31
1820	Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation. 2014 , 7, 300-6	45

1819	46th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC - Laboratory Medicine). 2014 , 52,		
1818	Current perspectives on cardioembolic ischemic stroke in very old patients. 2014 , 1		
1817	Novel oral anticoagulants in cardiovascular disease. 2014 , 19, 34-44		20
1816	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. 2014 , 130, e199-267		1016
1815	Comparison of the first and second cryoballoon: high-volume single-center safety and efficacy analysis. 2014 , 7, 293-9		65
1814	Protecting the brain and the heart: antithrombotic treatment in nonvalvular atrial fibrillation. <i>Angiology</i> , 2014 , 65, 372-8	2.1	1
1813	Screening for undiagnosed atrial fibrillation in the community. 2014 , 29, 28-35		17
1812	Left atrial volume and function in patients with atrial fibrillation. 2014 , 29, 437-44		10
1811	Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. 2014 , 1329, 93-106		18
1810	Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA ₂ DS ₂ -VASc score of 1. 2014 , 37, 1442-7		41
1809	Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation. 2014 , 171, 92-106		20
1808	Insights into onco-cardiology: atrial fibrillation in cancer. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 945-53	15.1	209
1807	Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. 2014 , 114, 70-8		46
1806	Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants. 2014 , 48, 136-40		7
1805	The Egyptian Hypertension Society: EGYPTIAN HYPERTENSION GUIDELINES. 2014 , 66, 79-132		16
1804	Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. 2014 , 23, 1142-7		11
1803	Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. 2014 , 174, 471-83		14
1802	Profile of CZECH AF 2012. Profile of atrial fibrillation patients receiving antithrombotic therapy. 2014 , 56, e207-e216		3

1801 [Atrial fibrillation in elder hospitalized patients]. **2014**, 143, 44-5

1800 Direct oral anticoagulants in atrial fibrillation. **2014**, 51, 139-46

2

1799 Atrial fibrillation: improvement in identification and stroke preventive therapy - data from the UK Clinical Practice Research Datalink, 2000-2012. **2014**, 171, 169-73

20

1798 Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation--could it refine clinical risk stratification in AF?. **2014**, 170, 344-9

36

1797 Radiotherapy and prevention of thrombosis in a patient with atrial fibrillation. **2014**, 173, e18-9

1796 Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. **2014**, 168, 239-247.e1

41

1795 Use of anticoagulants for atrial fibrillation in older subjects across different countries: Cyprus, France, Netherlands, Norway. **2014**, 5, 60-65

3

1794 Use of the HAS-BLED bleeding score in real-life settings. **2014**, 134, 202

2

1793 Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. **2014**, 127, 979-986.e2

26

1792 Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. **2014**, 19, 391-401

10

1791 Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. **2014**, 77, 626-41

97

1790 Atrial fibrillation in heart failure: drug therapies for rate and rhythm control. **2014**, 19, 315-24

10

1789 The HATCH and CHA2DS 2-VASc scores. Prognostic value in pulmonary vein isolation. **2014**, 39, 343-8

9

1788 The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation. **2014**, 27, 187-92

12

1787 Keine ausreichende Wirksamkeit von Dabigatran bei Patienten mit Kunstklappen. **2014**, 8, 117-119

1786 A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. **2014**, 38, 137-49

23

1785 R2CHADS2 score and thromboembolic events after catheter ablation of atrial fibrillation in comparison with the CHA2DS2-VASc score. **2014**, 30, 405-12

10

1784 Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. **2014**, 23, e73-83

30

1783	Management of cardiovascular diseases during pregnancy. 2014 , 39, 85-151		21
1782	Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. 2014 , 12, 5		26
1781	[Medicinal rhythm control in atrial fibrillation]. 2014 , 25, 19-25		
1780	Drug adherence in patients taking oral anticoagulation therapy. 2014 , 103, 173-82		41
1779	Left atrial mechanics predict the success of pulmonary vein isolation in patients with atrial fibrillation. 2014 , 40, 53-62		14
1778	Overweight is associated with improved survival and outcomes in patients with atrial fibrillation. 2014 , 103, 533-42		33
1777	Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases. 2014 , 19, 295-304		4
1776	[Drug-eluting coronary stents]. 2014 , 55, 103-6		
1775	Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). 2014 , 100 Suppl 2, ii1-ii67		34 ⁰
1774	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , 2014 , 64, e1-76	15.1	2768
1773	Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome. 2014 , 113, 888-96		7
1772	Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. 2014 , 7, 113-24		54
1771	First, let's see where we stand. Then, let's see how far we can or want to go. 2014 , 67, 249-50		
1770	Triple antithrombotic therapy: risky but sometimes necessary. 2014 , 67, 171-5		1
1769	Gait speed and comprehensive geriatric assessment: two keys to improve the management of older persons with aortic stenosis. 2014 , 173, 580-2		23
1768	Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. 2014 , 114, 1483-99		373
1767	Early diastolic strain rate in relation to systolic and diastolic function and prognosis in acute myocardial infarction: a two-dimensional speckle-tracking study. <i>European Heart Journal</i> , 2014 , 35, 648-56	9.5	90
1766	Edoxaban: a focused review of its clinical pharmacology. <i>European Heart Journal</i> , 2014 , 35, 1844-55	9.5	90

1765	Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2689-98	151	16
1764	Prognosis in patients hospitalized with permanent and nonpermanent atrial fibrillation in heart failure. 2014 , 113, 1189-95		15
1763	[Perioperative management of anticoagulation]. 2014 , 85, 513-9		7
1762	Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. 2014 , 23, 379-83		13
1761	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. 2014 , 130, 2071-104		1447
1760	Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. 2014 , 43, 48-59		19
1759	Left atrial appendage occlusion: opportunities and challenges. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 291-8	15.1	53
1758	Pharmacological Treatment of Acute Coronary Syndromes. 2014 ,		1
1757	CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation. 2014 , 127, 45-52		34
1756	Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. 2014 , 37, 362-71		11
1755	Cardiac procedures to prevent stroke: patent foramen ovale closure/left atrial appendage occlusion. 2014 , 30, 87-95		9
1754	Atrial Fibrillation Therapy. 2014 ,		2
1753	[Systematic implementation of transthoracic echocardiography, transesophageal echocardiography and 24-hour Holter ECG for the detection of cardiac sources of embolism in patients with stroke or transient ischemic attack. A retrospective study of 220 patients]. 2014 , 63, 217-21		1
1752	Novel oral anticoagulants for stroke prevention in the geriatric population. 2014 , 14, 15-29		3
1751	Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital. 2014 , 38, 98-104		13
1750	Cardiac Drugs in Pregnancy. 2014 ,		1
1749	Effect of remote ischemic preconditioning on platelet activation and reactivity induced by ablation for atrial fibrillation. 2014 , 129, 11-7		37
1748	Frequency and significance of right atrial appendage thrombi in patients with persistent atrial fibrillation or atrial flutter. 2014 , 27, 1200-7		23

1747	Increased risk of first-ever stroke in younger patients with atrial fibrillation not recommended for antithrombotic therapy by current guidelines: a population-based study in an East Asian cohort of 22 million people. 2014 , 89, 1487-97		12
1746	Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i> , 2014 , 45, 3754-832	6.7	921
1745	New oral anticoagulants and the cancer patient. 2014 , 19, 82-93		149
1744	Balancing ischaemia and bleeding risks with novel oral anticoagulants. 2014 , 11, 693-703		20
1743	Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. <i>European Heart Journal</i> , 2014 , 35, 3346-55	9.5	278
1742	CHA2DS2-VASc score is a useful-predictor of not prognosis but coronary-arteriosclerosis in chronic atrial-fibrillation compared with CHADS2 score: a two-center study of 320-slice CT, part 2. 2014 , 177, 368-73		14
1741	Percutaneous left atrial appendage closure: procedural techniques and outcomes. 2014 , 7, 1205-20		109
1740	Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. 2014 , 74, 1587-603		27
1739	[Complications associated with catheter ablation of atrial fibrillation]. 2014 , 25, 241-5		0
1738	Dual antiplatelet therapy in the anticoagulated patient undergoing percutaneous coronary intervention risks, benefits, and unanswered questions. 2014 , 16, 548		2
1737	Significance of the learning curve in left atrial appendage occlusion with two different devices. 2014 , 83, 642-6		23
1736	Atrial fibrillation: state of the art. 2014 , 126, 692-704		
1735	Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 2014 , 130, 1847-58		188
1734	Quantitative Analysis of Aortic Valve Stenosis and Aortic Root Dimensions by Three-Dimensional Echocardiography in Patients Scheduled for Transcatheter Aortic Valve Implantation. 2014 , 7, 9296		13
1733	Frequenz- oder Rhythmuskontrolle?. 2014 , 156, 49-55		
1732	Welche kardiale Diagnostik braucht Ihr Hypertoniker?. 2014 , 156, 51-54		
1731	Atrial fibrillation: AF prognosis and treatment--the European perspective. 2014 , 11, 689-90		
1730	Multicenter study on acute and long-term safety and efficacy of percutaneous left atrial appendage closure using an epicardial suture snaring device. 2014 , 11, 1853-9		68

1729	Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study. 2014 , 11, 1941-7		48
1728	Regulatory and occupational considerations in cardiology. 2014 , 42, 670-675		1
1727	Left atrial appendage exclusion for atrial fibrillation. 2014 , 32, 601-25		11
1726	Integrated Chronic Care Management bij atriumfibrilleren. 2014 , 12, 17-20		
1725	Integrated Chronic Care Management bij atriumfibrilleren. 2014 , 7, 12-15		
1724	Poststroke atrial fibrillation: cause or consequence? Critical review of current views. 2014 , 82, 1180-6		70
1723	Cryoballoon ablation for atrial fibrillation. 2014 , 6, 373-382		1
1722	Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. 2014 , 36, 1176-81		5
1721	New advances in the treatment of atrial fibrillation: focus on stroke prevention. 2014 , 15, 2193-204		3
1720	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2014 , 35, 2733-79	9.5	2361
1719	Rationale and Design of FIRE AND ICE: A multicenter randomized trial comparing efficacy and safety of pulmonary vein isolation using a cryoballoon versus radiofrequency ablation with 3D-reconstruction. 2014 , 25, 1314-20		21
1718	Preventing the rise of atrial fibrillation-related stroke in populations: a call to action. 2014 , 130, 1221-2		8
1717	Enfermedades cardiovasculares, respiratorias y renales. 2014 , 11, 3677-3690		
1716	Erratum: Management of unruptured intracranial aneurysms. 2014 , 4, 98		
1715	Nuevos anticoagulantes orales en fibrilaci3n auricular valvular: ¿Hasta d3nde llegan?. 2014 , 49, 99-101		0
1714	Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. 2014 , 16, 626-30		30
1713	Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence. 2014 , 46, 364-71		33
1712	Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. 2014 , 67, 1093-102		9

1711	Catheter ablation of persistent atrial fibrillation. 2014 , 10, 553-62		2
1710	[It is time to optimize the anticoagulant therapy in elderly patients with atrial fibrillation]. 2014 , 49, 201-2		1
1709	Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. 2014 , 17, 587-98		52
1708	Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. 2014 , 33, 535-544		13
1707	[Novel oral anticoagulants in patients with atrial fibrillation, how to avoid accidents?]. 2014 , 43, 775-83		
1706	AF burden is important - fact or fiction?. 2014 , 68, 444-52		41
1705	Catheter ablation of atrial fibrillation: an update. <i>European Heart Journal</i> , 2014 , 35, 2454-9	9.5	69
1704	Fibrilaci3 auricular no valvular: el problema de una definici3 indefinida. 2014 , 67, 670-671		3
1703	Nonvalvular atrial fibrillation: the problem of an undefined definition. 2014 , 67, 670-1		
1702	Percutaneous closure of baffle leaks in patients with atrial switch operation for D-transposition of the great arteries. 2014 , 67, 671-4		1
1701	Oral anticoagulants for stroke prevention in atrial fibrillation. 2014 , 39, 319-44		4
1700	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2014 , 35, 2551-88	9.5	3467
1699	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. 2014 , 148, 772-91		47
1698	When it comes to radiofrequency catheter ablation of atrial fibrillation, have all of our wishes been granted? A perspective on the SMART-AF trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 657-9	15.1	3
1697	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. 2014 , 148, e153-93		170
1696	Cierre percut3neo de comunicaciones interauriculares en pacientes con cirug3 de switch auricular para la D-transposici3 de grandes arterias. 2014 , 67, 671-674		
1695	Oral anticoagulant use in patients with chronic kidney disease: how to choose, and the importance of empiric human data. 2014 , 30, 853-4		2
1694	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. 2014 , 100, 1625-35		20

1693	Applying the atrial fibrillation guidelines update to manage your patients with atrial fibrillation. 2014 , 30, 1241-4		2
1692	Guías de la European Association for Cardiothoracic Surgery 2013 sobre el tratamiento quirúrgico de la fibrilación auricular. 2014 , 21, 199-203		
1691	Edoxaban: an update on the new oral direct factor Xa inhibitor. 2014 , 74, 1209-31		75
1690	Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014 , 35, 2639-54	9.5	76
1689	Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1658-65	15.1	136
1688	The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. 2014 , 36, 1135-44		42
1687	The diagnostic accuracy of the MyDiagnostick to detect atrial fibrillation in primary care. 2014 , 15, 113		48
1686	Cardiac glycosides use and the risk of lung cancer: a nested case-control study. 2014 , 14, 573		3
1685	Personalized approach to primary and secondary prevention of ischemic stroke. 2014 , 5, 9		7
1684	Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update. 2014 , 4, 96-98		1
1683	Increased risk of atrial fibrillation among elderly Norwegian men with a history of long-term endurance sport practice. 2014 , 24, e238-44		58
1682	Anticoagulation in atrial fibrillation. 2014 , 348, g2116		49
1681	Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1270-80	15.1	46
1680	Periprocedural intracardiac echocardiography for left atrial appendage closure: a dual-center experience. 2014 , 7, 1036-44		65
1679	Atrial fibrillation. 2014 , 42, 598-603		1
1678	[Re-align (randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran ftexilate in patients after heart valve replacement)]. 2014 , 55, 1108-9, 1111		
1677	Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia. 2014 , 146, 619-26		9
1676	Combined anticoagulation and antiplatelet therapy in AF patients: why do we not follow guidelines?. 2014 , 100, 1565-6		0

1675	[Direct anticoagulants for atrial fibrillation. Update 2014]. 2014 , 39, 357-67; quiz 368		2
1674	[New oral anticoagulants in perioperative medicine]. 2014 , 63, 347-62; quiz 363-4		12
1673	Impact of respiration gating on image integration guided atrial fibrillation ablation. 2014 , 103, 727-31		8
1672	Clinical significance of <i>Helicobacter pylori</i> infection in patients with acute coronary syndromes: an overview of current evidence. 2014 , 103, 855-86		14
1671	Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database. 2014 , 103, 887-93		19
1670	Robotic ablation of atrial fibrillation with a new remote catheter system. 2014 , 40, 215-9		10
1669	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2246-2280	15.1	505
1668	Left atrial appendage closure to prevent stroke in patients with atrial fibrillation. 2014 , 130, 202-12		27
1667	Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation. 2014 , 41, 107-16		15
1666	Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. 2014 , 20, 665-72		27
1665	Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. 2014 , 37, 457-62		8
1664	A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. 2014 , 9, 443-7		51
1663	Use of novel oral anticoagulants in patients with heart failure. 2014 , 16, 285		4
1662	Left atrial appendage devices for stroke prevention in atrial fibrillation. 2014 , 7, 458-64		4
1661	Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. 2014 , 37, 295-307		2
1660	Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. 2014 , 14, 113-23		30
1659	Safety relevant knowledge of orally anticoagulated patients without self-monitoring: a baseline survey in primary care. 2014 , 15, 104		13
1658	A novel treatment strategy of new onset atrial fibrillation after cardiac surgery: an observational prospective study. 2014 , 9, 83		5

1657	Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. 2014 , 11, 1752-9	60
1656	The prevalence of oral anticoagulation in patients with atrial fibrillation in Portugal: Systematic review and meta-analysis of observational studies. 2014 , 33, 555-560	10
1655	On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. 2014 , 134, 783-9	42
1654	Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. 2014 , 7, 841-52	101
1653	Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. 2014 , 7, 576-82	52
1652	Essentials of Atrial Fibrillation. 2014 ,	1
1651	Comparative evaluation of HAS-BLED and ATRIA scores by investigating the full potential of their bleeding prediction schemes in non-valvular atrial fibrillation patients on vitamin-K antagonists. 2014 , 176, 1259-61	9
1650	Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?. 2014 , 168, 611-21	29
1649	Prevalence of patent foramen ovale in atrial fibrillation patients with history of cerebral ischemia: a stand-alone additional risk?. 2014 , 172, e290-1	2
1648	The Impact of Early Detection of Atrial Fibrillation on Stroke Outcomes. 2014 , 6, 125-32	
1647	Left atrial appendage closure: a new technique for clinical practice. 2014 , 11, 514-21	25
1646	Multidetector computed tomography may be an adequate screening test to reduce periprocedural stroke in atrial fibrillation ablation: a multicenter propensity-matched analysis. 2014 , 11, 763-70	13
1645	Can silent brain lesions be a target to guide anticoagulation treatment in patients with low-risk atrial fibrillation to reduce cognitive impairment?. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2174-2175	15.1 2
1644	A quality study to improve prophylactic antithrombotic therapy prescribed to patients with atrial fibrillation. 2014 , 33, 89-94	4
1643	[The family doctor and the barriers to prescribing the new oral anticoagulants: Heterogeneity, inequality and confusion. Statement of the Spanish Primary Care and Family Medicine Societies]. 2014 , 46, 1-3	4
1642	A quality study to improve prophylactic antithrombotic therapy prescribed to patients with atrial fibrillation. 2014 , 33, 89-94	4
1641	Left atrial appendage occlusion: initial experience with the Amplatzer®Amulet® 2014 , 174, 492-6	67
1640	Left Atrial Appendage Closure for Stroke Prevention: Emerging Technologies. 2014 , 6, 141-60	5

1639	Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. 2014 , 36, 192-210.e20	62
1638	Primero conocer la realidad. A partir de ah� hasta donde queramos o podamos. 2014 , 67, 249-250	
1637	Mechanisms of Stroke in Atrial Fibrillation. 2014 , 6, 5-15	11
1636	Clinical Results with Percutaneous Left Atrial Appendage Occlusion. 2014 , 3, 291-300	
1635	Common Questions in Anticoagulation Management in Atrial Fibrillation. 2014 , 6, 79-86	1
1634	Impacto del score CHADS2 sobre el accidente cerebrovascular tard� tras el procedimiento de Cox-Maze. 2014 , 21, 66-67	
1633	Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). 2014 , 113, 480-4	19
1632	Tratamiento antitromb�tico combinado triple: arriesgado pero a � veces necesario. 2014 , 67, 171-175	5
1631	Gu� de pr�ctica cl�nica de la ESC 2013 sobre estimulaci�n cardiaca y terapia de resincronizaci�n cardiaca. 2014 , 67, 58.e1-58.e60	1
1630	Incidence and predictors of new-onset atrial fibrillation in noncardiac intensive care unit patients. 2014 , 29, 697.e1-5	38
1629	Software-based detection of atrial fibrillation in long-term ECGs. 2014 , 11, 933-8	13
1628	Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation. 2014 , 30, 58-64	5
1627	The concentration of troponin I is increased in patients with acute-onset atrial fibrillation. 2014 , 173, 579-80	9
1626	Left atrial appendage morphology and silent cerebral ischemia in patients with atrial fibrillation. 2014 , 11, 2-7	68
1625	[The family doctor and the barriers to prescribing the new oral anticoagulants: heterogeneity, inequality and confusion. Statement of the Spanish Primary Care and Family Medicine Societies]. 2014 , 40, 1-3	0
1624	Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. 2014 , 107, 381-90	13
1623	The role of rivaroxaban in atrial fibrillation and acute coronary syndromes. 2014 , 19, 526-32	2
1622	Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. 2014 , 134, 278-87	16

1621	Coronary embolization following electrical cardioversion in a patient treated with dabigatran. 2014 , 175, 571-2	5
1620	Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. 2014 , 127, 1075-1082.e1	167
1619	Mechanical closure devices for atrial fibrillation. 2014 , 24, 225-31	2
1618	Possible limitations of using the HAS-BLED bleeding score in real life settings. 2014 , 133, 959-60	3
1617	New oral anticoagulants--what the cardiothoracic surgeon needs to know. 2014 , 148, 1794-1801.e1	7
1616	Cerebrovascular Complications Related to Atrial Fibrillation Ablation and Strategies for Periprocedural Stroke Prevention. 2014 , 6, 111-23	4
1615	Validation of CHA ₂ DS ₂ -VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. 2014 , 78, 1593-9	71
1614	Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation. 2014 , 78, 2367-72	36
1613	Palpitations. 331-340	
1612	Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. 2014 , 111, 549-56	17
1611	Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. 2014 , 111, 1167-76	320
1610	Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. 2014 , 112, 276-86	94
1609	[Decisional algorithm to prescribe vitamin K antagonist in geriatric patients with atrial fibrillation]. 2014 , 12, 20-4	
1608	Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts. 2014 , 64, e275-81	27
1607	Latest advances in transseptal structural heart interventions-Percutaneous Mitral Valve Repair and Left Atrial Appendage Occlusion. 2014 , 78, 1782-90	10
1606	Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention. 2014 , 78, 2674-81	19
1605	Thromboembolic events in paroxysmal vs. permanent non-valvular atrial fibrillation. Subanalysis of the J-RHYTHM Registry. 2014 , 78, 2388-93	32
1604	Interventional closure of the left atrial appendage for stroke prevention. 2014 , 78, 619-24	18

1603	Thromboembolic risks that require consideration for antithrombotic therapy in Japanese patients with atrial fibrillation. 2014 , 78, 2373-5		1
1602	Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). 2014 , 78, 1997-2021		322
1601	Research Roundup. 2014 , 9, 530-531		
1600	Heart Rhythm Week 2014. 2014 , 9, 214-214		
1599	The nurse's role in the management and treatment of atrial fibrillation. 2014 , 9, 586-591		2
1598	Rate versus rhythm control in persistent atrial fibrillation. 2014 , 9, 489-494		
1597	Stroke prevention in atrial fibrillation: An update. 2014 , 9, 376-380		
1596	Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. 2014 , 111, 465-73		81
1595	Treatment for atrial flutter in a patient with heart failure and mesothelioma: a case study. 2014 , 9, 599-602		
1594	Occurrence of poor sleep quality in atrial fibrillation patients according to the EHRA score. 2014 , 69, 291-6		17
1593	ESC. 2014 , 69, 435-445		1
1592	Unusual Case of a Free-floating Ball Thrombus with Preserved Attachment to the Left Atrial Appendage Causing Recurrent Obstruction of the Left Ventricular Outflow Tract. 2014 , 8, 5-7		1
1591	Management of atrial fibrillation in people with haemophilia--a consensus view by the ADVANCE Working Group. 2014 , 20, e417-20		10
1590	The new postgraduate course in heart failure. <i>European Heart Journal</i> , 2014 , 35, 1009-10	9.5	0
1589	Perspectives: Direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. 2014 , 16, A56-A60		9
1588	Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation population: the Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study. 2014 , 146, 1073-1080		6
1587	WITHDRAWN: Safety of Multielectrode Phased Radiofrequency Pulmonary Vein Ablation Catheter and Irrigated Radiofrequency Catheter. 2014 ,		
1586	Exercise-based cardiac rehabilitation for adults with atrial fibrillation. 2014 ,		5

- 1585 Unterversorgung von Vorhofflimmer-Patienten mit oralen Antikoagulanzen in Deutschland. **2015**, 9, 379-392
- 1584 Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study. **2015**, 10, 836-42 77
- 1583 Atrial fibrillation, CHA2DS2-VASc score, antithrombotics and risk of non-traffic-, non-cancer-related bone fractures: A population-based cohort study. **2015**, 26, 798-806 8
- 1582 Incidence of thromboembolism following detection by trans-oesophageal echocardiography of left atrial thrombus. **2015**, 8, 95-97 1
- 1581 Oral anticoagulation in patients with atrial fibrillation and chronic kidney disease. **2015**, 144, 480
- 1580 Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study. **2015**, 201, 693-8 13
- 1579 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). *Journal of the American College of Cardiology*, **2015**, 66, 2767-2802 15.1 22
- 1578 Satisfacci3n con el cuidado m3dico de pacientes con fibrilaci3n auricular anticoagulados con antagonistas de la vitamina K o nuevos anticoagulantes. **2015**, 68, 537-539 7
- 1577 APOLLO I: Anticoagulation control in atrial fibrillation. **2015**, 34, 337-345 2
- 1576 WITHDRAWN: Cost-effectiveness analysis of left atrial appendage occlusion compared with seven pharmacological strategies for stroke prevention in atrial fibrillation. **2015**,
- 1575 Dabigatran for left ventricular thrombus. **2015**, 67, 495-6 22
- 1574 Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. **2015**, 15, 143 40
- 1573 Why do we need observational studies of everyday patients in the real-life setting?. **2015**, 17, D2-D8 67
- 1572 The future of left atrial appendage occlusions: When extraordinary claims require evidenceâ**2015**, 108, 613-6 4
- 1571 Diabetes mellitus und Herz. **2015**, 10, S124-S128
- 1570 Vorhofflimmern: welches Antikoagulans ff.welchen Patienten?. **2015**, 4, 104-109
- 1569 Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. **2016**, 18, 6 92
- 1568 Practical advice on safe and effective use of non-vitamin K antagonist oral anticoagulants. **2015**, 1, 146-7 0

1567	Decennial Analysis of Interventional Left Atrial Appendage Closure. 2015 , 26, 840-844	3
1566	Automatic detection of atrial fibrillation using MEMS accelerometer. 2015 ,	8
1565	Comparison of two approaches of INR-follow-up and determinants of INR-stability. 2015 , 70, 167-74	
1564	The value of magnetic resonance imaging in catheter ablation of atrial fibrillation. 2015 , 38, 190-4	4
1563	New oral anticoagulants: an approach in older people. 2015 , 45, 217-225	4
1562	Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. 2015 , 95, 389-404	56
1561	Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). 2015 , 38, 285-92	66
1560	Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta-analysis of 16 Clinical Trials and 9,185 Patients. 2015 , 38, 499-509	22
1559	Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review. 2015 , 38, 684-91	6
1558	Optimising stroke prevention in patients with atrial fibrillation. 2015 , 65, 117	3
1557	Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials. 2015 , 10, 816-822	29
1556	Is low body weight a novel risk factor for thromboembolic events in patients with non-valvular atrial fibrillation?. 2015 , 79, 960-1	2
1555	Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation. 2015 , 79, 914-23	10
1554	Telecardiology Tools and Devices. 2015 , 463-488	
1553	Catheter ablation of atrial fibrillation and thromboembolic risk. 2015 , 79, 444	
1552	Target intensity of anticoagulation with warfarin in Japanese patients with valvular atrial fibrillation âsubanalysis of the J-RHYTHM Registry. 2015 , 79, 325-30	23
1551	Intracranial Hemorrhage Caused by Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)- Multicenter Retrospective Cohort Study in Japan. 2015 , 79, 1018-23	28
1550	Oral anticoagulation in Japanese patients with atrial fibrillation âinsight to the use of non-vitamin K antagonist oral anticoagulants. 2015 , 79, 292-4	4

1549	Validation of Risk Scoring System Excluding Female Sex From CHA2DS2-VASc in Japanese Patients With Nonvalvular Atrial Fibrillation –Subanalysis of the J-RHYTHM Registry. 2015 , 79, 1719-26	30
1548	Left Atrial Function After Radiofrequency Catheter Ablation of Atrial Fibrillation--Can Pre-Ablation Function Predict Contractile Improvement During Follow-up?. 2015 , 79, 2576-83	4
1547	Use of Oral Anticoagulants According to the Degree of Renal Impairment in Japanese Patients With Atrial Fibrillation--Which Non-Vitamin K Antagonist Oral Anticoagulant to Select?. 2015 , 79, 1441-3	1
1546	Use of warfarin in elderly patients with non-valvular atrial fibrillation -- subanalysis of the J-RHYTHM Registry. 2015 , 79, 2345-52	25
1545	New Modified CHA2DS2-VA Scoring System for Japanese Patients With Non-Valvular Atrial Fibrillation. 2015 , 79, 1682-4	1
1544	Silent Atrial Fibrillation: Definition, Clarification, and Unanswered Issues. 2015 , 20, 518-25	15
1543	The Risk/Benefit Analysis of Oral Anticoagulant Treatment in Atrial Fibrillation Using HAS-BLED and CHA2DS2-VASc Score. 2015 , 61, 269-272	
1542	Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. 2015 , 148, 491-498	8
1541	[Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation]. 2015 , 70, 485-92	2
1540	Atrial fibrillation in the military patient: a review. 2015 , 161, 237-43	3
1539	Rotational method simplifies 3-dimensional measurement of left atrial appendage dimensions during transesophageal echocardiography. 2016 , 14, 36	9
1538	Atrial fibrillation guidelines for management: what's new?. 2015 , 10, 426-435	0
1537	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. 2015 , 65, e16-23	31
1536	Rhabdomyolysis complicating percutaneous radiofrequency ablation of persistent atrial fibrillation. 2015 , 1, 169-171	
1535	Anticoagulants for stroke prevention in patients with atrial fibrillation. 2015 , 11, 31-37	
1534	A new gap in the novel anticoagulants' era: undertreatment. 2015 , 26, 793-7	17
1533	Robotic ablation of atrial fibrillation. 2015 , e52560	5
1532	Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. 2015 , 37, 2476-2488.e27	5

1531	Antikoagulation und perioperatives Bridging. 2015 , 37, 413-426	0
1530	Mit Antiarrhythmika gegen Vorhofflimmern. 2015 , 15, 41-47	
1529	Vorhofflimmern: orale Antikoagulation. 2015 , 15, 52-56	
1528	Interventioneller Vorhofohrverschluss. 2015 , 15, 56-63	
1527	Clinical impact of left atrial appendage resection versus preservation during surgical ablation of atrial fibrillation. 2015 , 57, e176-e180	3
1526	Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study. 2015 , 31, 339-44	41
1525	Performance of the "CCS Algorithm" in real world patients. 2015 , 7, 18-21	
1524	"To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists". 2015 , 10, 765-7	
1523	Pathophysiologie des Vorhofflimmerns. 2015 , 15, 36-40	1
1522	Nieuwe orale anticoagulantia. 2015 , 44, 230-236	
1521	Recurrent syncope after left atrial appendage occlusion. 2015 , 85, E58-62	1
1520	Outcome of men and women after atrial fibrillation and stroke. 2015 , 132, 125-31	8
1519	Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation. 2015 , 117, 323-9	28
1518	Attitudes toward Catheter Ablation for Atrial Fibrillation: A Nationwide Survey among Danish Cardiologists. 2015 , 38, 1166-72	
1517	CHA2 DS2 VASc Score as a Predictor of Cardiovascular Events in Ambulatory Patients without Atrial Fibrillation. 2015 , 38, 1412-7	14
1516	Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ? 2. 2015 , 3, 2050312115613350	10
1515	Atrial fibrillation. 2015 , 8, 485-492	3
1514	HEart and BRain interfaces in Acute ischemic Stroke (HEBRAS)--rationale and design of a prospective observational cohort study. 2015 , 15, 213	8

1513	Prevention of cardiovascular diseases. 2015 , 13, 261	5
1512	Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. 2015 , 13, 22	29
1511	A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. 2015 , 13, 29	1
1510	Incident atrial fibrillation in the emergency department in Ontario: a population-based retrospective cohort study of follow-up care. 2015 , 3, E182-91	9
1509	Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. 2015 , 33, 177-83	48
1508	Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. 2015 , 69, 1341-8	13
1507	Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity-Matched Analysis. 2015 , 38, 1310-6	6
1506	Impact of aortic stiffness on the frequency of paroxysmal atrial fibrillation recurrences. 2015 , 70, 414-21	6
1505	Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis. 2015 , 114, 403-9	11
1504	Profile of atrial fibrillation inpatients: Cardiovascular risk factors and cardiac rehabilitation programme delivery and referral patterns. 2015 , 21, 749-55	3
1503	Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study. 2015 , 17, 828-36	28
1502	Do CHA2 DS2 VASc and HAS-BLED scores influence 'real-world' anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre. 2015 , 24, 1297-303	6
1501	Short-Term Heparin Kinetics during Catheter Ablation of Atrial Fibrillation. 2015 , 38, 1142-50	6
1500	Novel oral anticoagulants in atrial fibrillation: which novel oral anticoagulant for which patient?. 2015 , 16, 512-9	10
1499	Masked hypertension and cardiac remodeling in middle-aged endurance athletes. 2015 , 33, 1276-83	23
1498	Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?. 2015 , 94, e1627	5
1497	Thoracoscopic Occlusion of the Left Atrial Appendage. 2015 , 10, 179-82	17
1496	General anesthesia is not superior to local anesthesia for remote magnetic ablation of atrial fibrillation. 2015 , 38, 391-7	9

1495	Identifying predictors of cumulative healthcare costs in incident atrial fibrillation: a population-based study. 2015 , 4,	11
1494	The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?. 2015 , 66, 530-9	1
1493	Cardiac CT and echocardiographic evaluation of peri-device flow after percutaneous left atrial appendage closure using the AMPLATZER cardiac plug device. 2015 , 85, 306-12	51
1492	Smoking, atrial fibrillation, and ischemic stroke: a confluence of epidemics. 2015 , 30, 512-7	10
1491	Non-valvular atrial fibrillation: potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants. 2015 , 16, 491-6	16
1490	Acute embolic occlusion of the right common iliac artery after revision total hip arthroplasty treated with catheter-directed thrombolysis and balloon angioplasty: A case report. 2015 , 3, 2050313X15594816	16
1489	Disappointing Success of Electrical Cardioversion for New-Onset Atrial Fibrillation in Cardiosurgical ICU Patients. 2015 , 43, 2354-9	15
1488	Left Atrial Appendage Morphology and Physiology: "The Missing Piece in the Puzzle". 2015 , 26, 928-933	9
1487	Stroke and death prediction with CHA2DS2-vasc score after myocardial infarction in patients without atrial fibrillation. 2015 , 16, 497-502	20
1486	CE: Atrial Fibrillation: Updated Management Guidelines and Nursing Implications. 2015 , 115, 26-38; quiz 39, 49	7
1485	Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study. 2015 , 36, 1290-8	2
1484	Transcatheter closure of atrial septal defects improves cardiac remodeling and function of adult patients with permanent atrial fibrillation. 2015 , 128, 780-3	4
1483	Ten years differences in recently onset atrial fibrillation and flutter incidence and management. 2014 , 82, 153-9	4
1482	The Need for a Coagulation Assay after Initiation of New Oral Anticoagulants in Patients with Renal Dysfunction: A Case Report. 2015 , 11, 395-7	3
1481	Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study. 2015 , 10, 515-9	6
1480	Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition. 2015 , 56, 395-9	8
1479	Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review. 2015 , 105, 519-26	22
1478	Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?. 2015 , 8, 217-28	11

1477	Anticoagulation in Atrial Fibrillation - Current Concepts. 2015 , 4, 100-7	4
1476	Association of epicardial adipose tissue thickness and inflammation parameters with CHA2DS2-VASASc score in patients with nonvalvular atrial fibrillation. 2015 , 11, 1675-81	17
1475	Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. 2015 , 8, 283-91	6
1474	Flecainide: Current status and perspectives in arrhythmia management. 2015 , 7, 76-85	44
1473	PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION. 2015 , 11, 60-62	1
1472	[Rivaroxaban in non valvular atrial fibrillation: subgroups analysis]. 2014 , 82, 16-9	1
1471	The Role of MicroRNAs in Antiarrhythmic Therapy for Atrial Fibrillation. 2015 , 4, 146-55	26
1470	The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. 2015 , 45, 9-19	33
1469	Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients. 2015 , 11, 263-77	5
1468	Predictive factors for obtaining a correct therapeutic range using antivitamin K anticoagulants: a tertiary center experience of patient adherence to anticoagulant therapy. 2015 , 9, 1271-8	2
1467	The Use of Novel Oral Anticoagulants in Atrial Fibrillation. 2015 , 15, 97-100	1
1466	Developments and risk analysis in anticoagulation. 2015 , 10, 66-73	1
1465	Variation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation. 2015 , 3, 130-45	8
1464	The SAME-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?. 2015 , 114, 657-9	17
1463	Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre. 2015 , 12, 334-40	11
1462	Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation. 2015 , 4, 44-6	2
1461	Epidemiology, diagnosis, and management of atrial fibrillation in women. 2015 , 7, 605-14	23
1460	Percutaneous closure of the left atrial appendage for secondary prevention of stroke in patients with atrial fibrillation and contraindications to chronic anticoagulant therapy. 2015 , 11, 14-8	2

1459	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. 2015 , 10, 63-73		2
1458	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. 2015 , 11, 317-32		9
1457	Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management. 2015 , 15, 120-6		0
1456	CHADS2 and CHA2DS2-VASc scoring systems for predicting atrial fibrillation following cardiac valve surgery. <i>PLoS ONE</i> , 2015 , 10, e0123858	3.7	21
1455	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0126512	3.7	18
1454	Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0142222	3.7	6
1453	Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. 2015 , 114, 1076-84		18
1452	Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. <i>PLoS ONE</i> , 2015 , 10, e0123574	3.7	36
1451	New Oral Anticoagulants in Coronary Artery Disease. 2015 , 15, 101-5		5
1450	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. 2015 , 114, 1113-26		52
1449	Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. 2015 , 8, 231-42		29
1448	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. 2015 , 114, 826-34		77
1447	Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels. 2015 , 2015, 402481		3
1446	Improvement of Predictive Value for Thromboembolic Risk by Incorporating Left Atrial Functional Parameters in the CHADS2 and CHA2DS2-VASc Scores. 2015 , 56, 286-92		13
1445	Surgical Left Atrial Appendage Exclusion Does Not Impair Left Atrial Contraction Function: A Pilot Study. 2015 , 2015, 318901		14
1444	Rationale for Development of New Oral Anticoagulants. 2015 , 15, 89-91		
1443	Patients could provide initial differential diagnoses. 2015 , 65, 116-7		
1442	Atrial fibrillation: Reducing risks and enhancing lives. 2015 , 21, 208-214		

1441	Atrial fibrillation and its influence on stroke risk. 2015 , 11		
1440	Estudo FATA: Prevalência de Fibrilhação Auricular e Terapêutica Antitrombótica nos Cuidados de Saúde Primários de um Concelho do Norte de Portugal. 2015 , 28, 35		10
1439	Atrial Fibrillation: Pathophysiology and Therapeutic Options. 2015 , 29, 1333-40		17
1438	Ablation Therapy for Atrial Fibrillation: Implications for the Anesthesiologist. 2015 , 29, 1341-56		5
1437	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. <i>European Heart Journal</i> , 2015 , 36, 1470-7	9.5	42
1436	Incident perioperative AF increased risk for ischemic stroke at 1 year, with greater risk after noncardiac surgery. 2015 , 162, JC11		
1435	NUEVOS ANTICOAGULANTES ORALES EN FIBRILACION AURICULAR. 2015 , 26, 223-233		0
1434	Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VerT trial. 2015 , 11, 147-51		
1433	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. 2015 , 75, 979-98		9
1432	[Appropriate medication prescribing in older people]. 2015 , 36, 677-89		9
1431	Cardiac CT angiography for device surveillance after endovascular left atrial appendage closure. 2015 , 16, 1198-206		85
1430	The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. 2015 , 113, 671-3		17
1429	Imaging before and after catheter ablation of atrial fibrillation. 2015 , 96, 1113-23		7
1428	Underuse and overuse of anticoagulation for atrial fibrillation: A study in Indigenous and non-Indigenous Australians. 2015 , 191, 20-4		16
1427	Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation. 2015 , 15, 323-35		8
1426	'Realworld' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. 2015 , 113, 1159-61		16
1425	A prospective randomized evaluation of the TriGuard HDH embolic DEFLECTION device during transcatheter aortic valve implantation: results from the DEFLECT III trial. <i>European Heart Journal</i> , 2015 , 36, 2070-2078	9.5	178
1424	Comparison of contact force-guided procedure with non-contact force-guided procedure during left atrial mapping and pulmonary vein isolation: impact of contact force on recurrence of atrial fibrillation. 2015 , 104, 861-70		19

1423	Antithrombotic treatment in elderly patients with atrial fibrillation. 2015 , 215, 171-181		
1422	Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. 2015 , 13, 811-24		5
1421	Stroke and atrial fibrillation: where to go from here?. <i>Stroke</i> , 2015 , 46, 605-7	6.7	3
1420	Criteria for prescribing dabigatrin extexilate and rivaroxaban really appropriate? Authors' reply. 2015 , 49, 155		1
1419	Contraception and cardiovascular disease. <i>European Heart Journal</i> , 2015 , 36, 1728-34, 1734a-1734b	9.5	45
1418	Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials. 2015 , 8, 103-14		7
1417	Harnessing the power of real-life data. 2015 , 17, D9-D14		4
1416	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. 2015 , 170, 490-7.e1		22
1415	Ryanodine receptor cluster fragmentation and redistribution in persistent atrial fibrillation enhance calcium release. 2015 , 108, 387-98		58
1414	Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. 2015 , 69, 840-5		17
1413	Contemporary measures to reduce the risk of embolic events in patients with atrial fibrillation. 2015 , 11, 635-43		1
1412	New antihyarrhythmic drugs for atrial fibrillation. 2015 , 11, 705-17		1
1411	Experience of left atrial appendage closure performed under conscious sedation. 2015 , 23, 394-8		14
1410	Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. 2015 , 37, 2837-51		13
1409	Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. 2015 , 8, 1925-1932		61
1408	Left atrial appendage closure for stroke prevention in atrial fibrillation: response to an unmet need with an unclear direction. 2015 , 8, 8-10		1
1407	Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. 2015 , 4, e001349		6
1406	Monitoring and management of patients with chronic atrial fibrillation: Is there added value in the identification of clinical phenotypes?. 2015 , 14, 382-3		

1405	Conundrums for Atrial Fibrillation Management in Older Adults. 2015 , 4, 368-376		
1404	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. 2015 , 31, 1207-18		36
1403	Asian strategy for stroke prevention in atrial fibrillation. 2015 , 17 Suppl 2, ii31-9		21
1402	Management of Bleeding Associated with New Oral Anticoagulants. 2015 , 41, 788-801		14
1401	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> 2017 , 38, 1710-1716	9.5	38
1400	Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST. 2015 , 43, 1125-1125-64		20
1399	Percutaneous Left Atrial Appendage Closure With the Watchman Device: Long-Term Results Up to 5 Years. 2015 , 8, 1915-1921		29
1398	Symptom burden, Metabolic profile, Ultrasound findings, Rhythm, neurohormonal activation, haemodynamics and health-related quality of life in patients with atrial Fibrillation (SMURF): a protocol for an observational study with a randomised interventional component. 2015 , 5, e008723		9
1397	Progress of anticoagulation therapy in atrial fibrillation. 2015 , 145, 124-130		
1396	Direct factor Xa inhibitor edoxaban: from bench to clinical practice. 2015 , 8, 707-25		1
1395	Percutaneous left atrial appendage closure: a review of the WATCHMAN clinical trial experience. 2015 , 7, 333-344		
1394	Anticoagulants oraux directs (AOD): du retour d'expérience à la sécurisation de la prise en charge médicamenteuse. 2015 , 50, 370-379		
1393	Case 4-2015: use of the lariat device for left atrial appendage closure. 2015 , 29, 522-31		2
1392	The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. 2015 , 67 Suppl 2, S13-34		9
1391	Patient blood management implementation strategies and their effect on physicians' risk perception, clinical knowledge and perioperative practice - the frankfurt experience. 2015 , 42, 91-7		25
1390	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. <i>European Heart Journal</i> , 2015 , 36, 653-6	9.5	41
1389	The new Canadian Cardiovascular Society algorithm for antithrombotic therapy of atrial fibrillation is appropriately based on current epidemiologic data. 2015 , 31, 20-3		7
1388	Endoscopic ultrasound: an alternative to transesophageal echocardiography for patients with esophageal varices during a structural interventional procedure. 2015 , 68, 70-1		1

1387	A new mutation in the ryanodine receptor 2 gene (RYR2 C2277R) as a cause catecholaminergic polymorphic ventricular tachycardia. 2015 , 68, 71-3		3
1386	Guía de práctica clínica de la ESC 2014 sobre el diagnóstico y manejo de la miocardiopatía hipertrófica. 2015 , 68, 63.e1-63.e52		4
1385	Anticoagulant treatment in nonvalvular atrial fibrillation there is room for improvement. 2015 , 215, 98-9		
1384	La ecografía endoscópica, una alternativa a la ecografía transesofágica para pacientes con varices esofágicas durante el intervencionismo estructural. 2015 , 68, 70-71		5
1383	Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. 2015 , 40, 166-71		18
1382	Antithrombotic treatment in elderly patients with atrial fibrillation. 2015 , 215, 171-81		14
1381	Can the cost of atrial fibrillation be reduced?. 2015 , 34, 13-15		
1380	Antithrombotic management of atrial fibrillation in the elderly. 2015 , 99, 417-30		9
1379	Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study. 2015 , 183, 105-10		14
1378	Frailty Syndrome in cardiovascular disease: clinical significance and research tools. 2015 , 14, 303-9		17
1377	Guía de práctica clínica de la ESC sobre revascularización miocárdica, 2014. 2015 , 68, 144.e1-144.e95		1
1376	Catheter ablation for asymptomatic atrial fibrillation?. 2015 , 13, 243-8		1
1375	Detection of paroxysmal atrial fibrillation by prolonged electrocardiographic recording after ischaemic stroke in patients aged. 2015 , 108, 189-96		6
1374	Accuracy of methods for diagnosing atrial fibrillation using 12-lead ECG: A systematic review and meta-analysis. 2015 , 184, 175-183		23
1373	Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 635-42	15.1	187
1372	Association of the CHADS2 and CHA 2DS 2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients. 2015 , 40, 240-7		17
1371	[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room]. 2015 , 40, 1-9		4
1370	Is it possible to reduce the cost of atrial fibrillation?. 2015 , 34, 13-5		

1369	Data strengthen to support recommending anticoagulant therapy for all atrial fibrillation patients with a CHA2DS2-VASc score â1. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 643-4	15.1	4
1368	Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. 2015 , 180, 246-54		113
1367	Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. 2015 , 30, 777-82		8
1366	Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. 2015 , 128, 509-18.e2		166
1365	Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure. 2015 , 101, 877-83		61
1364	Device-detected atrial fibrillation: what to do with asymptomatic patients?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 281-94	15.1	43
1363	Predictors of conversion of recent-onset atrial fibrillation treated with vernakalant. 2015 , 38, 196-200		9
1362	Management of peri-operative anti-thrombotic therapy. 2015 , 70 Suppl 1, 58-67, e21-3		38
1361	The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders. 2015 , 135, 217-25		24
1360	Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin. 2015 , 35, 109-19		17
1359	Dilemmas in the use of new oral anticoagulants. 2015 , 108, 679-81		2
1358	Antithrombotic therapy after left atrial appendage closure. 2015 , 13, 105-9		8
1357	One-Year Outcomes of Emergency Department Patients With Atrial Fibrillation: A Prospective, Multicenter Registry in China. <i>Angiology</i> , 2015 , 66, 745-52	2.1	8
1356	[Interventional treatment for paroxysmal atrial fibrillation : which is the optimal ablation approach?]. 2015 , 40, 25-30		2
1355	Criteria for prescribing dabigatrin extexilate and rivaroxaban really appropriate? Comment. 2015 , 49, 154		1
1354	Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. 2015 , 39, 149-54		28
1353	Prediction of atrial fibrillation recurrence after cardioversion in patients with left-atrial dilation. 2015 , 16, 335-41		29
1352	Risikofaktoren ff.Schlaganfall und ihre therapeutische Beeinflussung. 2015 , 16, 32-44		

1351	The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on vitamin K antagonist. 2015 , 10, 157-63	8
1350	Assessment of CHADS2 and CHA 2DS 2-VASc scores in obstructive sleep apnea patients with atrial fibrillation. 2015 , 19, 531-7	17
1349	Safety and efficacy of external electrical cardioversion in patients with left ventricular leads. 2015 , 104, 439-45	3
1348	Outcome of cryoballoon ablation for atrial fibrillation. Medium-term follow-up from a single center. 2015 , 40 Suppl 2, 125-9	4
1347	Managing atrial fibrillation. 2015 , 65, 532-9	15
1346	[Innovative techniques in atrial fibrillation therapy]. 2015 , 40, 37-44	
1345	Indications des ablations dans le traitement des arythmies cardiaques. 2015 , 24, 172-182	
1344	Anticoagulation therapy in 2015: where we are and where we are going. 2015 , 39, 264-72	10
1343	Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. 2015 , 53, 185-97	59
1342	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. 2015 , 278, 1-18	53
1341	Increased stroke risk in atrial fibrillation patients with heart failure: does ejection fraction matter?. <i>Stroke</i> , 2015 , 46, 608-9	6.7 10
1340	Comparaci3n de las ecuaciones de filtrado glomerular estimado para determinar la posolog3a de los nuevos anticoagulantes orales para pacientes con fibrilaci3n auricular. 2015 , 68, 497-504	27
1339	Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. 2015 , 41, 146-53	14
1338	Target-specific oral anticoagulants and the hospitalist. 2015 , 43, 1-12	0
1337	Usefulness of intracardiac echocardiography during pulmonary vein isolation with the novel multipolar irrigated ablation catheter (nMARQâ) 2015 , 44, 39-45	4
1336	Left atrial appendage occlusion for stroke prevention. 2015 , 40, 429-76	6
1335	Management of stroke prevention in Bulgarian patients with non-valvular atrial fibrillation (BUL-AF Survey). 2015 , 187, 683-5	2
1334	Account should also have been taken of the harm versus benefit of aspirin use. 2015 , 187, 557-8	

1333	Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. 2015 , 8, S12-20		63
1332	Palpitaciones. 2015 , 19, 1-6		
1331	The case against using hypertension as the only criterion for oral anticoagulation in atrial fibrillation. 2015 , 31, 576-9		4
1330	A Systematic Review on the Progression of Paroxysmal to Persistent Atrial Fibrillation: Shedding New Light on the Effects of Catheter Ablation. 2015 , 1, 105-115		43
1329	Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis. <i>Stroke</i> , 2015 , 46, 2477-81	6.7	41
1328	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. 2015 , 26, e31-3		2
1327	Risk and prediction of dementia in patients with atrial fibrillation--a nationwide population-based cohort study. 2015 , 199, 25-30		63
1326	Epidemiologic Trends in Hospitalized Ischemic Stroke from 2002 to 2010: Results from a Large Italian Population-Based Study. 2015 , 24, 1917-23		16
1325	Dabigatran et rivaroxaban dans la prévention secondaire de l'accident vasculaire cérébral dans la fibrillation atriale: les outils. 2015 , 50, 201-209		
1324	Clinical Practice Guideline (CPG). Recommendations on strategy for reducing risk of heart failure patients requiring noncardiac surgery: Reducing risk of heart failure patients must be in noncardiac surgery. 2015 , 62, 359-419		1
1323	Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. 2015 , 136, 148-53		46
1322	Postinterventional use of dabigatran in patients undergoing ablation therapy using an accelerated loading dose scheme - a single center experience. 2015 , 136, 486-7		1
1321	Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). 2015 , 169, 464-71.e2		17
1320	Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. 2015 , 12, 2368-75		44
1319	NT-proBNP in "low risk" patients with atrial fibrillation. 2015 , 179, 493-4		2
1318	Reasons for non-adherence to practice guidelines on stroke prevention in patients with atrial fibrillation: A cross-sectional study in primary care. 2015 , 187, 525-6		7
1317	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial. <i>Stroke</i> , 2015 , 46, 2523-8	6.7	43
1316	Arrhythmia. 2015 , 707-734		

1315	Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery. 2015 , 11, 525-9		3
1314	Pericarditis-associated atrial fibrillation. 2015 , 101, 1439-40		7
1313	Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?. 2015 , 104, 799-802		7
1312	Temporal trends and sex differences in pulmonary vein isolation for patients with atrial fibrillation. 2015 , 12, 1979-86		37
1311	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. 2015 , 44, 874-8		51
1310	Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight. <i>Stroke</i> , 2015 , 46, 5-6	6.7	4
1309	Determinants and consequences of differences in quality of anticoagulation therapy with vitamin K antagonists. 2015 , 136, 183-4		1
1308	Patient outcomes according to adherence to treatment guidelines for rhythm control of atrial fibrillation. 2015 , 4,		9
1307	Patients with atrial fibrillation and CHA2DS2-VASc score 1: "To anticoagulate or not to anticoagulate? That is the question!". 2015 , 12, 2515-20		4
1306	Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. <i>European Heart Journal</i> , 2015 , 36, 1805-11	9.5	293
1305	How to define valvular atrial fibrillation?. 2015 , 108, 530-9		74
1304	Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. 2015 , 116, 733-9		49
1303	Management of Anticoagulation in Patients With Atrial Fibrillation. 2015 , 314, 291-2		9
1302	Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. 2015 , 58, 177-94		26
1301	La puntuació CHADS2 como predictor de riesgo de ictus en ausencia de fibrilación auricular en pacientes hipertensos de 65 o más años. 2015 , 68, 485-491		13
1300	Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term. <i>European Heart Journal</i> , 2015 , 36, 1794-7	9.5	10
1299	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. <i>Stroke</i> , 2015 , 46, 2168-74	6.7	56
1298	Polypharmacy in the Aging Patient: Management of Hypertension in Octogenarians. 2015 , 314, 170-80		83

1297	Atrial fibrillation, CHA2DS2-VASc score, antithrombotics and risk of traffic accidents: A population-based cohort study. 2015 , 197, 133-9	4
1296	Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: On-treatment analysis of the randomized controlled MANTRA-PAF trial. 2015 , 198, 108-14	24
1295	Management of atrial fibrillation: recommendations from NICE. 2015 , 76, C108-12	3
1294	Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice. 2015 , 49, 171-9	3
1293	The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis. 2015 , 195, 237-42	22
1292	Quality of Vitamin K Antagonist Anticoagulation in Spain: Prevalence of Poor Control and Associated Factors. 2015 , 68, 761-8	10
1291	Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. 2015 , 41, 178-87	22
1290	Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants?. 2015 , 41, 195-207	15
1289	Should patients on vitamin K antagonists be treated differently?. <i>European Heart Journal</i> , 2015 , 36, 1431-3	3
1288	Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks. 2015 , 136, 396-401	15
1287	Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation and contraindication for anticoagulation. 2015 , 171, 426-32	2
1286	Stroke detection and prevention in atrial fibrillation. 2015 , 65, 332-3	
1285	Asymptomatic atrial fibrillation after cryptogenetic stroke: incidence, clinical significance, and therapeutic implications. 2015 , 8, 249-51	
1284	Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. 2015 , 13, 341-53	7
1283	Should we administrate anticoagulants to critically ill patients with new onset supraventricular arrhythmias?. 2015 , 108, 217-9	5
1282	[Oral anticoagulation for non-valvular atrial fibrillation in the elderly]. 2015 , 50, 134-42	5
1281	Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patients. 2015 , 185, 250-5	11
1280	Anaesthetic and sedative agents used for electrical cardioversion. 2015 , CD010824	12

1279	[Should beta blockers remain as first-line therapy in the treatment of patients with atrial fibrillation and heart failure?]. 2015 , 41, 395-6	
1278	Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. 2015 , 26, 243-9	10
1277	Ablation of atrial fibrillation and esophageal injury: Role of bipolar and unipolar energy using a novel multipolar irrigated ablation catheter. 2015 , 12, 1120-7	8
1276	Reply: Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: A prospective observational study. 2015 , 190, 67	
1275	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. 2015 , 128, 1007-14.e2	29
1274	Ablation de FA : quel coût de séjour pour quel tarif de remboursement ?. 2015 , 50, 105-113	1
1273	[Cerebellar stroke by cannabis consumption]. 2015 , 144, 479-80	3
1272	Bibliometric analysis of the top 100 cited cardiovascular articles. 2015 , 115, 972-81	80
1271	Effective practical management of patients with atrial fibrillation when using new oral anticoagulants. 2015 , 47, 278-88	
1270	[Pre-interventional, peri-interventional and post-interventional anticoagulation in the setting of catheter ablation for atrial fibrillation : current practice and practical approach]. 2015 , 40, 45-9	1
1269	[Interventional stroke prophylaxis : endocardial and epicardial left atrial appendage closure]. 2015 , 40, 50-9	0
1268	[Prevalence and risk factors of atrial fibrillation in Germany : data from the Gutenberg Health Study]. 2015 , 40, 8-15	6
1267	[Rate and rhythm control in atrial fibrillation : pharmacological approaches]. 2015 , 40, 16-24	1
1266	[Treatment of atrial fibrillation in intensive care units and emergency departments]. 2015 , 110, 614-20	4
1265	Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. 2015 , 71, 549-67	106
1264	The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. 2015 , 104, 871-6	96
1263	Is diabetes a hypercoagulable state? A critical appraisal. 2015 , 52, 1007-16	35
1262	Pharmacists' role in handling problems with prescriptions for antithrombotic medication in Belgian community pharmacies. 2015 , 37, 656-68	7

1261	Diagnostik und Behandlung von Vorhofflimmern. 2015 , 12, 49-57	
1260	Perkutaner Vorhofohrverschluss. 2015 , 9, 54-60	
1259	Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide. 2015 , 23, 182-9	4
1258	Therapeutic management in ambulatory elderly patients with atrial fibrillation: the S.AGES cohort. 2015 , 19, 219-27	7
1257	Who gets stroke prevention? Stroke prevention in atrial fibrillation patients in the inpatient setting. 2015 , 24, 488-94	4
1256	Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. 2015 , 87, 1209-15	51
1255	Blood pressure control versus atrial fibrillation management in stroke prevention. 2015 , 17, 553	4
1254	Percutaneous interventions for left atrial appendage exclusion: options, assessment, and imaging using 2D and 3D echocardiography. 2015 , 8, 472-488	110
1253	Prevalence and antithrombotic management of atrial fibrillation in hospitalised patients. 2015 , 101, 884-93	14
1252	Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline?. 2015 , 127, 396-404	1
1251	Implications for your practice: Important changes in the 2014 guideline for the management of patients with atrial fibrillation. 2015 , 127, 535-8	2
1250	Reduction of Radiation Exposure in Atrial Fibrillation Ablation Using a New Image Integration Module: A Prospective Randomized Trial in Patients Undergoing Pulmonary Vein Isolation. 2015 , 26, 747-53	12
1249	Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda. 2015 , 191, 244-53	23
1248	[Anticoagulation in the aged patient with atrial fibrillation: What are prescribing cardiologists, geriatricians and general practitioners?]. 2015 , 36, 509-15	4
1247	Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). 2015 , 116, 37-42	25
1246	Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study. 2015 , 26, 508-14	15
1245	Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF study. 2015 , 215, 73-82	
1244	Optimizing atrial fibrillation management: from ICU and beyond. 2015 , 148, 859-864	35

1243	A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark. 2015 , 33, 967-79		11
1242	Ranolazine for the treatment of atrial fibrillation. 2015 , 24, 825-36		8
1241	2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. 2015 , 21, 3		9
1240	Comparison of left atrial dimensions in CT and echocardiography as predictors of long-term success after catheter ablation of atrial fibrillation. 2015 , 43, 237-44		25
1239	Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. 2015 , 1, 83-5		0
1238	[Oral anticoagulation in patients with atrial fibrillation and chronic kidney disease]. 2015 , 144, 480		
1237	Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. 2015 , 386, 303-10		97
1236	Safety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: a pilot study. 2015 , 108, 122-31		5
1235	Patients with atrial fibrillation and a CHA ₂ DS ₂ -VASc score of 1: are they at low or high stroke risk?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1395-7	15.1	8
1234	Prognostications of fibrillations. <i>Stroke</i> , 2015 , 46, 1155-7	6.7	2
1233	Safety of new oral anticoagulants. 2015 , 350, h1679		5
1232	Real-World Observations with Dronedaronone Compared to Other Anti-Arrhythmic Drugs in Recurrent Atrial Fibrillation. 2015 , 5, 1088-1095		0
1231	Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). 2015 , 15, 235-42		8
1230	Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. <i>Stroke</i> , 2015 , 46, 667-72	6.7	36
1229	Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. 2015 , 131, 2176-84		362
1228	Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin. 2015 , 20, 117		
1227	[Perioperative evaluation and treatment of cardiovascular risk patients for noncardiac surgery : Guidelines of the European Society of Cardiology/European Society of Anaesthesiology 2014]. 2015 , 64, 324-8		1
1226	Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation. 2015 , 11, 937-48		4

1225	Drugs acting on the heart: anti-arrhythmics. 2015 , 16, 232-236		
1224	Development and validation of an arrhythmia-specific scale in tachycardia and arrhythmia with focus on health-related quality of life. 2015 , 30, 98-108		15
1223	Misconceptions and Facts About Atrial Fibrillation. 2015 , 128, 938-42		8
1222	Sleep-disordered breathing and atrial fibrillation: review of the evidence. 2015 , 23, 79-86		10
1221	Anticoagulant therapy in atrial fibrillation: vitamin K antagonists or novel oral anticoagulant drugs?. 2015 , 16, 139-41		3
1220	Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines. 2015 , 94, e377		12
1219	Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. 2015 , 14, 683-95		9
1218	Practical management of anticoagulation in patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1340-1360	15.1	67
1217	Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice. 2015 , 108, 269-76		77
1216	The CHADS2 Score to Predict Stroke Risk in the Absence of Atrial Fibrillation in Hypertensive Patients Aged 65 Years or Older. 2015 , 68, 485-91		6
1215	New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials. 2015 , 13, 577-83		5
1214	Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting. 2015 , 35, 693-705		2
1213	A Clinical Decision Instrument for 30-Day Death After an Emergency Department Visit for Atrial Fibrillation: The Atrial Fibrillation in the Emergency Room (AFTER) Study. 2015 , 66, 658-668.e6		13
1212	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?. 2015 , 4, e001573		17
1211	Edoxaban: a review in nonvalvular atrial fibrillation. 2015 , 15, 351-61		4
1210	Effects of a new antiarrhythmic drug SS-68 on electrical activity in working atrial and ventricular myocardium of mouse and their ionic mechanisms. 2015 , 128, 202-7		2
1209	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. 2015 , 17, 64		1
1208	Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. <i>European Heart Journal</i> , 2015 , 36, 3291-6	9.5	31

1207	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. 2015 , 75, 1627-44		30
1206	Optimal Stroke Prevention in the Geriatric Patient with Atrial Fibrillation: Position Paper of an Interdisciplinary Expert Panel. 2015 , 65, 505-14		3
1205	2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). 2015 , 8, 1522-51		1
1204	Stroke prevention in atrial fibrillation: Still room for practice improvement. 2015 , 108, 541-3		
1203	Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. 2015 , 37, 2506-2514.e4		106
1202	Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation. 2015 , 24, 2845-53		5
1201	Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1339-47	15.1	92
1200	Clinical development of rivaroxaban: emerging new clinical evidences?. 2015 , 11, 565-83		
1199	Asymptomatic Atrial Fibrillation: The Case for Screening to Prevent Stroke. 2015 , 314, 1911-2		32
1198	[Non-vitamin K oral anticoagulants and cardioversion]. 2015 , 64, 368-71		
1197	Fibrillation atriale pfiopfatoire : facteurs de risque et conduite ^tenir (podcast). 2015 , 19, 178-185		
1196	Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes. 2015 , 10, 641-5		4
1195	Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study. <i>Stroke</i> , 2015 , 46, 2432-7	6.7	56
1194	The evolving role of dabigatran etexilate in clinical practice. 2015 , 16, 2053-72		
1193	International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events. 2015 , 16, 1109-18		10
1192	UK academic general practice and primary care. 2015 , 351, h4164		3
1191	Loss of local capture of the pulmonary vein myocardium after antral isolation: prevalence and clinical significance. 2015 , 26, 242-50		8
1190	Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. 2015 , 13, 182-90		20

1189	Second generation of cryoballoons can improve efficiency of cryoablation for atrial fibrillation. 2015 , 38, 129-35	22
1188	Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. 2015 , 63, 71-6	62
1187	Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1. 2015 , 17, D42-D52	4
1186	Are We Ready for Mass Screening to Detect Atrial Fibrillation?. 2015 , 131, 2167-8	14
1185	Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation. 2015 , 17, 61	11
1184	Percutaneous occlusion of the left atrial appendage: An expert consensus statement. 2015 , 108, 460-7	6
1183	The Long-Term Use of Warfarin Among Atrial Fibrillation Patients Discharged From an Emergency Department With a Warfarin Prescription. 2015 , 66, 347-354.e2	27
1182	Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation: a cohort study. 2015 , 13, 1971-9	28
1181	Anticoagulation after catheter ablation of atrial fibrillation guided by implantable cardiac monitors. 2015 , 38, 688-93	31
1180	Management of cardiovascular conditions in a cohort of patients with HIV: experience from a joint HIV/cardiology clinic. 2015 , 15, 442-6	6
1179	Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation. 2015 , 4, 367-76	1
1178	Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. 2015 , 37, 1111-20	44
1177	Impact of Sex Difference on Severity and Functional Outcome in Patients with Cardioembolic Stroke. 2015 , 24, 2613-8	17
1176	Role of Endovascular Closure of the Left Atrial Appendage in Stroke Prevention for Atrial Fibrillation. 2015 , 17, 65	2
1175	Cardiac computed tomography in current cardiology guidelines. 2015 , 9, 514-23	64
1174	Stroke Risk Factors Beyond the CHA ₂ DS ₂ -VASc Score: Can We Improve Our Identification of "High Stroke Risk" Patients With Atrial Fibrillation?. 2015 , 116, 1781-8	47
1173	Diabetes mellitus und Herz. 2015 , 9, S120-S124	1
1172	Medikamentöse Rhythmuskontrolle und orale Antikoagulation bei Patienten mit Vorhofflimmern: Bedeutung pharmakokinetischer Interaktionen ff.die klinische Praxis. 2015 , 4, 114-119	

1171 [Cardiac rehabilitation in patients with atrial fibrillation]. **2015**, 140, 1006-12

1170 Atrial fibrillation in heart failure: what should we do?. *European Heart Journal*, **2015**, 36, 3250-7 9.5 172

1169 Demonstrating the Value of Contact Force Sensing: More Difficult Than Meets the Eye. **2015**, 132, 901-3 16

1168 Incidence and prognostic significance of new onset atrial fibrillation/flutter in acute pericarditis. **2015**, 101, 1463-7 34

1167 Assessment of risk factors for bleeding in Japanese patients with non-valvular atrial fibrillation receiving warfarin treatment: A subanalysis of the J-RHYTHM Registry. **2015**, 201, 308-10 2

1166 International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor. **2015**, 24, 2223-8 9

1165 Thirty-day mortality in ED patients with new onset atrial fibrillation and actively treated cancer. **2015**, 33, 1483-8 12

1164 Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. **2015**, 199, 319-25 33

1163 Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3 days of treatment: Relation to coagulation factors and thrombin generation. **2015**, 136, 832-8 14

1162 Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. *Stroke*, **2015**, 46, 2830-7 6.7 5

1161 Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. **2015**, 132, 1252-60 140

1160 Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAME-TT2R2 score. **2015**, 1, 150-2 34

1159 Baseline Characteristics and Prognostic Implications of Pre-Existing and New-Onset Atrial Fibrillation After Transcatheter Aortic Valve Implantation: Results From the FRANCE-2 Registry. **2015**, 8, 1346-1355 77

1158 Gastrointestinal haemorrhage in atrial fibrillation patients: impact of quality of anticoagulation control. **2015**, 1, 265-72 9

1157 Controversies in Cardiology. **2015**,

1156 Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013. **2015**, 101, 1748-54 35

1155 Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients. **2015**, 4, 21

1154 Prise en charge de la fibrillation atriale en médecine d'urgence. Recommandations de la Société française de médecine d'urgence en partenariat avec la Société française de cardiologie. **2015**, 5, 260-279 3

1153	Stroke: cardiac causes and their management. <i>European Heart Journal</i> , 2015 , 36, 2339-41	9.5	1
1152	Reduction of radiation exposure during ablation of atrial fibrillation. 2015 , 40, 883-91		11
1151	Dosing of rivaroxaban by indication: getting the right dose for the patient. 2015 , 11, 1665-77		2
1150	Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study. 2015 , 170, 1033-1041.e1		9
1149	Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). 2015 , 4, e002031		30
1148	Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms. 2015 , 388, 1105-12		3
1147	Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey. 2015 , 108, 544-53		14
1146	Pulmonary Vein Isolation Compared to Rate Control in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis. 2015 , 24, 744-52		6
1145	Relationship between CHA2DS2-VASc score and atrial electromechanical function in patients with paroxysmal atrial fibrillation: A pilot study. 2015 , 66, 382-7		10
1144	Stroke Risk Perception in Atrial Fibrillation Patients is not Associated with Clinical Stroke Risk. 2015 , 24, 2527-32		3
1143	Comments about the status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. 2015 , 215, 542		
1142	Satisfaction with medical care in patients with atrial fibrillation treated with vitamin K antagonists versus new oral anticoagulants. 2015 , 68, 537-9		1
1141	Poor Anticoagulation Control in Atrial Fibrillation: How Much Longer?. 2015 , 68, 740-2		1
1140	Mal control de la anticoagulaci3n en la fibrilaci3n auricular. ¿Hasta cu3ndo?. 2015 , 68, 740-742		10
1139	Clinical Practice Guideline (CPG). Recommendations on strategy for reducing risk of heart failure patients requiring noncardiac surgery: reducing risk of heart failure patients in noncardiac surgery. 2015 , 62, 359-419		7
1138	[Therapeutic equivalence of the new oral anticoagulants]. 2015 , 41, 382-6		
1137	Long sheath filling defect during left atrial appendage occlusion device placement. 2015 , 199, 193-4		1
1136	Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. 2015 , 68, 497-504		11

1135	Calidad de la anticoagulación con antagonistas de la vitamina K en España: prevalencia de mal control y factores asociados. 2015 , 68, 761-768		68
1134	APOLLO I: Anticoagulation control in atrial fibrillation. 2015 , 34, 337-45		2
1133	Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2271-2281	15.1	127
1132	New antiarrhythmic targets in atrial fibrillation. 2015 , 11, 645-54		2
1131	Balloon-based pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation (cryoballoon and laserballoon). 2015 , 11, 663-71		3
1130	Identifying postoperative atrial fibrillation in cardiac surgical patients posthospital discharge, using iPhone ECG: a study protocol. 2015 , 5, e006849		5
1129	Stroke with atrial fibrillation or atrial flutter: a descriptive population-based study from the Brest stroke registry. 2015 , 15, 63		7
1128	Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. 2015 , 18, 2318-27		34
1127	Presence and extent of coronary artery disease as predictor for AF recurrences after catheter ablation: The Leipzig Heart Center AF Ablation Registry. 2015 , 181, 188-92		10
1126	Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. 2015 , 181, 247-54		5
1125	CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. 2015 , 135, 62-7		10
1124	The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review. 2015 , 14, 98-107		16
1123	Mid-regional proadrenomedullin levels predict recurrence of atrial fibrillation after catheter ablation. 2015 , 180, 129-33		7
1122	Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. 2015 , 33, 271-83		14
1121	Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation. 2015 , 39, 129-38		2
1120	Biomarkers: GDF-15 and risk stratification in atrial fibrillation. 2015 , 12, 8-9		14
1119	Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: a Danish nationwide cohort study. 2015 , 277, 447-55		22
1118	Omega-3 fatty acids in cardiovascular disease--an uphill battle. 2015 , 92, 41-7		65

1117	[Progress of anticoagulation therapy in atrial fibrillation]. 2015 , 145, 124-30	5
1116	Hemostasis and Thrombosis. 2015 ,	3
1115	Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome. 2015 , 40 Suppl 1, 18-26	17
1114	Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation. 2015 , 10, 128-33	33
1113	Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. 2015 , 30, 491-8	81
1112	Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. 2015 , 115, 47-51	53
1111	Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF Study. 2015 , 215, 73-82	15
1110	Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. 2015 , 39, 95-100	24
1109	Validation of the Risk Estimator Decision Aid for Atrial Fibrillation (RED-AF) for predicting 30-day adverse events in emergency department patients with atrial fibrillation. 2015 , 65, 13-21.e3	15
1108	[Anticoagulation in atrial fibrillation in the elderly: the geriatrician point of view with a focus on the direct oral anticoagulants]. 2015 , 36, 22-30	7
1107	Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. <i>European Heart Journal</i> , 2015 , 36, 120-8	9.5 82
1106	Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. 2015 , 14, 7-20	19
1105	Dissociated pulmonary vein activity after pulmonary vein isolation for paroxysmal atrial fibrillation: a predictor for recurrence?. 2015 , 26, 7-13	6
1104	Psychological effects of treatment with new oral anticoagulants in elderly patients with atrial fibrillation: a preliminary report. 2015 , 27, 99-102	20
1103	Dissolution of large intracardiac thrombus, potential role of the emerging oral fibrinolytic agent. 2016 , 25, 62-6	
1102	Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation. 2016 , 12, 443-449	
1101	Transcatheter left atrial appendage occlusion: patient selection and perspectives. 2016 , Volume 7, 91-97	
1100	Cardiovascular disease in men: An overview for primary care nurses. 2016 , 2016, 28-30	

1099	Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. 2016 , 12, 465-470	1
1098	Implications of the NICE technology appraisal of edoxaban. 2016 , 22, 297-299	
1097	British Society for Heart Failure: 18th Annual Meeting. 2016 , 11, 144-148	1
1096	The Correlation between Left Atrial Deformation Indices and the CHA2DS2 - VASc Risk Score in Patients with Atrial Fibrillation. 2016 , 07,	
1095	Editorial for "Computational Electrocardiography: Revisiting Holter ECG Monitoring". 2016 , 55, 303-4	1
1094	Cardiovascular pharmacotherapy-2015 was a good year. 2016 , 2, 209-11	
1093	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. 2016 , 115, 257-70	11
1092	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility. 2016 , 9, 309-16	1
1091	Effects of the availability of new oral anticoagulants in patients with non-valvular atrial fibrillation in the real world: the NAIF study. 2016 , 10,	
1090	Edoxaban in venous thromboembolism and stroke prevention: an appraisal. 2016 , 12, 45-51	4
1089	Stroke Prevention in Atrial Fibrillation: Focus on Latin America. 2016 , 107, 576-589	10
1088	Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease. 2016 , 10, 110-6	5
1087	Atrial fibrillation and silent stroke: links, risks, and challenges. 2016 , 12, 65-74	28
1086	Prevalence of unknown and untreated arrhythmias in an older outpatient population screened by wireless long-term recording ECG. 2016 , 11, 1083-90	2
1085	Atrial fibrillation with high ventricular rate in emergency room: What's the best strategy for treatment?. 2016 , 62, 879-885	1
1084	Value of Implantable Loop Recorders in Monitoring Efficacy of Radiofrequency Catheter Ablation in Atrial Fibrillation. 2016 , 22, 2846-51	5
1083	Clinical Significance of Additional Ablation of Atrial Premature Beats after Catheter Ablation for Atrial Fibrillation. 2016 , 57, 72-80	12
1082	Practical Guide to the New Oral Anticoagulants. 2016 , 03,	

1081	Individualising Anticoagulant Therapy in Atrial Fibrillation Patients. 2016 , 5, 102-9	4
1080	Discussion of "Computational Electrocardiography: Revisiting Holter ECG Monitoring". 2016 , 55, 312-21	1
1079	Percutaneous left atrial appendage closure: here to stay. 2016 , 8, 2420-2423	
1078	Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. 2016 , 4,	5
1077	Stroke Prevention with Percutaneous Left Atrial Appendage Closure. 2016 , 8, CMT.S18886	
1076	Comparison between First- and Second-Generation Cryoballoon for Paroxysmal Atrial Fibrillation Ablation. 2016 , 2016, 5106127	18
1075	Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. 2016 , 115, 939-49	76
1074	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. 2016 , 116, S33-S40	7
1073	[Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation]. 2016 , 144, 1103-1111	
1072	Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation. 2016 , 240, 259-268	9
1071	CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation. 2016 , 11, 941-6	5
1070	Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: a cost-minimization analysis. 2016 , 134, 322-9	10
1069	Efficacy and safety of ablation for patients with non-paroxysmal atrial fibrillation. 2016 ,	2
1068	New Direct Oral Anticoagulants (DOAC) and Their Use Today. 2016 , 4,	11
1067	The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study. 2016 , 8,	8
1066	Accelerometry-Based Activity Recognition and Assessment in Rheumatic and Musculoskeletal Diseases. 2016 , 16,	7
1065	Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study. 2016 , 44, 258-267	20
1064	Rivaroxaban for Periprocedural Anticoagulation Therapy in Japanese Patients Undergoing Catheter Ablation of Paroxysmal Non-Valvular Atrial Fibrillation. 2016 , 57, 712-716	4

1063	The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. 2016 , 116, 480-5		4
1062	Patient with Arrhythmias. 2016 , 13-16		
1061	Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation. 2016 , 116, 679-86		5
1060	Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. 2016 , 115, 184-92		17
1059	Simulation of Daily Snapshot Rhythm Monitoring to Identify Atrial Fibrillation in Continuously Monitored Patients with Stroke Risk Factors. <i>PLoS ONE</i> , 2016 , 11, e0148914	3-7	16
1058	Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population. <i>PLoS ONE</i> , 2016 , 11, e0163171	3-7	2
1057	Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. 2016 , 9, 337-347		12
1056	Left Atrial Remodeling Assessed by Transthoracic Echocardiography Predicts Left Atrial Appendage Flow Velocity in Patients With Paroxysmal Atrial Fibrillation. 2016 , 57, 177-82		10
1055	Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. 2016 , 8, 93-107		23
1054	Management of Patients with Atrial Fibrillation: Focus on Treatment Options. 2016 , 9, 1450		1
1053	Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature. 2016 , 115, 663-77		43
1052	Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. 2016 , 69, 280-5		1
1051	Which components of the CHA2DS2-VASc score are the most important in obstructive sleep apnea patients with atrial fibrillation?. 2016 , 27, 347-51		2
1050	Recent Advances in the Pharmacological Management of Atrial Fibrillation. 2016 , 23, e118-38		2
1049	New Mechanism-based Approaches to Ablating Persistent AF: Will Drug Therapy Soon Be Obsolete?. 2016 , 67, 1-8		
1048	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. 2016 , 179, 59-68		29
1047	Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. 2016 , 220, 794-801		14
1046	Predictors of Early (1-Week) Outcomes Following Left Atrial Appendage Closure With Amplatzer Devices. 2016 , 9, 1374-83		34

1045	Lessons From Drive-By Left 'Atrial' Appendage Occlusion. 2016 , 9, 1384-5		
1044	Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. 2016 , 64, 1416-24		26
1043	Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists. 2016 , 14, 1715-24		12
1042	Left atrial appendage closure: beyond the artifact. 2016 , 17 Suppl 2, e171-e173		1
1041	P-wave indices as predictors of atrial fibrillation recurrence after pulmonary vein isolation in normal left atrial size. 2016 , 17, 194-200		20
1040	Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. 2016 , 33, 42-6		14
1039	Long-term events following atrial fibrillation rate control or transcatheter ablation: a multicenter observational study. 2016 , 17, 187-93		17
1038	Stroke Risk Stratification in Atrial Fibrillation: Bridging the Evidence Gaps. 2016 , 27, 271-3		4
1037	Left Atrial Appendage Closure Guided by 3D Printed Cardiac Reconstruction: Emerging Directions and Future Trends. 2016 , 27, 768-71		46
1036	Association of Increased Epicardial Adipose Tissue Thickness With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation. 2016 , 95, e2874		25
1035	How to manage patients on rivaroxaban in the emergency department: a statement of the Italian society of emergency medicine advisory board. 2016 , 23, 320-9		2
1034	Perioperative Management of Anticoagulation-Review of Latest Evidence. 2016 , 23, e474-84		7
1033	Smart detection of atrial fibrillation. 2017 , 19, 753-757		62
1032	Comparing Measurements of CT Angiography, TEE, and Fluoroscopy of the Left Atrial Appendage for Percutaneous Closure. 2016 , 27, 414-22		50
1031	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 525-568	15.1	38
1030	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 2016 , 9, 443-88		23
1029	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. 2016 , 18, 1455-1490		268
1028	Dabigatran in clinical practice: Contemporary overview of the evidence. 2016 , 220, 417-28		6

1027	Long-Term Persistence of Newly Initiated Warfarin Therapy in Chinese Patients With Nonvalvular Atrial Fibrillation. 2016 , 9, 380-7	19
1026	Circulating Biomarkers Predictive of Postoperative Atrial Fibrillation. 2016 , 24, 76-87	25
1025	Acenocoumarol vs. low-dose dabigatran in real-world patients discharged after ischemic stroke. 2016 , 27, 185-9	1
1024	Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. 2016 , 13, 549-59	59
1023	Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial. 2016 , 264, 244-51	33
1022	Left atrial appendage closure: First in man with the 4th generation WATCHMAN device. 2016 , 87, 787-94	7
1021	EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. 2016 , 88, 460-5	25
1020	Intraoperative Assessment of Left Atrial Diverticulum and Remnant Stump after Left Atrial Appendage Epicardial Occlusion. 2016 , 33, 1368-73	2
1019	Home medicines reviews in Australian war veterans taking warfarin do not influence international normalised ratio control. 2016 , 46, 288-94	2
1018	New oral anticoagulants: appropriateness of prescribing in real-world setting. 2016 , 46, 812-8	41
1017	Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. 2016 , 64, 1054-60	13
1016	Combined Left Atrial Appendage Closure and Pacemaker Implant through a Single Right Femoral Vein Access. 2016 , 39, 900-2	2
1015	Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database. 2016 , 6, e010144	7
1014	Detection of atrial fibrillation with seismocardiography. 2016 , 2016, 4369-4374	3
1013	Prognostic Significance of Atrial Fibrillation in Lower Limb Amputee Patients. 2016 , 52, 823-829	1
1012	Arterial Thrombosis. 2016 , 229-239	
1011	Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation. 2016 , 102, 1969-1973	23
1010	Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting. 2016 , 5,	142

1009	Towards patient-specific modelling of lesion formation during radiofrequency catheter ablation for atrial fibrillation. 2016 , 2016, 489-492	3
1008	Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. 2016 , 3, e000441	27
1007	Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. 2016 , 6, e011471	41
1006	Usefulness of CHADS-VASc Scoring Systems for Predicting Risk of Perioperative Embolism in Patients of Cardiac Myxomas Underwent Surgical Treatment. 2016 , 6, 39323	8
1005	CHA2DS2-VASc score, left atrial size and atrial fibrillation as stroke risk factors in the Tromsø Study. 2016 , 3, e000439	14
1004	Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011-2014. 2016 , 42, 447-51	11
1003	How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?. 2016 , 18, 11-16	1
1002	How I use anticoagulation in atrial fibrillation. 2016 , 128, 2891-2898	8
1001	2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. 2016 , 115, 893-952	76
1000	QTc interval predicts outcome of catheter ablation in paroxysmal atrial fibrillation patients with type 2 diabetes mellitus. 2016 , 36, 646-652	4
999	A planning system of the implant size and position for minimally-invasive closure of the left atrial appendage. 2016 ,	1
998	Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. 2016 , 6, 20432	31
997	Gamma-glutamyl transferase predicts recurrences of atrial fibrillation after catheter ablation. 2016 , 71, 205-210	6
996	Long-term outcomes after ablation of persistent atrial fibrillation: an observational study over 6 years. 2016 , 3, e000394	19
995	Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study. 2016 , 95, e4672	22
994	Antithrombotic drug use: scientific breakthroughs, biological limits and physician behaviour. 2016 , 102, 1859-1860	2
993	Individualized antithrombotic therapy. 2016 , 36, 26-32	4
992	Advanced Left Atrial Remodeling and Appendage Contractile Dysfunction in Women Than in Men Among the Patients With Atrial Fibrillation: Potential Mechanism for Stroke. 2016 , 5,	19

991	Validation of satisfaction questionnaire ACTS in outpatients with atrial fibrillation treated with oral anticoagulants in Spain. ALADIN Study. 2016 , 147, 192-198		
990	Thoughts about anticoagulation in older patients. 2016 , 147, 151-153		
989	Crioablaci3n con bal3n en fibrilaci3n auricular. 2016 , 23, 138-142		
988	Dispositivos de cierre percut3neo de orejuela para la prevenci3n de embolia en fibrilaci3n auricular. 2016 , 23, 165-169		
987	Tratamiento farmacol3gico de la fibrilaci3n auricular. Antiarr3tmicos y anticoagulantes orales. 2016 , 16, 33-39		
986	Tratamiento no farmacol3gico de la fibrilaci3n auricular. Ablaci3n, cardioversi3n el3ctrica, marcapasos y cierre de la orejuela. 2016 , 16, 40-46		
985	Fibrilaci3n auricular en pacientes con dispositivos cardiacos electr3ficos implantables. 2016 , 16, 47-51		
984	Antithrombotic stewardship: a multidisciplinary team approach towards improving antithrombotic therapy outcomes during and after hospitalisation: a study protocol. 2016 , 6, e011537		5
983	Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation. 2016 , 16, 167		7
982	IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. 2016 , 6, e012241		10
981	Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016 , 2, 299-305	4.6	23
980	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. 2016 , 6, 24376		40
979	A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. 2016 , 176, 107-13		7
978	Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data. 2016 , 214, 292-8		66
977	Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study. 2016 , 13, 1581-8		29
976	[Perception of physicians on factors that influence the choice of a dicoumarin or a new oral anticoagulant in patients with non-valvular atrial fibrillation]. 2016 , 48, 527-534		3
975	Coment3rio a «Abla3n cir3rgica de fibrilha3n auricular, durante cirurgia da v3lvula mitral». 2016 , 35, 251-252		
974	Unexpectedly High Incidence of Stroke and Left Atrial Appendage Thrombus Formation After Electrical Isolation of the Left Atrial Appendage for the Treatment of Atrial Tachyarrhythmias. 2016 , 9, e003461		103

973	Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects. 2016 , 38, 1228-1236.e1		18
972	Cardiac surgery interventions for stroke prevention in patients with atrial fibrillation. 2016 , 58, e242-e249		2
971	En el camino de un mejor uso de los anticoagulantes en la fibrilaci3n auricular no valvular. Propuesta de modificaci3n del posicionamiento terap6utico UT/V4/23122013. 2016 , 69, 551-553		25
970	Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. 2016 , 55, 641-55		117
969	Focal-, Circular-, or Balloon-Based Atrial Fibrillation Ablation: How to Interpret the Data in a Rapidly Developing Field?. 2016 , 2, 391-392		
968	Aislamiento el6ctrico venoso pulmonar con cat6ter l6ser en el tratamiento de la fibrilaci3n auricular parox6stica y persistente. Resultados a un a6o. 2016 , 69, 488-493		5
967	Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?. <i>Stroke</i> , 2016 , 47, 1831-6	6.7	47
966	Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. 2016 , 42, 671-81		5
965	Electrical Isolation of Pulmonary Veins Using Laser Catheter in the Treatment of Paroxysmal and Persistent Atrial Fibrillation. One-year Results. 2016 , 69, 488-93		3
964	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination. 2016 , 42, 662-70		11
963	Optimal antithrombotic treatment in patients with atrial fibrillation and coronary stents: an update. 2016 , 31, 356-65		1
962	Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). 2016 , 178, 126-34		95
961	Descripci3n de los pacientes con fibrilaci3n auricular no valvular que ingresan al servicio de urgencias. 2016 , 23, 270-276		2
960	On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013. 2016 , 69, 551-3		1
959	Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. 2016 , 72, 671-9		18
958	A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras. 2016 , 33, 427-36		24
957	Multimorbidity in Older Adults with Atrial Fibrillation. 2016 , 32, 315-29		13
956	Underutilization of Anticoagulation for Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2444-2446	15.1	16

955	Safety and efficacy of pharmacological cardioversion of recent-onset atrial fibrillation: a single-center experience. 2016 , 34, 1486-90		9
954	Relation of the SAME-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. 2016 , 216, 168-72		14
953	Service redesign. 2016 , 21, 43-50		
952	Prolonged transesophageal echocardiography during percutaneous closure of the left atrial appendage without general anesthesia: the utility of the Janus mask. 2016 , 63, 962-5		13
951	Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. 2016 , 129, 1110-6		17
950	CHADS-VASc Recalibration With an Additional Age Category (50-64 Years) Enhances Stroke Risk Stratification in Chinese Patients With Atrial Fibrillation. 2016 , 32, 1381-1387		14
949	The evolution of left atrial appendage occlusion: EWOLUTION and the WATCHMAN in practice. <i>European Heart Journal</i> , 2016 , 37, 2475-7	9.5	6
948	Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) guided by implantable loop recorder: multicentre Italian trial based on stroke unit network with paired cardio-arrhythmology units (Italian Neurocardiology Unit Network). 2016 , 11, 361-7		12
947	Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. 2016 , 149, 960-8		43
946	Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran. 2016 , 23, 115-22		1
945	Atrial fibrillation in first generation Chinese migrants living in Europe: A proof of concept study. 2016 , 215, 269-72		6
944	Net Clinical Benefit of Dabigatran Over Warfarin in Patients With Atrial Fibrillation Stratified by CHADS-VASc and Time in Therapeutic Range. 2016 , 32, 1247.e15-1247.e21		12
943	Atrial fibrillation: novel risk factors, mechanisms and ablation techniques. <i>European Heart Journal</i> , 2016 , 37, 1553-5	9.5	3
942	Eficacia en nuestro entorno del vernakalant para la cardioversi3n farmacol3gica del paciente con fibrilaci3n auricular de reciente comienzo. 2016 , 69, 619-620		6
941	Efectos aditivos de la exenatida, la glucosa-insulina-potasio y el condicionamiento isqu3mico a distancia frente a las arritmias ventriculares de la reperfusi3n en cerdos. 2016 , 69, 620-622		3
940	[Comment on "Surgical ablation of atrial fibrillation during mitral-valve surgery"] 2016 , 35, 251-2		
939	Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study. 2016 , 16, 25		12
938	Cryo-Balloon Catheter Localization Based on a Support-Vector-Machine Approach. 2016 , 35, 1892-902		4

937	Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. 2016 , 13, 321-32	150
936	[Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation]. 2016 , 35, 141-8	4
935	Early Postoperative Care After CABG. 2016 , 75-97	
934	Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry. 2016 , 25, 585-99	19
933	[Current state of treatment strategies for atrial fibrillation]. 2016 , 41, 253-66; quiz 267-9	1
932	Left Atrial Appendage Closure for Atrial Fibrillation Is Safe and Effective After Intracranial or Intraocular Hemorrhage. 2016 , 32, 349-54	12
931	The Risk of Hospital Admission Due to Traumatic Brain Injury Is Increased in Older Persons With Severe Functional Limitations. 2016 , 17, 609-12	9
930	Does catheter ablation reduce mortality and stroke in patients with atrial fibrillation? Patient selection or causality?. <i>European Heart Journal</i> , 2016 , 37, 2488-9	9.5 5
929	Impact on Outcomes of Changing Treatment Guideline Recommendations for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study. 2016 , 91, 567-74	23
928	[Thoughts about anticoagulation in older patients]. 2016 , 147, 151-3	0
927	CHA2DS2-Vasc score, age and body mass index as the main risk factors of hyperintense brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation. 2016 , 215, 476-81	6
926	Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation. 2016 , 18, D7-D15	2
925	Left atrial thrombi and spontaneous echo contrast in patients with atrial fibrillation : Systematic analysis of a single-center experience. 2016 , 41, 706-714	9
924	Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study. 2016 , 129, 843-9	75
923	Dronedarone: Basic Pharmacology and Clinical Use. 2016 , 8, 453-65	10
922	Atrial fibrillation in chronic kidney disease. 2016 , 33, 3-13	7
921	Carotid Atherosclerosis and Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. <i>Stroke</i> , 2016 , 47, 1643-6	6.7 24
920	Electrocardiogram interpretation and arrhythmia management: a primary and secondary care survey. 2016 , 66, e291-6	12

919	Contact force sensing during atrial fibrillation ablation: clinical experience and effects on outcomes. 2016 , 14, 749-59		6
918	How to treat post-operative complications: An evidence-based approach. 2016 , 30, 229-36		1
917	Amiodarone and dronedarone: An update. 2016 , 26, 597-602		21
916	Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. 2016 , 13, 1777-83		19
915	Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. 2016 , 18, D1-D6		6
914	North American Thrombosis Forum, AF Action Initiative Consensus Document. 2016 , 129, S1-S29		19
913	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017 , 38, 877-887	9.5	41
912	[Atrial fibrillation - Update 2016]. 2016 , 158 Spec No 1, 20-28		
911	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. 2016 , 29, 537-44		22
910	The role of comprehensive geriatric assessment and functional status in evaluating the patterns of antithrombotic use among older people with atrial fibrillation. 2016 , 65, 248-54		5
909	Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives. 2016 , 120, 148-59		11
908	Atrial Fibrillation Ablation and Stroke. 2016 , 34, 307-16		2
907	Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. 2016 , 42, 205-11		20
906	Role of Vitamin K Antagonists in the Prevention of Thrombotic Bypass Occlusion After Infrainguinal Venous Bypass. 2016 , 52, 124-31		1
905	Results of Cryoablation for Atrial Fibrillation Concomitant With Video-Assisted Minimally Invasive Mitral Valve Surgery. 2016 , 28, 271-280		6
904	Electrical Isolation of the Left Atrial Appendage: Is It Safe?. 2016 , 9, e004209		
903	Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization. 2016 , 168, 126-142		21
902	Cardiac rehabilitation versus usual care for patients treated with catheter ablation for atrial fibrillation: Results of the randomized CopenHeart trial. 2016 , 181, 120-129		36

8901	EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. 2016 , 32, 247-78	59
900	Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. 2016 , 194, 1319-1336	115
899	Management of Perioperative Arrhythmias. 2016 , 111-124	
898	Diagnosis and Management of Acute Intracerebral Hemorrhage. 2016 , 34, 883-899	50
897	Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System. 2016 , 179, 186-91	5
896	Screening for Atrial Fibrillation Using a Smartphone: Is There an App for That?. 2016 , 5,	21
895	Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. 2016 , 4, 870-880	41
894	Stroke incidence in patients with cardiac implantable electronic devices remotely controlled with automatic alerts of atrial fibrillation. A sub-analysis of the HomeGuide study. 2016 , 219, 251-6	11
893	Long-term adherence to dronedarone in patients with atrial arrhythmias. 2016 , 222, 676-677	
892	[Validation of satisfaction questionnaire ACTS in outpatients with atrial fibrillation treated with oral anticoagulants in Spain. ALADIN Study]. 2016 , 147, 192-198	15
891	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. 2016 , 113, 484-489	18
890	Comparaci3n entre tres sistemas de puntuaci3n de hemorragia en pacientes con fibrilaci3n auricular no valvular. ¿Qu3 puede ofrecer la nueva puntuaci3n ORBIT?. 2016 , 69, 1112-1114	8
889	Gu3a ESC 2016 sobre prevenci3n de la enfermedad cardiovascular en la pr3ctica cl3nica. 2016 , 69, 939.e1-939.e87	10
888	Late atypical atrial flutter after ablation of atrial fibrillation. 2016 , 35, 539.e1-6	1
887	The HIPOGAIA study: Monitoring of oral anticoagulation with vitamin K antagonists in the municipality of Gaia. 2016 , 35, 459-65	4
886	The HIPOGAIA study: Monitoring of oral anticoagulation with vitamin K antagonists in the municipality of Gaia. 2016 , 35, 459-465	3
885	Associations of Emotional Distress and Perceived Health in Persons With Atrial Fibrillation and Their Partners Using the Actor-Partner Interdependence Model. 2016 , 22, 368-91	10
884	Pitfalls in the Acute Management of Atrial Fibrillation. 2016 , 145-173	

883	Pathophysiology of Atrial Fibrillation and Clinical Correlations. 2016 , 19-26	
882	Novel oral anticoagulants in non-valvular atrial fibrillation: Pharmacological properties, clinical trials, guideline recommendations, new antidote drugs and real-world data. 2016 , 2, 167-173	3
881	Use of the new contact force sensing ablation catheter dramatically reduces fluoroscopy time during atrial fibrillation ablation procedures. 2016 , 16, 83-87	5
880	Assessing Intracardiac Thrombus Before Atrial Fibrillation Ablation: Challenges Faced After Testing. 2016 , 2, 304-306	
879	Cost-Effectiveness of a National Opportunistic Screening Program for Atrial Fibrillation in Ireland. 2016 , 19, 985-995	12
878	Técnicas de imagen en el intervencionismo percutáneo estructural: cierre de comunicación interauricular y oclusión de la orejuela izquierda. 2016 , 69, 766-777	8
877	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. 2016 , 20, 273	16
876	[Choosing wisely together with the patient]. 2016 , 57, 540-50	0
875	Real-life use of digoxin in patients with non-valvular atrial fibrillation: data from the RAMSES study. 2016 , 41, 711-717	4
874	Selecting Optimum Antihypertensive Therapy. 2016 , 217-247	
873	Comparing the effectiveness of pharmacist-managed warfarin anticoagulation with other models: a systematic review and meta-analysis. 2016 , 41, 602-611	20
872	Patient factors associated with quality of life in atrial fibrillation. 2016 , 182, 135-143	32
871	Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review. 2016 , 30, 1073-84	12
870	Cardiovascular pharmacotherapy. 2016 , 224, 412-415	
869	Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. 2016 , 18, 65	6
868	New Oral Anticoagulants and Their Reversal Agents. 2016 , 18, 47	12
867	Medication management strategy for older people with polypharmacy in general practice: a qualitative study on prescribing behaviour in primary care. 2016 , 66, e540-51	21
866	Risk Prediction With Electronic Health Records: The Importance of Model Validation and Clinical Context. 2016 , 1, 976-977	15

865	Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. 2016 , 34, 19-25	1
864	Late atypical atrial flutter after ablation of atrial fibrillation. 2016 , 35, 539.e1-539.e6	
863	Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. 2016 , 150, 1302-1312	165
862	Place of non-vitamin K antagonist oral anticoagulants in anticoagulant-antiplatelet combinations in peripheral artery disease. 2016 , 109, 634-640	1
861	New oral anticoagulants versus Warfarin in patients undergoing cardioversion of atrial fibrillation. 2016 , 225, 244-246	4
860	Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA ₂ DS ₂ -VASc Score of 1 (Men) or 2 (Women)?. 2016 , 5,	16
859	Direct oral anticoagulants: unique properties and practical approaches to management. 2016 , 102, 1620-6	15
858	Left Atrial Appendage Closure Under Intracardiac Echocardiographic Guidance: Feasibility and Comparison With Transesophageal Echocardiography. 2016 , 5,	28
857	Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants. 2016 , 11, 950-967	2
856	New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban. 2016 , 225, 154-158	
855	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. 2016 , 17, 2033-47	4
854	Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. 2016 , 129, 1278-1287	90
853	Hypertension and Comorbidities. 2016 ,	2
852	Adenosine-Guided Pulmonary Vein Antral Isolation for Paroxysmal Atrial Fibrillation: A Randomized Study. 2016 , 27, 1288-1292	8
851	Addition of TGF- β to existing clinical risk scores does not improve prediction for arrhythmia recurrences after catheter ablation of atrial fibrillation. 2016 , 221, 52-4	4
850	Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease. 2016 , 222, 1079-1083	9
849	Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation. 2016 , 14, 2124-2131	20
848	Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention. 2016 , 223, 186-194	22

847	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. 2016 , 18, 1153-61	59
846	Inadequate stroke prevention in Korean atrial fibrillation patients in the post-warfarin era. 2016 , 220, 647-52	15
845	Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications. 2016 , 5,	33
844	Outpatient Medications in Atrial Fibrillation. 2016 , 195-217	
843	Clinical Case 5: Patient with Essential Hypertension and Congestive Heart Failure. 2016 , 81-99	
842	Geographic and socio-demographic differences in uptake of population-based screening for atrial fibrillation: The STROKESTOP I study. 2016 , 222, 430-435	5
841	Reversal agents for direct oral anticoagulants: A focused review. 2016 , 223, 244-250	9
840	Short Stay Management of Atrial Fibrillation. 2016 ,	1
839	Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. 2016 , 30, 891-4	7
838	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives. 2016 , 2, 32-36	
837	Impact of Warfarin on Atrial-Fibrillation Outcomes Related to Economic Consumption Patterns: Hospitalization, Cost, and Mortality may be Predictable and Modifiable at the Population Level. 2016 , 33, 1579-99	
836	Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients. 2016 , 82, 633-44	14
835	A New Method for Direct Three-Dimensional Measurement of Left Atrial Appendage Dimensions during Transesophageal Echocardiography. 2016 , 33, 69-76	17
834	Novel oral anticoagulant management issues for the stroke clinician. 2016 , 11, 759-67	4
833	Underuse of anticoagulation in stroke patients with atrial fibrillation--the FibStroke Study. 2016 , 23, 133-9	26
832	What have we learned of ablation procedures for atrial fibrillation?. 2016 , 279, 439-48	2
831	Comparison Between 3 Bleeding Scoring Systems in Nonvalvular Atrial Fibrillation Patients. What Can the New ORBIT Score Provide?. 2016 , 69, 1112-1114	2
830	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. 2016 , 134, 1697-1707	58

829	Fundamentals of Cardiology for the Non-Cardiologist. 2016 , 21-44	
828	Letter by Zhang et al Regarding Article, "Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA ₂ DS ₂ -VASc Risk Factor Be Anticoagulated?". <i>Stroke</i> , 2016 , 47, e238	6.7
827	[Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation]. 2016 , 27, 295-306	2
826	Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. 2016 , 129, S54-S63	9
825	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. 2016 , 5,	79
824	NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach. 2016 , 223, 74-81	33
823	Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation: Outcomes From a Controlled Nonrandomized Study. 2016 , 9,	15
822	Therapeutic compliance with rivaroxaban in preventing stroke in patients with non-valvular atrial fibrillation: CUMRIVAFA study. 2016 , 32, 2013-2020	10
821	Atrial fibrillation and stroke: risk factors, anticoagulation, and left atrial appendage occluders. <i>European Heart Journal</i> , 2016 , 37, 2443-5	9.5
820	[Catheter-based closure of the left atrial appendage : Stroke prevention in atrial fibrillation]. 2016 , 57, 844-55	2
819	Clinical Case 6: Patient with Essential Hypertension and Atrial Fibrillation. 2016 , 101-119	
818	Oral anticoagulation in octogenarians with atrial fibrillation. 2016 , 223, 87-90	9
817	Burden of atrial fibrillation: a retrospective review of patients presenting to acute medical services. 2016 , 46, 1166-1171	1
816	Stroke and Cerebrovascular Diseases. 2016 , 133-185	
815	Stroke prevention in atrial fibrillation. 2016 , 388, 806-17	228
814	Drug-drug interactions of non-vitamin K oral anticoagulants. 2016 , 12, 1445-1461	24
813	Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. 2016 , 80, 605-12	3
812	Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. 2016 , 11, CD012088	16

811	The CHADS-VASc score as a predictor of high mortality in hospitalized heart failure patients. <i>ESC Heart Failure</i> , 2016 , 3, 261-269	3.7	25
810	[Atrial fibrillation: rate or rhythm control?]. 2016 , 141, 1611-1616		0
809	Pearls and Pitfalls in Catheter Ablation of Persistent Atrial Fibrillation. 2016 , 80, 306-13		9
808	Ultra-High-Definition Mapping of Atrial Arrhythmias. 2016 , 80, 579-86		16
807	Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation - Results of the J-RHYTHM Registry 2. 2016 , 80, 843-51		35
806	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. 2016 , 80, 2102-8		12
805	Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. <i>Stroke</i> , 2016 , 47, 2462-9	6.7	55
804	A prospective study investigating the causes of warfarin under-utilization in Chinese patients. 2016 , 38, 1286-93		4
803	Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. 2016 , 9, CD003333		6
802	Knowledge gaps in patients with atrial fibrillation revealed by a new validated knowledge questionnaire. 2016 , 223, 906-914		44
801	[Imaging in structural heart disease : Impact on interventional therapy]. 2016 , 41, 639-652		0
800	Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation. 2016 , 5, 215-221		7
799	The C of CHADS: Historical perspective and clinical applications for anticoagulation in patients with non valvular atrial fibrillation and congestive heart failure. 2016 , 224, 431-436		3
798	Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1452-1464	15.1	80
797	Prevention of Gastrointestinal Bleeding in Patients Receiving Direct Oral Anticoagulants. 2016 , 3, 2-12		12
796	Appropriate Apixaban Dosing: Prescribers Take Note. 2016 , 1, 635-6		10
795	Valvular-CHADS-VASc as a safer alternative to CHADS-VASc score. 2016 , 221, 1051-2		1
794	Imaging Techniques in Percutaneous Cardiac Structural Interventions: Atrial Septal Defect Closure and Left Atrial Appendage Occlusion. 2016 , 69, 766-77		0

793	Association between Renal Function and Bleeding Risk for Dabigatran after Switching from Warfarin. 2016 , 44, 11-8		5
792	Topical Issues in Anesthesia and Intensive Care. 2016 ,		
791	Update on Echocardiographic Assessment in Diabetes Mellitus. 2016 , 18, 85		8
790	Simple predictors for new onset atrial fibrillation. 2016 , 221, 515-20		9
789	Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. <i>European Heart Journal</i> , 2017 , 38, 1285-1293	9.5	63
788	New concepts for anticoagulant therapy in persons with hemophilia. 2016 , 128, 2471-2474		25
787	Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline. 2016 , 107, 190-198		14
786	Non-vitamin K antagonist oral anticoagulants and heart failure. 2016 , 109, 641-650		10
785	European Society of Cardiology Guideline-Adherent Antithrombotic Treatment and Risk of Mortality in Asian Patients with Atrial Fibrillation. 2016 , 6, 30734		11
784	Electronic Alert System for Improving Stroke Prevention Among Hospitalized Oral-Anticoagulation-Naïve Patients With Atrial Fibrillation: A Randomized Trial. 2016 , 5,		19
783	Applications of 3D printing in cardiovascular diseases. 2016 , 13, 701-718		230
782	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017 , 38, 1455-1462	9.5	63
781	Clinical Implications of Brief Device-Detected Atrial Tachyarrhythmias in a Cardiac Rhythm Management Device Population: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes. 2016 , 134, 1130-1140		98
780	Atrial fibrillation. 2016 , 2, 16016		115
779	Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. 2016 , 18, 1507-1513		7
778	The ABC risk score for patients with atrial fibrillation - Authors' reply. 2016 , 388, 1980-1981		3
777	Assessment and Management of Gastrointestinal Hemorrhage in the Setting of Direct Oral Anticoagulants: The Hematology Perspective. 2016 , 3, 29-35		2
776	Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis. 2015 , 5, 17731		5

775	Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban. 2016 , 116, S2-S12		6
774	Brain embolism. 2016 , 15-18		
773	Stroke occurring on medical wards. 47-57		
772	Left atrial appendage occlusion with the Amplatzer Cardiac Plug could improve survival and prevent thrombo-embolic and major bleeding events in atrial fibrillation patients with increased bleeding risk. 2016 , 71, 135-143		1
771	Prognostic value of CHA2DS2-VASc score in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. 2016 , 71, 663-669		4
770	Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses. 2016 , 355, i5826		33
769	Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. 2016 , 353, i2607		23
768	Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study. 2018 , 2, 497-507		12
767	Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014. <i>European Heart Journal</i> , 2018 , 39, 4020-4029	9.5	62
766	Computational Fluid Dynamic Analysis of the Left Atrial Appendage to Predict Thrombosis Risk. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 34	5.4	43
765	Differential Association of Cx37 and Cx40 Genetic Variants in Atrial Fibrillation with and without Underlying Structural Heart Disease. 2018 , 19,		6
764	Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis. 2018 , 27, 2296-2305		11
763	Reducing age bias in decision analyses of anticoagulation for patients with nonvalvular atrial fibrillation - A microsimulation study. <i>PLoS ONE</i> , 2018 , 13, e0199593	3.7	2
762	Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. 2018 , 13, 1144-1152		29
761	Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function : Post hoc analysis of a prospective cohort. 2018 , 13, 1059-1067		13
760	Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation. 2018 , 18, 11		7
759	Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. 2018 , 19, 957-965		4
758	Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study. 2018 , 8, e020191		9

757	Editorial commentary: Evolving paradigms for stroke prevention in patients with atrial fibrillation. 2018 , 28, 481-482		
756	Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding. 2018 , 130, 722-734		1
755	Atrial Fibrillation, Cognitive Decline, and Dementia: an Epidemiologic Review. 2018 , 5, 252-261		23
754	CHA ₂ DS ₂ -VASc Score in the Prediction of Ischemic Stroke in Patients after Radiofrequency Catheter Ablation of Typical Atrial Flutter. 2018 , 59, 236-242		9
753	Mortality in heart failure with atrial fibrillation: Role of digoxin and diuretics. 2018 , 48, e13014		4
752	The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. 2018 , 27, 3280-3288		26
751	Patient and facility variation in costs of catheter ablation for atrial fibrillation. 2018 , 29, 1081-1088		4
750	Multiple spontaneous hemorrhages after commencing warfarin therapy. 2018 , 6, 2050313X18778380		1
749	Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. 2018 , 154, 1121-1201	502	
748	Silent Cerebral Infarction in East Asian vs. Non-Asian Atrial Fibrillation Patients - Meta-Analysis. 2018 , 82, 672-676		0
747	Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis. 2018 , 46, 332-338		6
746	L'anticoagulation orale en prévention du risque thromboembolique dans la fibrillation atriale. 2018 , 57, 15-19		
745	Trends in warfarin use and its associations with thromboembolic and bleeding rates in a population with atrial fibrillation between 1996 and 2011. <i>PLoS ONE</i> , 2018 , 13, e0194295	3-7	8
744	Role of cardiac imaging and three-dimensional printing in percutaneous appendage closure. 2018 , 111, 411-420		8
743	Assessment of the clinical efficacy of the heart spectrum blood pressure monitor for diagnosis of atrial fibrillation: An unblinded clinical trial. <i>PLoS ONE</i> , 2018 , 13, e0198852	3-7	1
742	Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis. <i>PLoS ONE</i> , 2018 , 13, e0197583	3-7	44
741	Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. 2019 , 34, 173-190		35
740	Stroke risk in female patients with atrial fibrillation: Relationship to current guideline recommendations. 2019 , 29, 150-152		1

739	Contribution of routine cardiac biological markers to the etiological workup of ischemic stroke. 2019 , 37, 194-198	4
738	Approaches to Direct Oral Anticoagulant Selection in Practice. 2018 , 1074248418793137	4
737	Acute kidney injury is linked to higher mortality in elderly hospitalized patients with non-valvular atrial fibrillation. 2019 , 31, 455-461	3
736	Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. 2019 , 105, 27-33	45
735	Within trial cost-utility analysis of disease management program for patients hospitalized with atrial fibrillation: results from the SAFETY trial. 2019 , 22, 945-952	3
734	Regional collaboration to improve atrial fibrillation care: Preliminary data from the Netherlands heart network. 2019 , 35, 604-611	2
733	2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations. 2019 , 25, 19	18
732	Predicting stroke and death in patients with heart failure using CHADS-VASc score in Asia. 2019 , 19, 193	6
731	High incidence of atrial fibrillation after successful catheter ablation of atrioventricular nodal reentrant tachycardia: a 15.5-year follow-up. 2019 , 9, 11784	4
730	Predictive validity of automated oscillometric blood pressure monitors for screening atrial fibrillation: a systematic review and meta-analysis. 2019 , 16, 503-514	1
729	Shorter Hospital Stay and Fewer Hospitalizations in Patients With Visible Hematuria on Direct Oral Anticoagulants Compared to on Vitamin K Antagonists. 2019 , 132, 101-108	1
728	Usefulness of CHADS-VASc Score to Predict Stroke Risk Independent of Atrial Fibrillation. 2019 , 124, 1059-1063	5
727	Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain. 2019 , 45, 396-405	1
726	A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project. <i>PLoS ONE</i> , 2019 , 14, e0218919	3-7 32
725	Cost of Healthcare Associated With Deep Vein Thrombosis in Patients Treated With Warfarin in Turkey: 2010-2013 Database Analysis of a Tertiary Care Center. 2019 , 19, 81-86	1
724	Vernakalant in Atrial Fibrillation: A Relatively New Weapon in the Armamentarium Against an Old Enemy. 2019 , 13, 1177392819861114	4
723	Adverse Clinical Events during Long-Term Follow-Up After Catheter Ablation of Atrial Fibrillation. 2019 , 60, 812-821	10
722	Alternative Facts: A Different Perspective on Left Atrial Appendage Closure. 2019 , 12, 1053-1054	

721	Reply: Off-Label Use of Direct Oral Anticoagulants in Patients With Mitral Stenosis. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3362-3363	15.1	
720	[Interventional management of atrial fibrillation]. 2019 , 40, 722-728		1
719	Long-term clinical outcomes from real-world experience of left atrial appendage exclusion with LARIAT device. 2019 , 30, 2849-2857		5
718	CHA2DS2-VASC Score Predicts Risk of Contrast-Induced Nephropathy in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions. 2019 , 5, 266-271		2
717	Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs). 2019 , 257, 2671-2676	3	
716	A study to assess a novel automated electrocardiogram technology in screening for atrial fibrillation. 2019 , 42, 1383-1389		1
715	Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. 2019 , 5, 1384-1392		5
714	A high BNP level predicts an improvement in exercise tolerance after a successful catheter ablation of persistent atrial fibrillation. 2019 , 30, 2283-2290		4
713	Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database. 2019 , 10, 2042098619876737		3
712	Physiological Computing Systems. 2019 ,		
711	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. 2019 , 119, 1901-1919		36
710	Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. <i>PLoS ONE</i> , 2019 , 14, e0222658	3.7	12
709	Percutaneous left atrial appendage closure in a patient with haemophilia and atrial fibrillation: a case report. 2019 , 3,		5
708	Interventions to Improve Emergency Department-Related Transitions in Care for Adult Patients With Atrial Fibrillation and Flutter. 2019 , 57, 501-516		1
707	Nurse-led vs. usual-care for atrial fibrillation. <i>European Heart Journal</i> , 2020 , 41, 634-641	9.5	30
706	Burden-based classification of atrial fibrillation predicts multiple-procedure success of pulmonary vein isolation. 2019 , 74, 53-59		4
705	Life-Threatening Complications of Atrial Fibrillation Ablation: 16-Year Experience in a Large Prospective Tertiary Care Cohort. 2019 , 5, 284-291		16
704	Esmolol Compared with Amiodarone in the Treatment of Recent-Onset Atrial Fibrillation (RAF): An Emergency Medicine External Validity Study. 2019 , 56, 308-318		1

703	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. 2019 , 119, 576-585		6
702	Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study. 2019 , 15, 109-118		1
701	Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. <i>PLoS ONE</i> , 2019 , 14, e0216831	3.7	12
700	Anticoagulation: a practical guide for strabismus surgeons. 2019 , 23, 193-199		2
699	Medication taking behaviors in patients taking warfarin versus direct oral anticoagulants: A systematic review. 2019 , 17, 427-434		8
698	Prediction of acute coronary syndrome, ischemic stroke, and mortality in patients with heart failure: a comparison of CHADS-VASc and AHEAD scores. 2019 , 55, 225-231		1
697	Withdrawal Notice: Atrial Fibrillation and Hypertension: "Quo Vadis" 2019 ,		2
696	Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). <i>European Heart Journal</i> , 2020 , 41, 1086-1096	9.5	19
695	Risk of Atrial Fibrillation in Patients with Congenital Heart Disease: Results of a Propensity Score-Matched, Nationwide Cohort Study. 2019 , 26, 670-677		6
694	Do Restoring and Maintaining Sinus Rhythm Have a Beneficial Effect on Secondary Prevention of Stroke in Patients With Atrial Fibrillation? A Pilot Study. <i>Angiology</i> , 2019 , 70, 916-920	2.1	8
693	Sarcopenia, frailty, cognitive impairment and mortality in elderly patients with non-valvular atrial fibrillation. 2019 , 219, 424-432		4
692	CHADS-VASc score and left atrial volume dilatation synergistically predict incident atrial fibrillation in hypertension: an observational study from the Campania Salute Network registry. 2019 , 9, 7888		3
691	Efficacy and safety of left atrial appendage closure in non-valvular atrial fibrillation in patients over 75 years. 2019 , 34, 1858-1865		5
690	Manejo de la fibrilaci3n auricular no valvular desde la perspectiva del paciente en Espa1a. 2019 , 2, 37-46		1
689	Warfarin therapy in Chinese patients with atrial fibrillation treated with percutaneous coronary intervention: a 5 year follow-up retrospective cohort study. 2019 , 35, 1777-1783		2
688	High incidence of atrial fibrillation in patients treated with ibrutinib. 2019 , 6, e001049		20
687	Postoperative atrial fibrillation is associated with higher scores on predictive indices. 2019 , 157, 2279-2286		16
686	Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. 2019 , 8, e011427		23

685	Kontrazeption bei Frauen mit angeborenen Herzfehlern. 2019 , 52, 463-472		
684	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2243-2250	15.1	24
683	Prevalence and risk factors for atrial fibrillation and its anticoagulant requirement in adults aged ≥60 in Jimma Town, Southwest Ethiopia: A community based cross-sectional study. 2019 , 22, 199-204		8
682	Comparison of incidence of acute kidney injury, chronic kidney disease and end-stage renal disease between atrial fibrillation and atrial flutter: real-world evidences from a propensity score-matched national cohort analysis. 2019 , 14, 1113-1118		4
681	Evaluation of a clinical score for predicting atrial fibrillation in cryptogenic stroke patients with insertable cardiac monitors: results from the CRYSTAL AF study. 2019 , 12, 1756286419842698		11
680	Effect of Warfarin on Ischemic Stroke, Bleeding, and Mortality in Patients with Atrial Fibrillation Receiving Peritoneal Dialysis. 2019 , 19, 509-515		4
679	Should we abandon the term 'lone atrial fibrillation'?. 2019 , 60, 216-223		1
678	Long-term safety and efficacy of combined percutaneous LAA and PFO/ASD closure: a single-center experience (LAAC combined PFO/ASD closure). 2019 , 16, 429-435		3
677	Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. 2019 , 9, e026645		33
676	CHADS-Vasc score and CHADS-Vasc-HS score are poor predictors of in-stent restenosis among patients with coronary drug-eluting stents. 2019 , 47, 2533-2544		2
675	Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation. 2019 , 22, 798-805		0
674	Heart Rate Estimation From Wrist-Worn Photoplethysmography: A Review. 2019 , 19, 6560-6570		76
673	Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice. 2019 , 14, 858-863		1
672	Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation. 2019 , 48, 225-232		1
671	Long-term efficacy and safety of radiofrequency catheter ablation of atrial fibrillation in patients with cardiac implantable electronic devices and transvenous leads. 2019 , 30, 679-687		10
670	Atrioventricular block can be used as a risk predictor of clinical atrial fibrillation. 2019 , 42, 452-458		6
669	Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation. 2019 , 49, 252-263		7
668	Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation. 2019 , 42, 694-704		14

667	Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1123-1131	15.1	40
666	Clinical characteristics and rhythm outcome of catheter ablation of hemodynamically corrected valvular atrial fibrillation. 2019 , 73, 488-496		7
665	Cost-effectiveness analysis of case management for optimized antithrombotic treatment in German general practices compared to usual care - results from the PICANT trial. 2019 , 9, 4		1
664	ECG Diagnosis: Ibutilide-induced Torsade de Pointes. 2019 , 23,		1
663	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. 2019 , 213, 35-46		28
662	Atrial fibrillation case finding in over 65 s with cardiovascular risk factors - Results of initial Scottish clinical experience. 2019 , 288, 94-99		5
661	Recurrent ischemic stroke in atrial fibrillation with non-vitamin K antagonist oral anticoagulation. 2019 , 64, 127-133		5
660	Serum relaxin level predicts recurrence of atrial fibrillation after radiofrequency catheter ablation. 2019 , 34, 1543-1551		4
659	Effect of cryoballoon and radiofrequency ablation for pulmonary vein isolation on left atrial function in patients with nonvalvular paroxysmal atrial fibrillation: A prospective randomized study (Cryo-LAEF study). 2019 , 30, 991-998		8
658	The point of no return for percutaneous left atrial appendage closure: Towards to CHA DS -VALAAC Score?. 2019 , 42, 764-766		1
657	CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience. 2019 , 19, 74		3
656	Towards Non-invasive Mapping and Imaging of Cardiac Arrhythmias. 2019 , 180-196		
655	Image-based Risk Stratification for Stroke in Atrial Fibrillation. 2019 , 553-564		
654	Mechanisms of Antifibrillatory Agents for Atrial Fibrillation. 2019 , 580-586		
653	High CHADS-VASc score without atrial fibrillation: 'NAO yes, NAO no'. 2019 , 21, B67-B68		1
652	The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. 2019 , 35, e3145		4
651	Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. 2019 , 20, 66-73		11
650	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. 2019 , 35, 619-633		35

649	Efficacy and safety of bivalirudin during percutaneous coronary intervention in high-bleeding-risk elderly patients with chronic total occlusion: A prospective randomized controlled trial. 2019 , 93, 825-831	6
648	Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon. 2019 , 47, 384-391	3
647	Factors affecting general practitioners' decisions to adopt new prescription drugs - cohort analyses using Australian longitudinal physician survey data. 2019 , 19, 94	8
646	Early differentiation of long-standing persistent atrial fibrillation using the characteristics of fibrillatory waves in surface ECG multi-leads. 2019 , 9, 2746	3
645	Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. 2019 , 13, 345-364	8
644	Shorter cryoballoon applications times do effect efficacy but result in less phrenic nerve injury: Results of the randomized 123 study. 2019 , 42, 508-514	12
643	Peripheral blood metabolite profiles associated with new onset atrial fibrillation. 2019 , 211, 54-59	2
642	Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights. 2019 , 119, 355-357	10
641	Twelve-month outcome in patients with stroke and atrial fibrillation not suitable to oral anticoagulant strategy: the WATCH-AF registry. 2019 , 6, e001187	2
640	Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City. 2019 , 15, 43-48	2
639	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. 2019 , 26, e679-e703	3
638	Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation. 2019 , 28, 835-842	6
637	Trastuzumab-Associated Dermatomyositis. 2019 , 26, e647-e649	2
636	Hypotension and Transient ST Elevation After Reversal of Heparin With Protamine. 2019 , 26, e646-e647	3
635	Kolmogorov Complexity of Coronary Sinus Atrial Electrograms before Ablation Predicts Termination of Atrial Fibrillation after Pulmonary Vein Isolation. 2019 , 21, 970	0
634	[Medical Methods: What Makes them Necessary? Part I: Medical Methods, medical Necessity and its Main Criteria]. 2019 , 81, 933-944	0
633	Imbalance of ER and Mitochondria Interactions: Prelude to Cardiac Ageing and Disease?. 2019 , 8,	22
632	Blood pressure measurement in atrial fibrillation: review and meta-analysis of evidence on accuracy and clinical relevance. 2019 , 37, 2430-2441	14

631	Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). 2019 , 98, e16560	10
630	Fertility Control in the Cardiac Patient. 2019 , 497-512	
629	Understanding non-response to cardiac resynchronisation therapy: common problems and potential solutions. 2019 , 24, 41-54	26
628	Trends in Atrial Fibrillation and Prescription of Oral Anticoagulants and Embolic Strokes in Germany. 2019 , 20, 399-402	4
627	The 4q25 variant rs13143308T links risk of atrial fibrillation to defective calcium homoeostasis. 2019 , 115, 578-589	22
626	Haemorrhagic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?. 2019 , 274, 179-185	11
625	Anticoagulation after catheter ablation of atrial fibrillation: An unnecessary evil? A systematic review and meta-analysis. 2019 , 30, 468-478	18
624	Prevalence of atrial fibrillation and associated anticoagulant therapy in the nonagenarian population of the Community of Madrid, Spain. 2019 , 19, 203-207	4
623	Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: A systematic review and meta-analysis. 2019 , 51, 489-495	36
622	Comparison between blood coagulability in the intra-atrial and peripheral regions during the acute phase after rapid atrial pacing. 2019 , 68, 137-146	2
621	Atrial fibrillation detected initially during acute medical illness: A systematic review. 2019 , 8, 130-141	22
620	Double factor single shot to diminish complications in cryoballoon ablation procedures for atrial fibrillation. 2019 , 55, 17-26	4
619	Relation of Neutrophil to Lymphocyte Ratio to Risk of Incident Atrial Fibrillation. 2019 , 123, 396-401	14
618	Sex-differences in post-discharge outcomes among patients hospitalized for atrial fibrillation. 2019 , 42, 84-92	2
617	Assessment of peri-device leaks after interventional left atrial appendage closure using standardized imaging by cardiac computed tomography angiography. 2019 , 35, 725-731	8
616	Usefulness of platelet to lymphocyte ratio for predicting recurrence of atrial fibrillation after direct current cardioversion. 2019 , 24, e12616	4
615	Direct comparison of prognostic ability of cardiac biomarkers for cardiogenic stroke and clinical outcome in patients with stroke. 2019 , 34, 1178-1186	9
614	Prevalencia e implicaci3n pron3stica de la enfermedad valvular en pacientes con fibrilaci3n auricular que inician anticoagulantes orales. 2019 , 72, 935-943	

613	Accuracy of automated blood pressure measurements in the presence of atrial fibrillation: systematic review and meta-analysis. 2019 , 33, 352-364	16
612	Atrial flutter and embolic risk: The relationship between atrial flutter cycle length and left atrial appendage function. 2019 , 52, 11-16	1
611	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. 2019 , 74, 309-318	11
610	The Canadian Community Utilization of Stroke Prevention Study in Atrial Fibrillation in the Emergency Department (C-CUSP ED). 2019 , 73, 382-392	8
609	Thoracoscopic Left Atrial Appendage Occlusion for Stroke Prevention Compared with Long-Term Warfarin Therapy in Patients With Nonvalvular Atrial Fibrillation. 2019 , 123, 50-56	3
608	Prevalence and Prognostic Implications of Valve Disease in Patients With Atrial Fibrillation Initiating Direct Oral Anticoagulants. 2019 , 72, 935-943	2
607	Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study. 2019 , 19, 223-230	4
606	Safety, long-term outcomes and predictors of recurrence following a single catheter ablation procedure for atrial fibrillation. 2019 , 74, 319-324	4
605	Comparison of CHADS-VASc and AHEAD scores for the prediction of incident dementia in patients hospitalized for heart failure: a nationwide cohort study. 2019 , 14, 395-402	2
604	Risk of incident atrial fibrillation after a prior critical illness: A retrospective cohort study. 2019 , 60, 90-95	1
603	Refining Prediction of Atrial Fibrillation-Related Stroke Using the P-CHADS-VASc Score. 2019 , 139, 180-191	45
602	Risk Stratification in Atrial Fibrillation. 2019 , 47-66	
601	Management of Bleeding Associated With Anticoagulation. 2019 , 91-103	
600	Risk of new-onset atrial fibrillation among heart, kidney and liver transplant recipients: insights from a national cohort study. 2019 , 14, 71-76	8
599	Left Atrial Appendage Exclusion Using the AtriClip Device: A Case Series. 2019 , 28, 430-435	4
598	Echocardiography is useful to predict postoperative atrial fibrillation in patients undergoing isolated coronary bypass surgery: A prospective study. 2019 , 8, 104-113	7
597	The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. 2017 , 12, 273-284	26
596	Bivalirudin Use During Pulmonary Vein Isolation in a Patient With Heparin-Induced Thrombocytopenia. 2020 , 27, e514-e517	0

595	The impact of steerable sheaths on unblinded contact force during catheter ablation for atrial fibrillation. 2020 , 57, 417-424	5
594	Left atrium size and red cell distribution width predict atrial fibrillation progression from paroxysmal or persistent to permanent. 2020 , 75, 205-211	7
593	Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation. 2020 , 27, e270-e285z	
592	[Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score]. 2020 , 52, 176-184	4
591	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. 2020 , 220, 145-154	1
590	Thromboembolic, bleeding, and mortality risks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: A population-based study. 2020 , 17, 33-40	4
589	Female sex and stroke in atrial fibrillation: an intriguing relationship. 2020 , 15, 175-179	2
588	Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation. 2020 , 25, 57-64	0
587	Management of Arrhythmias and Device Therapy in Heart Failure. 2020 , 549-567	
586	Plasma Metabolites as Predictors of Warfarin Outcome in Atrial Fibrillation. 2020 , 20, 169-177	5
585	Determinants of anticoagulant therapy in atrial fibrillation at discharge from a geriatric ward: cross sectional study. 2020 , 49, 18-26	6
584	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. 2020 , 76, 470-485	18
583	The presence of fragmented QRS may predict the recurrence of nonvalvular atrial fibrillation after successful electrical cardioversion. 2020 , 25, e12700	3
582	Relevance of esophageal position and temperature on thermal injuries and rhythm outcome in atrial fibrillation ablations. 2020 , 43, 194-200	4
581	CHADS-VASc Score and the Risk of Ventricular Tachyarrhythmic Events and Mortality in MADIT-CRT. 2020 , 9, e014353	3
580	Coagulation factors and fibrinolytic activity in the left atrial appendage and other heart chambers in patients with atrial fibrillation: is there a local intracardiac prothrombotic state? (HEART-CLOT study). 2020 , 301, 103-107	13
579	The CHADS-VASc score is a predictor of no-reflow in patients with non-ST-segment elevation myocardial infarction. 2020 , 31, 7-12	12
578	Risk of atrial fibrillation in patients with pneumoconiosis: A nationwide study in Taiwan. 2020 , 43, 66-70	2

577	What are the Characteristics of Patients Experiencing Adverse Drug Reactions to Oral Anticoagulants and How Can Such Reactions be Prevented?. 2020 , 15, 38-44		3
576	Endothelial Dysfunction, Fibrinolytic Activity, and Coagulation Activity in Patients With Atrial Fibrillation According to Type II Diabetes Mellitus Status. 2020 , 125, 751-758		4
575	Plasma Level of Interferon- γ Predicts the Prognosis in Patients With New-Onset Atrial Fibrillation. 2020 , 29, e168-e176		4
574	Cerebrovascular Dysfunction in Atrial Fibrillation. 2020 , 11, 1066		6
573	Adherence and the Moral Construction of the Self: A Narrative Analysis of Anticoagulant Medication. 2020 , 30, 2316-2330		5
572	Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio. 2020 , 76, 472-477		8
571	A pilot study on the acute conversion and maintenance of sinus rhythm in rheumatic atrial fibrillation using oral flecainide. 2020 , 72, 383-388		1
570	Temporal Trends in Pharmacological Stroke Prevention in Patients with Acute Ischemic Stroke and Known Atrial Fibrillation. 2020 , 29, 105266		1
569	Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study). 2020 , 59, 471-477		2
568	Assessment of a standalone photoplethysmography (PPG) algorithm for detection of atrial fibrillation on wristband-derived data. 2020 , 197, 105753		10
567	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. 2020 , 22, 11-112		2
566	Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants. 2020 , 2020, 1743927		5
565	Inhibition of the NFATc4/ERK/AKT Pathway and Improvement of Thiol-Specific Oxidative Stress by Dronedarone Possibly Secondary to the Reduction of Blood Pressure in an Animal Model of Ventricular Hypertrophy. 2020 , 11, 967		
564	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 594-622	15.1	69
563	Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation: WATCH-AF Registry. <i>Stroke</i> , 2020 , 51, 2355-2363	6.7	1
562	High incidence of (ultra)low oesophageal temperatures during cryoballoon pulmonary vein isolation for atrial fibrillation. 2020 , 28, 662-669		2
561	Atrial fibrillation: villain or bystander in vascular brain injury. 2020 , 22, M51-M59		8
560	Antithrombotic therapy and the risk of new-onset dementia in elderly patients with atrial fibrillation. 2020 ,		0

559	An integrated care solution for the electrocardiogram monitoring. 2020 , 29, 61-71		0
558	Medical Risk Management. 2020 , 227-270		
557	. 2020 ,		3
556	Safety and efficacy of anticoagulant monotherapy in atrial fibrillation and stable coronary artery disease: A systematic review and meta-analysis. 2020 , 81, 54-59		1
555	The possibility to have 1 mm positioning accuracy of intracardiac catheter via electrical measurement. 2020 ,		
554	Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants. 2020 , 48, 030006051989443		1
553	Evaluation of the Long-Term Impact on Quality After the End of Pharmacist-Driven Warfarin Therapy Management in Patients With Poor Quality of Anticoagulation Therapy. 2020 , 11, 1056		0
552	The Impact of Novel Anticoagulants on the Upper Gastrointestinal Tract Mucosa. 2020 , 56,		5
551	Stroke prevention and guideline adherent antithrombotic treatment in elderly patients with atrial fibrillation: A real-world experience. 2020 , 99, e21209		2
550	Advantages and challenges for noninvasive atrial fibrillation ablation. 2021 , 62, 319-327		1
549	Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy : Piazza: outcomes of high-bleeding risk AF patients. 2021 , 52, 281-290		1
548	A two-part model to estimate inpatient, outpatient, prescribing and care home costs associated with atrial fibrillation in Scotland. 2020 , 10, e028575		4
547	Relationship between initial international normalized ratio and prognosis in patients with cardiogenic cerebral embolism. 2020 , 9, 2448-2454		0
546	Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome-Triple Therapy, Dual Antithrombotic Therapy with an AnticoagulantâDr, Rather, Temporary Dual Antiplatelet Therapy?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
545	Nurse led Atrial Fibrillation Management: The NEAT Study: A Randomized Controlled Trial. 2020 , 35, 456-467		5
544	Cardioversion Safety - Are We Doing Enough?. 2020 , 145, 740-745		
543	Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: A study protocol using Real-World Data from Catalonia (FantasTIC Study). 2020 , 99, e22054		1
542	Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial. 2020 , 9, e016239		7

541	The Predictive Value of Growth Differentiation Factor-15 in Recurrence of Atrial Fibrillation after Catheter Ablation. 2020 , 2020, 8360936		3
540	Atrial fibrillation and stroke prevention: state of the art-epidemiology and pathophysiology: new risk factors, concepts and controversies. 2020 , 22, O1-O13		4
539	Full Issue PDF. 2020 , 13, I-CCXI		
538	Nutritional Risk and Mortality at One Year for Elderly Patients Hospitalized with Nonvalvular Atrial Fibrillation. NONAVASC Registry. 2020 , 24, 981-986		0
537	Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study. 2021 , 30, 1293-1320		2
536	Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR. 2020 , 13, 2587-2597		24
535	Adherence to guidelines regarding anticoagulation and risk factors for progression of atrial fibrillation in a nurse-led clinic. 2021 , 51, 1136-1142		5
534	Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction. 2020 , 106, 1160-1168		11
533	Serum and Echocardiographic Markers May Synergistically Predict Adverse Cardiac Remodeling after ST-Segment Elevation Myocardial Infarction in Patients with Preserved Ejection Fraction. 2020 , 10,		4
532	Detection of Atrial Fibrillation from Single Lead ECG Signal Using Multirate Cosine Filter Bank and Deep Neural Network. 2020 , 44, 114		16
531	Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population: The COOL-AF Registry. <i>Stroke</i> , 2020 , 51, 1772-1780	6.7	10
530	Sex Differences in Oral Anticoagulation and Outcomes of Stroke and Intracranial Bleeding in Newly Diagnosed Atrial Fibrillation. 2020 , 9, e015689		15
529	Pharmacokinetics and Safety of Dabigatran Etxilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. 2020 , 45, 601-609		3
528	A Delphi consensus on the management of oral anticoagulation in patients with non-valvular atrial fibrillation in Spain: ACOPREFERENCE study. <i>PLoS ONE</i> , 2020 , 15, e0231565	3.7	3
527	Effects of amiodarone on rodent ventricular cardiomyocytes: Novel perspectives from a cellular model of Long QT Syndrome Type 3. 2020 , 255, 117814		3
526	Nutritional Risk and Mortality at One Year for Elderly Patients Hospitalized with Nonvalvular Atrial Fibrillation. Nonavasc Registry. 2020 , 24, 981-986		
525	Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. 2020 , 80, 73-77		3
524	Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. <i>Stroke</i> , 2020 , 51, 2066-2075	6.7	15

- 523 Katheterablation von Vorhofflimmern. **2020**, 16, 19-37
- 522 CHA2DS2-VASc and SAMe-TT2R2 scores as predictors of recurrence for nonvalvular atrial fibrillation patients on vitamin K antagonists after radiofrequency catheter ablation. **2020**, 21, 200-208 1
- 521 2. Aktuelle funktionale Implantate. **2020**, 19-144
- 520 A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany. **2020**, 10, 16 7
- 519 A self-management support intervention for patients with atrial fibrillation: a randomized controlled pilot trial. **2020**, 6, 87 0
- 518 Impact of the social context on the prognosis of Chagas disease patients: Multilevel analysis of a Brazilian cohort. **2020**, 14, e0008399 6
- 517 Management of atrial fibrillation after transcatheter aortic valve replacement: Challenges and therapeutic considerations. **2021**, 31, 361-367 3
- 516 An expert consensus document on the management of cardiovascular manifestations of Fabry disease. **2020**, 22, 1076-1096 33
- 515 Discrepancy in recognition of symptom burden among patients with atrial fibrillation. **2020**, 226, 240-249 4
- 514 Feasibility and Safety of Transnasal Transesophageal Echocardiography Guiding Left Atrial Appendage Closure Without General Anesthesia. **2020**, 13, 2043-2044
- 513 Is the risk of stroke in permanent and paroxysmal atrial fibrillation really the same? Therein lies the dilemma. **2020**, 21, 540-546 2
- 512 Ten-year trends in the incidence, treatment and outcomes of patients with mitral stenosis in Korea. **2020**, 106, 746-750 2
- 511 Rhythm versus rate control strategies regarding anticoagulant use in elderly non-valvular atrial fibrillation patients: Subanalysis of the ANAFIE (All Nippon AF In the Elderly) Registry. **2020**, 76, 87-93 4
- 510 Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya. **2020**, 18, 165-173 1
- 509 Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants. **2020**, 50, 718-723 4
- 508 Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program. **2020**, 29, 104717 0
- 507 Antithrombotic therapy in patients with non-traumatic intracerebral haemorrhage and atrial fibrillation: A retrospective study. **2020**, 6, e03219
- 506 Gender issues in cardiovascular diseases. Focus on energy metabolism. **2020**, 1866, 165722 2

505	Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden. 2020 , 76, 525-537	1
504	Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan - Insight From the ANAFIE (All Nippon AF In Elderly) Registry. 2020 , 84, 388-396	4
503	Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study. 2020 , 20, 22	5
502	Persistence, effectiveness and safety of dabigatran in "real-world" Chinese patients with nonvalvular atrial fibrillation. 2020 , 35, 977-984	1
501	The Use of Oral Anticoagulants in Patients with Atrial Fibrillation in the Emergency Department. 2020 , 29, 104599	1
500	Global research productions pertaining to atrial fibrillation from 2004 to 2018: A bibliometric analysis. 2020 , 99, e18971	3
499	Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses. 2020 , 20, 42	16
498	Serum N-Acetylneuraminic Acid Is Associated with Atrial Fibrillation and Left Atrial Enlargement. 2020 , 2020, 1358098	3
497	Clinical characteristics and antithrombotic prescription in elderly hospitalized atrial fibrillation patients: A cross-sectional analysis of a Swedish single-center clinical cohort. 2020 , 27, 100505	3
496	How I assess and manage the risk of bleeding in patients treated for venous thromboembolism. 2020 , 135, 724-734	30
495	Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC. 2020 , 9, 59-81	31
494	Impact of Sustained Cardiac Tachyarrhythmias Recorded in Coronary Intensive Care Unit on Short- and Long-Term Mortality and Duration of Hospitalization. 2021 , 36, 775-782	1
493	Comments on-Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose. 2021 , 7, 74	1
492	Anticoagulation for atrial fibrillation patients with the CHA2DS2-VASc score =1 (beyond sex). 2021 , 76, 258-264	0
491	Cerebro-renal interaction and stroke. 2021 , 53, 1279-1299	6
490	Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. 2021 , 51, 419-429	10
489	Comparison of effects of triple antithrombotic therapy and dual antiplatelet therapy on long-term outcomes of acute myocardial infarction. 2021 , 36, 345-358	1
488	Changing paradigms: from prevention of thromboembolic events to improved survival in patients with atrial fibrillation. 2021 , 23, 837-843	5

487	The epidemiology of atrial fibrillation in Chinese postmenopausal women and its association with age of menopause. 2021 , 143, 151-156		3
486	2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 326-341	15.1	5
485	Thromboembolism in Patients with Hypertrophic Cardiomyopathy. 2021 , 18, 727-735		0
484	Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORP-AF General Long-Term Registry. 2021 , 75, e13701		1
483	2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 2021 , 14, e000100		2
482	Comment on-Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose: reply. 2021 , 7, 75		
481	Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients. 2021 , 21, 265-275		2
480	Preoperative monocyte-to-HDL-cholesterol ratio predicts early recurrence after radiofrequency maze procedure of valvular atrial fibrillation. 2021 , 35, e23595		3
479	Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score. 2020 ,		0
478	A Standardized Bolus of 5 000 IU of Heparin Does not Lead to Adequate Heparinization during Non-cardiac Arterial Procedures. 2021 , 71, 280-287		2
477	Direct oral anticoagulants and cardiac surgery: A descriptive study of preoperative management and postoperative outcomes. 2021 , 161, 1864-1874.e2		2
476	Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose. 2021 , 7, 20-30		4
475	A Survey of Challenges and Opportunities in Sensing and Analytics for Risk Factors of Cardiovascular Disorders. 2021 , 2,		1
474	Surveys and Registries on Catheter Ablation of Atrial Fibrillation: Fifteen Years of History. 2021 , 14, e008073		1
473	Oxidized CaMKII and O-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms. 2021 , 131,		14
472	Thromboembolism in Older Adults. 2020 , 7, 470016		1
471	[Observational study of the prevalence of non-valvular atrial fibrillation and ischemic stroke and the factors associated with non-valvular atrial fibrillation in hypertensive patients: about 2887 cases]. 2021 , 38, 31		1
470	Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?. 2021 , 22, 1061-1070		3

- 469 Leaks after Left Atrial Appendage Closure: Ignored or Neglected?. **2021**, 146, 384-391 1
- 468 Reversing the Effect of Anticoagulants Safety in Patients Undergoing Emergency Surgery. **2021**, 79-95
- 467 Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrillation. **2021**, 93-119
- 466 The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis. **2021**, 131, 1946-1951 2
- 465 Echocardiographic Findings in Patients with Atrial Fibrillation in a Tertiary Care Center of Nepal: A Descriptive Cross-sectional Study. **2021**, 59, 46-50
- 464 Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region. **2021**, 77, 182-188 3
- 463 Atrial Fibrillation is Associated with Femoropopliteal Totally Occlusive In-Stent Restenosis: A Single-Center, Retrospective, Observational Study. **2021**, 2021, 8852466
- 462 Relationship between thiol, disulphide volume and contrast-induced nephropathy in acute coronary syndrome patients treated with percutaneous coronary intervention. **2021**, 81, 173-180 1
- 461 Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area. **2021**, 13, 1
- 460 Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study. **2021**, 38, 2391-2405 1
- 459 Ischemic Stroke and Heart Failure: Facts and Numbers. An Update. *Journal of Clinical Medicine*, **2021**, 10, 5-1 3
- 458 Cost Analysis of a Dedicated Outpatient Clinic in Patients With Newly Diagnosed Atrial Fibrillation. **2021**, 36, 1
- 457 Conception and bicentric validation of the proSCANNED score, a simplified bedside prognostic score for Heart Failure patients. **2021**, 11, 6179
- 456 Implementation and Evaluation of Virtual Anticoagulation Clinic Care to Provide Incessant Care During COVID-19 Times in an Indian Tertiary Care Teaching Hospital. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 648265 5-4 3
- 455 Utility of the CHA2DS2-VASc score for predicting ischaemic stroke in patients with or without atrial fibrillation: a systematic review and meta-analysis. **2021**, 8
- 454 Using Artificial Intelligence With Natural Language Processing to Combine Electronic Health Record's Structured and Free Text Data to Identify Nonvalvular Atrial Fibrillation to Decrease Strokes and Death: Evaluation and Case-Control Study. **2021**, 23, e28946 1
- 453 Incomplete neo-endothelialization of left atrial appendage closure devices is frequent after 6 months: a pilot imaging study. **2021**, 37, 2291-2298 2
- 452 Effectiveness and Safety of Under or Over-dosing of Direct Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-analysis of 148909 Patients From 10 Real-World Studies. **2021**, 12, 645479 2

451	Pharmacotherapy of patients with atrial fibrillation and restored sinus rhythm â is the medication with spironolactone beneficial in this case?. 2021 , 68, 301-306		
450	Screening and management of atrial fibrillation in primary care. 2021 , 373, n379		4
449	Safety and Efficacy of Apixaban versus warfarin in patients with atrial fibrillation or Venous Thromboembolism and End-Stage renal disease on hemodialysis: A systematic review and meta-analysis. 2021 , 21, 221-226		
448	Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. 2021 , 143, 1377-1390		46
447	Perioperative Application of Transesophageal Echocardiography in Left Atrial Appendage Occlusion in an Elderly Patient with Mirror-Image Dextrocardia and Atrial Fibrillation. 2021 , 2021, 1-4		
446	Septicemia and mortality after noncardiac surgery associated with CHA2DS2-VASc score: a retrospective cohort study based on a real-world database. 2021 , 21, 209		1
445	New-generation Computed Tomography Scanners for Coronary Artery Disease Imaging â Implications for Future Service Provision. 2021 , 16, 208-214		0
444	The Role of the Contextual Cohort to Resolve Some Challenges and Limitations of Comparisons in Pharmacoepidemiology. 2021 , 44, 835-841		1
443	More Effective Anticoagulation During Non-Cardiac Arterial Procedures Using Activated Clotting Time Guided Heparin Administration. 2021 , 76, 378-388		2
442	Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis. 2021 , 12, 581293		8
441	Socioeconomic inequality in oral anticoagulation therapy initiation in patients with atrial fibrillation with high risk of stroke: a register-based observational study. 2021 , 11, e048839		4
440	Role of Different Antithrombotic Regimens after Percutaneous Left Atrial Appendage Occlusion: A Large Single Center Experience. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
439	Atrial Fibrillation and Endothelial Dysfunction: A Potential Link?. 2021 , 96, 1609-1621		4
438	Indications de lâocclusion de lâauricule gauche comme substitut ^ lâanticoagulation chez les patients qui ont un AVC li^ une fibrillation atriale : le registre WATCH-AF. 2021 , 205, 619-630		
437	Oral Anticoagulation Use in High-Risk Patients Is Improved by Elimination of False-Positive and Inactive Atrial Fibrillation Cases. 2021 , 134, e366-e373		0
436	Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS. <i>PLoS ONE</i> , 2021 , 16, e0251325	3.7	1
435	Discontinuation of oral anticoagulation and risk of stroke and death after ablation for typical atrial flutter: A nation-wide Danish cohort study. 2021 , 333, 110-116		2
434	The CHA2DS2-VASc Risk Score Predicts Total Occlusion in Infarct-Related Arteries in Patients With Non-ST Elevation Myocardial Infarction. <i>Angiology</i> , 2021 , 33197211031324	2.1	3

433	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a scandinavian population-based cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	0
432	Kardia Mobile applicability in clinical practice: A comparison of Kardia Mobile and standard 12-lead electrocardiogram records in 100 consecutive patients of a tertiary cardiovascular care center. 2021 , 28, 543-548		20
431	Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. 2021 , 203, 121-130		2
430	Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. 2021 , 237, 68-78		2
429	Effect of Evidence-Based Pharmacy Care on Satisfaction and Cognition in Patients with Non-Valvular Atrial Fibrillation Taking Rivaroxaban. 2021 , 15, 1661-1670		0
428	Association of atrial fibrillation and various cancer subtypes. 2021 , 37, 1205-1214		1
427	Possibilities of the efficiency and safety control of rivaroxaban application in patients with atrial fibrillation. 2021 , 23, 9-16		
426	Usage Patterns of Web-Based Stroke Calculators in Clinical Decision Support: Retrospective Analysis. 2021 , 9, e28266		1
425	Use of NOACs Versus Vitamin K Antagonist in Atrial Fibrillation Catheter Ablation: An Updated Meta-analysis With Subgroup Analysis. 2021 ,		
424	The Hidden Value of a CHADS-VASc Score. 2021 , 29, 69-70		
423	Effects of a pharmacist-managed anticoagulation outpatient clinic in Taiwan: evaluation of patient knowledge, satisfaction, and clinical outcomes. 2021 , 133, 964-973		0
422	Left atrial appendage occlusion device infection: Take it or leave it?. 2021 , 7, 750-753		1
421	Convenience and satisfaction in direct oral anticoagulant-treated patients with atrial fibrillation. 2021 , 5, e12577		1
420	Quality indicators in the management of elderly Chinese patients with atrial fibrillation: A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	2
419	One-year Follow-up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. 2021 , 37, 1227-1239		2
418	Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. 2021 , 14, 819-830		4
417	Changes in anticoagulant prescription in a general hospital in 2008-2018. 2021 , 17, 544-551		
416	Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. 2021 , 91, 75-80		

415	Comparison of Low and Full Dose Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Renal Dysfunction (from a National Registry). 2021 , 159, 87-93	
414	Current Recommendations on Atrial Fibrillation: a comparison of the recent European and Canadian Guidelines. 2021 ,	
413	The Effect of Myocardial Fat Thickness and Myocardial Impedance on Bipolar Radiofrequency Catheter Ablation Using Computer Simulation. 2021 , 6, 83-89	
412	Experimental study on the effect of chrysin on skin injury induced by amiodarone extravasation in rats. 2022 , 139, 104257	0
411	Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. 2021 ,	2
410	A Retrospective Study of Perioperative Nursing Care of Patients After Percutaneous Left Atrial Appendage Occlusion. 2021 , 36, 638-641	
409	Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment. 2021 , 1	1
408	Reduced Risk of Atrial Fibrillation Following Cholecystectomy: A Nationwide Population-Based Study. 2021 , 13, 706815	
407	Preintervention imaging and intraoperative management care of the hypertrophic obstructive cardiomyopathy patient. 2021 , 2184923211047126	
406	Automated classification of five arrhythmias and normal sinus rhythm based on RR interval signals. 2021 , 181, 115031	10
405	Contraception and Cardiovascular Diseases. 2021 , 269-298	
404	A Comparative Prospective Observational Study on the Use of Direct Oral Anticoagulants after Cardiac Surgery for the Management of Atrial Fibrillation. 2021 , 27, 191-199	1
403	Changing the Paradigm to Understand and Manage Atrial Fibrillation. 2014 , 127-164	1
402	The Use of Intracardiac Echocardiography (ICE) to Guide LAA Closure. 2016 , 101-115	1
401	Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation. 2020 , 222, 83-92	5
400	Ischemic stroke and non-valvular atrial fibrillation: When to introduce anticoagulant therapy?. 2020 , 45, 72-80	1
399	Sarcopenia, frailty, cognitive impairment and mortality in elderly patients with non-valvular atrial fibrillation. 2019 , 219, 424-432	19
398	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. 2020 ,	2

397	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016 , 37, 2882-2889	9.5	167
396	Avoiding non-responders to cardiac resynchronization therapy: a practical guide. <i>European Heart Journal</i> , 2017 , 38, 1463-1472	9.5	117
395	Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk: navigating between limited evidence and clinical concerns. 2015 , 30, 325-32		8
394	Automated blood pressure measurement in atrial fibrillation: validation process modification and evaluation of a novel professional device which detects atrial fibrillation and adapts its blood pressure measurement algorithm. 2021 , 39, 614-620		1
393	Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus. 2018 , 10, 240-248		3
392	Emergency reversal of dabigatran for emergency surgery. 2015 , 2015,		6
391	Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. 2018 , 361, k1717		15
390	Atrial Cardiopathy in the Absence of Atrial Fibrillation Increases Risk of Ischemic Stroke, Incident Atrial Fibrillation, and Mortality and Improves Stroke Risk Prediction. 2020 , 9, e013227		8
389	Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience. 2018 , 23, 155-161		8
388	Pulmonary embolism. 15-31		1
387	Atrial fibrillation: the current epidemic. 2017 , 14, 195-203		125
386	Management of atrial fibrillation. 2014 , 6, 22		4
385	Expanding use of new oral anticoagulants. 2014 , 6, 93		15
384	Atrial Heterogeneity Generates Re-entrant Substrate during Atrial Fibrillation and Anti-arrhythmic Drug Action: Mechanistic Insights from Canine Atrial Models. 2016 , 12, e1005245		31
383	Improved detection of paroxysmal atrial fibrillation utilizing a software-assisted electrocardiogram approach. <i>PLoS ONE</i> , 2014 , 9, e89328	3.7	17
382	Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. <i>PLoS ONE</i> , 2014 , 9, e100478	3.7	20
381	Cardiovascular complications secondary to Graves' disease: a prospective study from Ukraine. <i>PLoS ONE</i> , 2015 , 10, e0122388	3.7	17
380	Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. <i>PLoS ONE</i> , 2015 , 10, e0125257	3.7	20

379	Multiscale Entropy of the Heart Rate Variability for the Prediction of an Ischemic Stroke in Patients with Permanent Atrial Fibrillation. <i>PLoS ONE</i> , 2015 , 10, e0137144	3-7	23
378	Young Male Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study. <i>PLoS ONE</i> , 2016 , 11, e0151485	3-7	12
377	Shensongyangxin Capsules for Paroxysmal Atrial Fibrillation: A Systematic Review of Randomized Clinical Trials. <i>PLoS ONE</i> , 2016 , 11, e0151880	3-7	8
376	Screening for Atrial Fibrillation--A Cross-Sectional Survey of Healthcare Professionals in Primary Care. <i>PLoS ONE</i> , 2016 , 11, e0152086	3-7	13
375	Chronic Kidney Disease and the Risk of New-Onset Atrial Fibrillation: A Meta-Analysis of Prospective Cohort Studies. <i>PLoS ONE</i> , 2016 , 11, e0155581	3-7	23
374	Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study. <i>PLoS ONE</i> , 2016 , 11, e0166218	3-7	22
373	Prediction of Thromboembolic Events in Heart Failure Patients in Sinus Rhythm: The Hong Kong Heart Failure Registry. <i>PLoS ONE</i> , 2016 , 11, e0169095	3-7	6
372	Effectiveness and usage of a decision support system to improve stroke prevention in general practice: A cluster randomized controlled trial. <i>PLoS ONE</i> , 2017 , 12, e0170974	3-7	37
371	Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. <i>PLoS ONE</i> , 2017 , 12, e0189495	3-7	58
370	Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study. <i>PLoS ONE</i> , 2020 , 15, e0240489	3-7	3
369	Efficacy of Oral Anticoagulation in Stroke Prevention among Sinus-Rhythm Patients Who Lack Left Atrial Mechanical Contraction after Cryoablation. 2015 , 42, 430-7		4
368	Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. 2016 , 43, 287-90		9
367	Minimally Symptomatic Atrial Fibrillation Patients Derive Significant Symptom Relief Following Rate Control or Rhythm Control Therapy. 2015 , 7, 690-3		2
366	ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). 2016 , 16, 734-741		14
365	The Potential Role of Edoxaban in Stroke Prevention Guidelines. 2014 , 3, 40-3		1
364	Relevance of Monitoring Atrial Fibrillation in Clinical Practice. 2012 , 1, 54-58		3
363	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary. 2013 , 2, 115-9		2
362	Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions. 2014 , 3, 194-200		1

361	Balloon Devices for Atrial Fibrillation Therapy. 2015 , 4, 58-61	14
360	Pharmacological Therapy of Tachyarrhythmias During Pregnancy. 2016 , 5, 41-4	7
359	Management of Complications in Anticoagulated Patients with Atrial Fibrillation. 2017 , 6, 167-178	1
358	Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation. 2017 , 6, 50-54	5
357	Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal. 2016 , 11, 118-122	2
356	Real World Outcomes of Left Atrial Appendage Occlusion. 2015 , 10, 109-111	2
355	Left Atrial Appendage Closure Devices for Stroke Prevention in Patients with Non-Valvular AF. 2018 , 12, 87	1
354	Standards of the Polish Ultrasound Society - update. Ultrasound examination of thyroid gland and ultrasound-guided thyroid biopsy. 2014 , 14, 49-60	8
353	[Off-pump coronary artery bypass grafting and left atrium ligation]. 2016 , 69-71	0
352	[Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter]. 2015 , 87, 38-48	10
351	Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHADS-VASc score-a nationwide cohort study. 2018 , 9, 7623-7630	11
350	A Nurse-led Approach to Improving Cardiac Lifestyle Modification in an Atrial Fibrillation Population. 2019 , 10, 3826-3835	1
349	The burden of cardiac arrhythmias in sarcoidosis: a population-based inpatient analysis. 2018 , 6, 330	13
348	Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. 2013 , 6, 167-80	13
347	The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS. 2014 , 10, 303-8	9
346	Left Atrial Appendage Closure -The WATCHMAN Device. 2015 , 11, 334-340	12
345	A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin. 2019 , 7, e13329	1
344	Management of atrial fibrillation: easy as ABC. 2019 , 110, 27-34	1

343	HAS-BLED score and actual bleeding in elderly patients undergoing transcatheter aortic valve implantation. 2020 , 111, 203-212	2
342	Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation. 2021 , 19, 487-494	2
341	Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block: a systematic review and economic evaluation. 2015 , 19, 1-210	11
340	Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation. 2020 , 24, 1-164	3
339	Effect of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. 2014 , 55, 69-72	2
338	Anticoagulation Management in Patients with Pacemaker-Detected Atrial Fibrillation. 2016 , 4, 243-7	1
337	DOACs vs Vitamin K Antagonists: a Comparison of Phase III Clinical Trials and a Prescriber Support Tool. 2019 , 7, 1226-1232	8
336	A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF). 2020 , 35, 99-108	10
335	Predictors of Progression and Prognosis of Paroxysmal Atrial Fibrillation. 2015 , 88, 672	1
334	Selecting antithrombotic therapy for patients with atrial fibrillation. 2015 , 82, 49-63	3
333	Practical issues in the management of novel oral anticoagulants-cardioversion and ablation. 2015 , 7, 115-31	8
332	Management Of Atrial Fibrillation In Patients With Heart Failure. 2014 , 7, 1105	1
331	Electroanatomical mapping of atrial fibrillation: Review of the current techniques and advances. 2014 , 7, 1140	11
330	Diagnosis and Therapy of Atrial Fibrillation: The Past, The Present and The Future. 2015 , 8, 1216	11
329	Phased RF Ablation: Results and Concerns. 2015 , 8, 1240	3
328	Advanced Mapping Systems To Guide Atrial Fibrillation Ablation: Electrical Information That Matters. 2016 , 8, 1337	15
327	Safety of The Direct Oral Anticoagulant Edoxaban for Atrial Fibrillation After Cardiac Surgery: Pilot Study. 2016 , 9, 1456	8
326	Incorporating Stroke and Bleeding Risk Stratification Tools into Atrial Fibrillation Management Making Sense of the Alphabet Soup. 2017 , 9, 1497	2

325	Bonus vs No Bonus Cryoballoon Isolation for Paroxysmal Atrial Fibrillation Ablation. 2017 , 9, 1513	1
324	Left Atrial Strain Predicts Pro-Thrombotic State in Patients with Non-Valvular Atrial Fibrillation. 2017 , 10, 1641	10
323	Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation. 2012 , 5, 718	6
322	Different transeptal puncture for different procedures: Optimization of left atrial catheterization guided by transesophageal echocardiography. 2016 , 19, 589-593	17
321	Clinicians-related determinants of anticoagulation therapy and prophylaxis in Nigeria. 2017 , 16, 164-169	2
320	Cardiac tachyarrhythmias and anaesthesia: General principles and focus on atrial fibrillation. 2017 , 61, 712-720	4
319	Prevalence of Atrial Fibrillation in the Elderly in Korea. 2016 , 20, 29-35	2
318	Design and Baseline Patient Characteristics of the Prospective, Observational, Multicenter and Multinational Cohort Study Comparing Radiofrequency with Cryoablation for Pulmonary Vein Isolation in Patients with Atrial Fibrillation—the Freeze Cohort Study. 2014 , 05, 1161-1172	4
317	Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. 2018 , 13, 2003-2011	25
316	Comparison of cardiac computed tomography angiography and transoesophageal echocardiography for device surveillance after left atrial appendage closure. 2019 , 15, 663-670	29
315	Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniques. 2014 , 10, 497-504	31
314	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. 2015 , 10, 1015-21	16
313	Left atrial appendage occlusion with the AMPLATZER Amulet device: an expert consensus step-by-step approach. 2016 , 11, 1512-21	70
312	Percutaneous left atrial appendage occlusion in 2016. 2016 , 11, e1576-8	5
311	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. 2016 , 12, 103-11	63
310	Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey. 2016 , 12, 112-8	2
309	Left atrial appendage closure: patient, device and post-procedure drug selection. 2016 , 12 Suppl X, X48-X54	9
308	Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?. 2013 , 9 Suppl, S43-7	11

307	Optical coherence tomography assessment of a PLGA-polymer with electro-grafting base layer versus a PLA-polymer sirolimus-eluting stent at three-month follow-up: the BuMA-OCT randomised trial. 2014 , 10, 806-14	26
306	2014 ESC/EACTS guidelines on myocardial revascularization. 2015 , 10, 1024-94	195
305	Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities. 2016 , 11, 996-1003	69
304	Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. 2016 , 11, 1170-9	337
303	Medical management of connector pin thrombosis with the Amplatzer cardiac plug left atrial closure device. 2013 , 5, 391-3	3
302	Ibutilide and novel indexes of ventricular repolarization in persistent atrial fibrillation patients. 2013 , 5, 242-6	1
301	Clinical Practice and Guidelines for Managing Antithrombotics before and after Endoscopy: A National Survey Study. 2020 , 14, 316-322	4
300	The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. 2016 , 16, 595-600	11
299	A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?. 2015 , 15, 1020-9	15
298	The rs6817105 polymorphism on chromosome 4q25 is associated with the risk of atrial fibrillation in the Chinese Han population. 2016 , 16, 662-666	1
297	Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. 2015 , 17, 210-5	7
296	How and When to Screen for Atrial Fibrillation after Stroke: Insights from Insertable Cardiac Monitoring Devices. 2016 , 18, 121-8	9
295	Focused Update on Primary Stroke Prevention in Patients with Atrial Fibrillation in Korean Clinical Practice Guidelines for Stroke. 2012 , 14, 106	4
294	Prevalence of oral anticoagulation in atrial fibrillation. 2014 , 69, 615-20	8
293	Diagnosed, undiagnosed and overall atrial fibrillation research on population over 60 year-old. AFABE study. 2014 , 2, 2	2
292	Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation Treatment: Rural and Urban Trends in Medicare Beneficiaries. 2021 , 1	1
291	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. 2021 , 174, 1490	0
290	Surface modification to enhance cell migration on biomaterials and its combination with 3D structural design of occluders to improve interventional treatment of heart diseases. 2021 , 279, 121208	6

- 289 Transesophageal echocardiography for cardiovascular risk estimation in patients with sepsis and new-onset atrial fibrillation: a multicenter prospective pilot study. **2021**, 11, 146 1
- 288 Risk Stratification and Anticoagulation in Low-risk Non-valvular Atrial Fibrillation. **2013**, 2, 76-7
- 287 [Novel agents for antithrombotic therapy in cardiology]. **2012**, 153, 2016-20
- 286 [Better anticoagulation therapy?]. **2013**, 133, 1906
- 285 Atrial fibrillation ablation by use of electroanatomical mapping: efficacy and recurrence factors. **2014**, 102, 30-8 2
- 284 Recent Atrial Fibrillation Guidelines - Looking at Both Sides of the Atlantic. **2013**, 2, 8-15
- 283 Predictive value of CHA2DS2-VASc and CHA2DS2-VASc-HS scores for failed reperfusion after thrombolytic therapy in patients with ST-segment elevation myocardial infarction. **2019**, 26, 169-175 4
- 282 Umsatzveränderungen in einzelnen Indikationsgruppen. **2013**, 47-373
- 281 Stroke in Atrial Fibrillation - Long-term Follow-up of Cardiovascular Events. **2013**, 2, 105-8 3
- 280 Anticoagulation for Atrial Fibrillation and Prosthetic Cardiac Valves. **2013**, 786-799
- 279 Kardiologische Therapie bei Hochbetagten. **2013**, 433-446
- 278 THE INCIDENCE AND POSSIBLE CAUSES OF ATRIAL FIBRILLATION IN HOSPITALIZED PATIENTS DURING 1985-2010. **2013**, 19, 109-116 1
- 277 Dabigatran, electrical cardioversion and measuring the aPTT. A safety measure or an unnecessary assessment?. **2013**, 2013,
- 276 Factor Xa inhibitors: a step forward in the treatment of atrial fibrillation?. **2013**, ED000064
- 275 Triple Therapy: Risky but Sometimes Necessary. **2014**, 185-212
- 274 Anticoagulation in atrial fibrillation: NOAC's the word. **2013**, 110, 523-4 4
- 273 Epidemiology, Burden and Unmet Needs in Atrial Fibrillation. **2014**, 1-22
- 272 Guidelines and Current Recommendations in Atrial Fibrillation. **2014**, 165-179

271 Upstream Therapy in the Treatment of Atrial Fibrillation. **2014**, 91-107

270 Novel Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation. **2014**, 55-89

269 Cardiac embolism after implantable cardiac defibrillator shock in non-anticoagulated atrial fibrillation: The role of left atrial appendage occlusion. **2014**, 6, 213-5

268 Left atrial appendage closure with the watchman device: New option for patients with atrial fibrillation and high-risk of thromboembolic events. **2014**, 33, 35-40

267 Herzrhythmusstörungen in der Intensivmedizin. **2014**, 565-573

266 Pharmacological Secondary Prevention of Ischemic Stroke. **2014**, 7, 76

1

265 Leitsymptom Herzrasen. **2014**, 71-110

264 [Antithrombotic treatment in atrial fibrillation and cardiovascular disease]. **2014**, 134, 923

263 Safety of oral anticoagulant therapy for thromboprophylaxis in atrial fibrillation: Results of the randomized clinical trials phase III and their clinical implications. **2014**, 33, 204-210

262 Umsatzveränderungen in einzelnen Indikationsgruppen. **2014**, 49-376

261 Tromboprofilaksa kod bolesnika sa atrijalnom fibrilacijom - da li se snovi ostvaruju?. **2014**, 33, 177-178

260 Does the Role of Generalists in Stroke Prevention Change with the Novel Oral Anticoagulants?. **2014**, 34, 167-174

259 Acquired hemophilia with inhibitors presenting as an emergency: misinterpretation of clotting results during direct oral anticoagulation. **2014**, 111, 345-8

10

258 Rapport sur les anticoagulants oraux directs (AOD) (antifiquement appelés « nouveaux anticoagulants oraux » ou NACO). **2014**, 198, 1157-1195

257 Dabigatran su eficacia y seguridad en el tratamiento de la fibrilación auricular de origen no valvular. Experiencia personal de tres años. **2014**, 2, 94-99

256 Antithrombotic Therapy for Cardiac Disease. **2015**, 101-106

255 Cardiovascular Consequences of Addiction. **2015**, 1577-1609

254 Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital. **2015**, 21, 518-25

2

253 Cardiovascular Disease. **2015**, 25-53

252 How to apply knowledge that we have: Rivaroxaban effective protection and therapy. **2015**, 34, 39-43

251 Fundamentals of Cardiology for the Non-cardiologist. **2015**, 1-24

250 When Should Ablation Be Considered in the Treatment of Atrial Fibrillation – A Clinician’s View. **2015**, 349-359

249 Prevention of adverse ischemic events with Watchman device in non-valvular patients with atrial fibrillation and contraindications for long-term anticoagulation therapy. **2015**, 34, 29-32

248 What is Established and What is New in Ablation of Persistent Atrial Fibrillation?. **2015**, 4, 80

247 Basic knowledge of oral anticoagulant therapy. **2015**, 34, 46-50

○

246 Thoracoscopic Occlusion of the Left Atrial Appendage. **2015**, 10, 179-182

○

245 Do we always need anticoagulation before cardioversion of atrial fibrillation in ladies?. **2015**, 15, 602-4

244 Vorhofflimmern.

243 Thromboprophylaxis in Patients with Atrial Fibrillation: A Real Practice Analysis. **2016**, 3, GRHTA.5000203a

242 [The use of new oral anticoagulants in surgery. Part 1]. **2016**, 72-75

○

241 [The use of new oral anticoagulants in surgery]. **2016**, 4-8

240 Atrial Fibrillation. **2016**, 221-281

239 Anticoagulation Quality and Complications of using Vitamin K Antagonists in the Cardiac Surgery Outpatient Clinic. **2016**, 31, 239-245

○

238 Blutmanagement in der Orthopädie und Unfallchirurgie. **2016**, 157-172

237 Angiologie. **2016**, 1-46

236 Prevention and Treatment of Arterial Thromboembolism. **2016**, 417-428

235 Atrial Fibrillation: Epidemiology and Demographics. **2016**, 3-17

234 Artföopathie athromatöuse de l'aorte. **2016**, 209-214

233 ACP and Amulet: Trials and Registries Results. **2016**, 195-203

232 Kardiologie. **2016**, 277-355

231 15. Cardiovascular Disease. **2016**,

230 Stroke prevention in atrial fibrillation patients with a single stroke risk factor: Clinical decision-making and guideline recommendations: A case report and comparative analysis of the European Society of Cardiology (ESC) and American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guidelines on the management of atrial

229 Rückenmarknahe Regionalanästhesie: Anatomie, Physiologie, Kontraindikationen, Komplikationen, Antikoagulation. **2016**, 1-23

228 Amplatzer Cardiac Plug and Amulet. **2016**, 181-193

227 Efficacy and Limitations of Warfarin and Novel Oral Anticoagulants with Atrial Fibrillation. **2016**, 17-36

226 Catheter-based left atrial appendage occlusion guided by intracardiac echocardiography. **2016**, 15, 33-36

225 Atrial fibrillation: An update. **2016**, 2016, 30-31

224 Atrial Fibrillation. 198-232

223 Barriers for a Wider Use of Left Atrial Appendage Occlusion as an Alternative to Oral Anticoagulation. **2016**, 6,

222 What should a general practitioner know about the diagnosis and treatment of atrial fibrillation. **2016**, 13, 171-174

221 Recurrence of Stroke in Patients with AF Using NOACs. **2017**, 11-23

220 Bioprosthetic Heart Valves: Can they be Anticoagulated with NOACs?. **2016**, 7,

219 Atrial Fibrillation on Non-vitamin K Antagonist Oral Anticoagulant Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. **2017**, 19-38

218 New-Onset Atrial Fibrillation in a Stable Patient with Remote Percutaneous Coronary Intervention. **2017**, 141-152

- 217 Kardiologie. **2017**, 203-314
- 216 Major Bleeding Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy with Vitamin K antagonist, Aspirin, and Clopidogrel. **2017**, 183-195
- 215 Major Bleeding Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy with a Non-vitamin K-Antagonist Oral Anticoagulant, Aspirin, and Clopidogrel. **2017**, 197-212
- 214 Urgent Surgery Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy with a Vitamin K Antagonist, Aspirin, and Clopidogrel. **2017**, 153-167
- 213 Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction. **2017**, 95-120
- 212 Urgent Surgery Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy of Non-vitamin K Antagonist Oral Anticoagulant, Aspirin, and Clopidogrel. **2017**, 169-182
- 211 Atrial Fibrillation Early Complicating Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention. **2017**, 121-140
- 210 Intensivmedizinische Arbeitstechniken. **2017**, 3-54
- 209 The Role of Multimodality Cardiac Imaging in the Management of Patients with Atrial Fibrillation. **2017**, 1, 177
- 208 Closure of the left atrial appendage by means of the AtriClip System. **2017**, 63, 31-35 1
- 207 Percutaneous Left Atrial Appendage Closure: Rational, Patient Selection, and Preoperative Evaluation. **2017**, 191-198
- 206 Evolution of Force Sensing Technologies. **2017**, 6, 75-79 1
- 205 Contraception and Cardiovascular Disease. **2017**, 23-33
- 204 Leitsymptom Herzrasen. **2017**, 69-113
- 203 Kardiologie. **2017**, 61-143
- 202 Myokardinfarkt mit Herzrhythmusstörungen. **2017**, 97-108
- 201 Female Aspects of Electrocardiography and Cardiac Arrhythmias. **2017**, 153-165
- 200 Cardiac Arrhythmias in Cancer Patients. **2017**, 175-190

- 199 Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. **2017**, 18, 328-333 2
- 198 Non-Obvious, Post-Traumatic, Life-Threatening Bleeding in Two Elderly Patients. **2017**, 3, 79-83
- 197 Preprocedural and procedural transesophageal echocardiography in patients with left atrial appendage occluder implantation. **2017**, 12, 131-131
- 196 Notification of international normalized ratio test in atrial fibrillation patients treated with warfarin via short message service: Study protocol for a randomized controlled trial. **2017**, 9, 4732-4736
- 195 Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants. **2017**, 13, 68-78 2
- 194 Changes in stroke risk by freedom-from-stroke time in simulated populations with atrial fibrillation: Freedom-from-event effect when event itself is a risk factor. *PLoS ONE*, **2018**, 13, e0194307 3-7
- 193 Adaptation of New Oral Anticoagulants for Warfarin Anticoagulated Patient with Traumatic Ongoing Hemorrhage. **2018**, 8, 33-37
- 192 [Comparison of the efficacy and safety of dronedarone and flecainide as maintenance antiarrhythmic therapy for sinus rhythm in atrial fibrillation]. **2018**, 88, 204-211 2
- 191 EFFICACY OF ISCHEMIC STROKE PREVENTION IN PATIENTS WITH IMPLANTED OCCLUDER OF THE LEFT ATRIUM. FIVE YEAR FOLLOW-UP. **2018**, 16-20 1
- 190 Myocardial fibrosis and atrial fibrillation. **2018**, 71-76 7
- 189 Fibrilaci3 auricular en el anciano. **2018**, 22, 1-7
- 188 The Impact of Cancer on Major Bleeding and Stroke/Systemic Emboli in Patients Using Direct Oral Anticoagulants:From the Database of a Single-Center Registry. **2018**, 11, 2105 3
- 187 Comparative evaluation of markers of inflammation and fibrosis in patients with various clinical forms of atrial fibrillation. **2018**, 17, 26-31 1
- 186 R3ckenmarknahe Regionalan3sthesie: Anatomie, Physiologie, Kontraindikationen, Komplikationen, Antikoagulation. **2019**, 811-833
- 185 Relationship between Epicardial Fat Accumulation and Left Atrial Reverse Remodeling after Catheter Ablation of Atrial Fibrillation. **2019**, 80, 930
- 184 Antithrombotic Therapy During and After Transcatheter Aortic Valve Implantation. **2019**, 377-385
- 183 Heart Rhythm Qualitative Analysis Using Low-Cost and Open Source Electrocardiography: A Study Based on Atrial Fibrillation Detection. **2019**, 198-217
- 182 A Retrospective Study of Atrial Fibrillation Following Cavotricuspid Isthmus Ablation for Atrial Flutter. **2019**, 25, 3316-3320 3

- 181 [Control of blood pressure in patients with atrial fibrillation treated with acenocoumarol and with an altered Rosendaal index]. **2019**, 36, 165-166
- 180 Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing. **2019**, 6, 142-159
- 179 Clinical evaluation of paroxysmal and permanent atrial fibrillation patients in cardiac inpatient unit: Cross-sectional study.
- 178 Prevention of gastrointestinal bleeding in patients receiving oral anticoagulants: focus on proton pump inhibitors. **2019**, 18, 128-137
- 177 Prediction of the Possibility of Hemorrhagic Syndrome during Combined Antiplatelet Therapy According to the Krasnodar Region Registry. **2019**, 15, 697-705
- 176 The association between CHA2DS2-VASc score and erectile dysfunction: a cross-sectional study. **2019**, 45, 1204-1208 ○
- 175 Association of neutrophil lymphocyte ratio and C-reactive protein with left atrial appendage thrombus: a transesophageal echocardiography study. **2019**, 178,
- 174 Two-dimensional versus three-dimensional transesophageal echocardiography in percutaneous left atrial appendage occlusion. **2019**, 26, 687-695 ○
- 173 Leitsymptom Herzrasen. **2020**, 73-116
- 172 CHA2DS2-VASc Score Is Correlated with Cardiac Performance in Chronic Atrial Fibrillation. **2020**, 2, 56
- 171 The impact of continuous positive airway pressure on cardiac arrhythmias in patients with sleep apnea. **2020**, 25, 42 3
- 170 Problem of prescribing anticoagulant therapy in patients with atrial fibrillation on the regional level. **2020**, 19-25
- 169 Review of Deep Learning-Based Atrial Fibrillation Detection Studies. *International Journal of Environmental Research and Public Health*, **2021**, 18, 4.6 9
- 168 Association of Plasma C1q/TNF-Related Protein 3 (CTRP3) in Patients with Atrial Fibrillation. **2020**, 2020, 8873152 4
- 167 Management of patients on oral anticoagulants in dental practice. **2020**, 47, 912-922
- 166 Modern aspects of surgical treatment of patients with atrial fibrillation. Development of uniform criteria for selecting patients for radiofrequency ablation. **2020**, 58-64
- 165 Devices for continuous embolic protection. **2020**, 979-1005
- 164 SCHLAGANFALL. **2020**, M-1-M1-13

163	Atrial Fibrillation. 2020 , 141-168	
162	Risk factors for recurrence of atrial fibrillation. 2021 , 25, 338-345	0
161	Using mobile ECG devices to increase detection of atrial fibrillation across a range of settings in south London. 2020 , 7, 86-89	1
160	O-GlcNAcylation, oxidation and CaMKII contribute to atrial fibrillation in type 1 and type 2 diabetes by distinct mechanisms.	1
159	Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology. 2021 , 2021, 5230947	2
158	Performance of four bleeding risk scores in patients with atrial fibrillation receiving antithrombotics.. 2022 , 209, 115-116	
157	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. 2020 , 7, 1-42	0
156	Role of miRNA in the development of atrial fibrillation in patients with valvular heart disease. 2020 , 19, 2420	
155	Changes in Antithrombotic Therapy of Atrial Fibrillation in the Hospital in 2011-2012 and 2016-2017 (Pharmacoepidemiological Analysis). 2020 , 16, 686-692	1
154	Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection. 2020 ,	
153	Quality of care in patients with atrial fibrillation in primary care: a cross-sectional study comparing clinical and claims data. 2016 , 14, Doc13	0
152	Screening, isolation, and decolonization strategies for vancomycin-resistant enterococci or extended spectrum Beta-lactamase-producing organisms: a systematic review of the clinical evidence and health services impact. 2013 , 3, e3202	12
151	Long term Anticoagulation at Crossroads. 2013 , 8, 3-4	1
150	Supporting shared decision making within the MobiGuide project. 2013 , 2013, 1175-84	7
149	Atrial fibrillation. 2013 , 82, 135-40	0
148	Approach to the new oral anticoagulants in family practice: part 1: comparing the options. 2014 , 60, 989-95	11
147	Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. 2014 , 39, 858-80	6
146	Response. 2015 , 61, 24-5	

145	Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives. 2015 , 7, 199-203	8
144	Can oral anticoagulants be stopped safely after a successful atrial fibrillation ablation?. 2015 , 7, 172-7	12
143	Atrial fibrillation (chronic). 2015 , 2015,	1
142	A meta-analysis of left atrial appendage closure for stroke prevention in atrial fibrillation-adding to the debate but elements remain unresolved. 2015 , 7, E226-9	3
141	Oral direct thrombin inhibition: a double-edged sword?. 2015 , 7, 191-7	2
140	Transcatheter closure of the left atrial appendage: initial experience with the WATCHMAN device. 2015 , 8, 15230-7	
139	Outcome of Circumferential Pulmonary Vein Isolation for Ablation of Atrial Fibrillation: A Single Center Experience. 2013 , 29, 457-61	1
138	Stroke Risk Predictor Scoring Systems in Atrial Fibrillation. 2014 , 6, 998	5
137	How To Follow Atrial Fibrillation Ablation Patients?. 2014 , 7, 1087	1
136	Influence of Age and Gender on Complications of Catheter Ablation for Atrial Fibrillation. 2015 , 7, 1197	3
135	Cardiac Plug I and Amulet Devices: Left Atrial Appendage Closure for Stroke Prophylaxis in Atrial Fibrillation. 2015 , 7, 1236	5
134	How we treat bleeding associated with direct oral anticoagulants. 2016 , 14, 465-73	8
133	Clinical characteristics and one year outcomes in Chinese atrial fibrillation patients with stable coronary artery disease: a population-based study. 2016 , 13, 665-671	3
132	Ablation of Atrial Fibrillation in Combination with Left Atrial Appendage Occlusion in A Single Procedure. Rationale and Technique. 2016 , 8, 1346	2
131	The Cost Effectiveness of LAA Exclusion. 2016 , 8, 1374	2
130	Which Factors Influence Resident Physicians to Prescribe NOACs to Patients with Non-Valvular Atrial Fibrillation?. 2016 , 9, 1462	3
129	Lone Atrial Fibrillation: Risk Factors, Triggers And Ablation Techniques. 2015 , 8, 1203	
128	Complications From Left Atrial Appendage Exclusion Devices. 2014 , 7, 1034	10

127 Who Needs Pharmacologic Therapy?. **2014**, 7, 1084

126 Integrated Chronic Care Management For Patients With Atrial Fibrillation - A Rationale For Redesigning Atrial Fibrillation Care. **2015**, 7, 1177

6

125 Management of Atrial Fibrillation in Patients With Kidney Disease. **2014**, 6, 989

124 Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Non-Valvular Atrial Fibrillation: Which one Should be Used for Risk Stratification?. **2013**, 6, 896

3

123 Role of Cardiac Imaging for Catheter-based Left Atrial Appendage Closure. **2013**, 6, 702

1

122 Hybrid Therapy for Atrial Fibrillation: where the Knife meets the Catheter. **2013**, 6, 775

121 Cost-Effectiveness of Atrial Fibrillation Ablation. **2013**, 6, 880

2

120 Prevention of Stroke by Antithrombotic Therapy in Patients with Atrial Fibrillation. **2013**, 5, 732

119 Atrial Remodelling : Role in Atrial Fibrillation Ablation. **2012**, 5, 691

1

118 Collateral Damage from Catheter Ablation of Atrial Fibrillation Lessons Learnt in the Past Decade. **2013**, 5, 831

2

117 Atrial Fibrillation and Renal Disease. **2013**, 6, 837

116 Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know. **2016**, 16, 531-541

4

115 Integrated Machine Learning Approaches for Predicting Ischemic Stroke and Thromboembolism in Atrial Fibrillation. **2016**, 2016, 799-807

10

114 Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment. **2017**, 17, 1-106

1

113 The Management and Prognostic Factors of Acute Coronary Syndrome: Evidence from the Taiwan Acute Coronary Syndrome Full Spectrum Registry. **2017**, 33, 329-338

18

112 Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?. **2018**, 15, 229-234

1

111 Bootstrap-based Feature Selection to Balance Model Discrimination and Predictor Significance: A Study of Stroke Prediction in Atrial Fibrillation. **2017**, 2017, 1130-1139

2

110 Dynamic Electrocardiography is Useful in the Diagnosis of Persistent Atrial Fibrillation Accompanied with Second-Degree Atrioventricular Block. **2018**, 34, 409-416

2

- 109 Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation. **2017**, 21, 67-73 11
- 108 Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation. **2019**, 35, 42-54 5
- 107 Atrial fibrillation: a leading cause of heart failure-related hospitalizations; a dual epidemic. **2019**, 9, 109-115 5
- 106 Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management. **2021**, 18, 376-397
- 105 The safety and efficacy of the use of oral anticoagulant medications in patients with diabetes mellitus: A systematic review.. **2021**, 29, 1374-1382 0
- 104 Perioperative management and optimization of atrial fibrillation for noncardiac surgery.. **2022**, 60, 16-23
- 103 The efficacy and safety of insertable cardiac monitor on atrial fibrillation detection in patients with ischemic stroke: a systematic review and meta-analysis. **2021**, 1 0
- 102 The Combined Effects of Patient Activation and Relational Aspects on the Quality of Life in Atrial Fibrillation Patients. **2021**, 12, 761149 0
- 101 Prognostic value of interleukin-6 in atrial fibrillation: A cohort study and meta-analysis. **2021**, 25, 872-879 0
- 100 Speed Spot as a method of graphical visualization and analysis of the state of the heart activity. **2020**,
- 99 The Characteristics and Clinical Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease: From the Database of A Single-Center Registry.. **2020**, 13, 2308
- 98 Atrial Fibrillation and Hypertension: "Quo Vadis".. **2022**, 0
- 97 Inter-patient detection of atrial fibrillation in short ECG segments based on LSTM network with multiple input layers. 1
- 96 Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region. **2022**, 14, 462-467
- 95 Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany.. *Drugs - Real World Outcomes*, **2022**, 1 2.2 2
- 94 Comparisons of HATCH, HAVOC and CHA2DS2-VASc scores for all-cause mortality prediction in atrial fibrillation: a real-world evidence study.. **2022**,
- 93 Left Atrial Dysfunction, Fibrosis and the Risk of Thromboembolism in Patients With Paroxysmal and Persistent Atrial Fibrillation. **2022**, 4, 42 3
- 92 Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants. **2022**, 23, 0

91	Appropriateness of Prescribing Rivaroxaban at King Khalid University Hospital Riyadh.. <i>Cureus</i> , 2022 , 14, e20977	1.2
90	Atrial Fibrillation. 2022 , 294-318	
89	Atrial Fibrillation Underlies Cardiomyocyte Senescence and Contributes to Deleterious Atrial Remodeling during Disease Progression.. 2022 , 13, 298-312	0
88	Indirect comparison of nonvitamin K oral anticoagulants and left atrial appendage occlusion. 2022 , 4, 18-25	
87	4S-AF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients.. 2022 , e13751	3
86	Sacubitril/Valsartan Can Reduce Atrial Fibrillation Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation.. 2022 , 1	0
85	Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation.. 2022 , 11, e022638	2
84	Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.. 2022 , 24, A19-A31	0
83	Active FXI Can Independently Predict Ischemic Stroke in Anticoagulated Atrial Fibrillation Patients: A Cohort Study.. 2022 ,	0
82	Socioeconomic and geographic differences in ablation of atrial fibrillation in Norway - a national cohort study.. 2022 , 22, 303	0
81	Cryoballoon Ablation for Persistent and Paroxysmal Atrial Fibrillation: Procedural Differences and Results from the Spanish Registry (RECABA).. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1
80	Weight based heparin dosage with ACT monitoring leads to adequate and safe anticoagulation in Non-Cardiac Arterial Procedures.. 2022 ,	0
79	Undertreatment of Anticoagulant Therapy in Hospitalized Acute Ischemic Stroke Patients With Atrial Fibrillation.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 841020	5.4 0
78	Machine-learning-based radiomics identifies atrial fibrillation on the epicardial fat in contrast-enhanced and non-enhanced chest CT.. 2022 , 20211274	1
77	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.	
76	Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention.. 2022 ,	1
75	Concomitant Atrial Fibrillation Procedures During Cardiac Surgery in a UK Center: Reflection of Worldwide Practice?. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 780893	5.4
74	Cross-country skiing and risk of atrial fibrillation: A meta-analysis of cohort studies. 2022 ,	

73	Development and Validation of UPLC-MS/MS Method for Quantifying of Free and Total Dabigatran in Human Plasma: An Application for a Bioequivalence Study.. 2022 , e5382		
72	Risk of Stroke With Mitral Stenosis: The Underlying Mechanism, Treatment, and Prevention.. <i>Cureus</i> , 2022 , 14, e23784	1.2	
71	Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state.. 2022 , 213, 1-7		1
70	Improving the causal treatment effect estimation with propensity scores by the bootstrap. 1		
69	Evaluation of adherence of patients with atrial fibrillation to anticoagulant therapy at the outpatient stage of treatment. 2021 , 50-56		
68	The Role of Hyperuricemia in the Development of Atrial Fibrillation. 2021 , 1, 7-16		
67	Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.. <i>ESC Heart Failure</i> , 2022 ,	3.7	0
66	Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.. <i>PLoS ONE</i> , 2022 , 17, e0266658	3.7	0
65	Safety and efficacy of direct oral anticoagulants in comparison with warfarin across different BMI ranges: A systematic review and meta-analysis. <i>Annals of Medicine and Surgery</i> , 2022 , 103610		2
64	image_1.jpeg. 2017 ,		
63	table_1.docx. 2017 ,		
62	Video_1.MP4. 2018 ,		
61	Video_2.MP4. 2018 ,		
60	Can CHA2DS2-VASc and HAS-BLED Foresee the Presence of Cerebral Microbleeds, Lacunar and Non-Lacunar Infarcts in Elderly Patients With Atrial Fibrillation? Data From StratAF Study. <i>Frontiers in Neurology</i> , 2022 , 13,	4.1	1
59	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1932-1948	15.1	5
58	Temporal Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients between 2004 and 2019.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	0
57	Predictive Value of C2HEST Score for Atrial Fibrillation Recurrence Following Successful Cryoballoon Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation.. <i>Angiology</i> , 2022 , 33197221102230 ¹		
56	Integrating Multidisciplinary Individualized Medication Recommendations Into the Traditional Pharmacists' Consultation Method: A Retrospective Study Using Propensity Score Matching Analysis. <i>Inquiry (United States)</i> , 2022 , 59, 004695802210814	1.4	

55	Association of income and educational levels with adherence to direct oral anticoagulant therapy in patients with incident atrial fibrillation: A Finnish nationwide cohort study. <i>Pharmacology Research and Perspectives</i> , 2022 , 10,	3.1	0
54	ABO Blood Type Is Associated with Thrombotic Risk in Patients with Nonvalvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3064	5.1	0
53	Inversion of Left Atrial Appendage Will Cause Compressive Stresses in the Tissue: Simulation Study of Potential Therapy. <i>Journal of Personalized Medicine</i> , 2022 , 12, 883	3.6	0
52	Strategies for Maintaining Brain Health: The Role of Stroke Risk Factors Unique to Elderly Women. <i>Stroke</i> ,	6.7	
51	Qualitative Evaluation of an Artificial Intelligence-based Clinical Decision Support System to Guide Rhythm Management of Atrial Fibrillation: A Survey Study (Preprint). <i>JMIR Formative Research</i> ,	2.5	
50	Adherence of patients with atrial fibrillation after acute coronary syndrome to antithrombotic therapy at stage III of cardiac rehabilitation: data from the local register of the Kirov region. <i>Kardiologiya</i> , 2022 , 62, 27-32	1.5	
49	Racial and sex differences in optimizing anticoagulation therapy for patients with atrial fibrillation. <i>American Heart Journal Plus</i> , 2022 , 18, 100170		0
48	Increased Risk of Stroke Due to Non-adherence and Non-persistence with Direct Oral Anticoagulants (DOACs): Real-World Analyses Using a Nested Caseâ€“Control Study from The Netherlands, Italy and Germany. <i>Drugs - Real World Outcomes</i> ,	2.2	0
47	Social determinants of health and catheter ablation after an incident diagnosis of atrial fibrillation: A Danish nationwide cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> ,	4.6	0
46	Protecting the Brain, From the Heart: Safely Mitigating the Consequences of Thrombosis in Intracerebral Hemorrhage Survivors With Atrial Fibrillation. <i>Stroke</i> , 2022 , 53, 2152-2160	6.7	1
45	Embolitic Cerebrovascular Accident Secondary to Device-Related Thrombus Post WATCHMAN Device Implantation. <i>Cureus</i> , 2022 ,	1.2	
44	CACHET-CADB: A Contextualized Ambulatory Electrocardiography Arrhythmia Dataset. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	0
43	Epidemiology of atrial fibrillation and risk of CVD mortality among hypertensive population: A prospective cohort study in Northeast China. 9,		
42	Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.		
41	CHA2DS2-VASc Score, Mortality and Acute Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. 2022 ,		
40	Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation. 10, e13853		
39	Concurrent use of Chinese herbal medicine and anticoagulants may reduce major bleeding events. 2022 , 17, e0271965		
38	Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation. 2022 , 365, 1-7		0

- 37 Impact of Catheter Ablation on Long-Term Outcomes in Patients With Atrial Fibrillation: A Meta-Analysis. **2022**, 1
- 36 Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit. **2022**, 42, 101117 0
- 35 The Association Between High CHA2DS2-VASc Scores and Short and Long-Term Mortality for Coronary Care Unit Patients. **2022**, 28, 107602962211179 0
- 34 Predictors of Adherence to Stroke Prevention in the BALKAN-AF Study: A Machine-Learning Approach. **2022**, 06, e283-e290 0
- 33 Less Known but Clinically Relevant Comorbidities of Atrial Fibrillation: A Narrative Review. **2022**, 20, 0
- 32 Association of CHA2DS2-VASC Score with in-Hospital Cardiovascular Adverse Events in Patients with Acute ST-Segment Elevation Myocardial Infarction. **2022**, 2022, 1-7 0
- 31 Non-Contact Atrial Fibrillation Detection From Face Videos by Learning Systolic Peaks. **2022**, 26, 4587-4598 0
- 30 Long term follow up of direct oral anticoagulants and warfarin therapy on stroke, with all-cause mortality as a competing risk, in people with atrial fibrillation: Sentinel network database study. **2022**, 17, e0265998 0
- 29 Comparison of Efficacy and Safety of Anticoagulant Monotherapy and Combined Therapy of Anticoagulant and Antiplatelets in Patients With Stable Coronary Artery Disease and Atrial Fibrillation: A Meta-Analysis. **2022**, 0
- 28 Comparison of non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study. **2022**, 0
- 27 Comparative Effectiveness and Safety of Cryoablation Versus Radiofrequency Ablation Treatments for Persistent Atrial Fibrillation. **2022**, 0
- 26 Efficacy and safety of left atrial appendage closure in patients with atrial fibrillation and high thromboembolic and bleeding risk. **2022**, 27, 5182 0
- 25 Mining of Potential Biomarkers and Pathway in Valvular Atrial Fibrillation (VAF) via Systematic Screening of Gene Coexpression Network. **2022**, 2022, 1-21 0
- 24 Disruption of Sarcoplasmic Reticulum-Mitochondrial Contacts Underlies Contractile Dysfunction in Experimental and Human Atrial Fibrillation: A Key Role of Mitofusin 2. **2022**, 11, 1
- 23 Can I Send This Patient With Atrial Fibrillation Home From the Emergency Department?. **2022**, 0
- 22 What is the Best Agent for Rate Control of Atrial Fibrillation With Rapid Ventricular Response?. **2022**, 0
- 21 Generation of two PITX2 knock-out human induced pluripotent stem cell lines using CRISPR/Cas9 system. **2022**, 65, 102940 1
- 20 Low lipoprotein(a) concentration is associated with atrial fibrillation: a large retrospective cohort study. **2022**, 21, 0

- 19 A comparison of Atrial Fibrillation Detection Strategies After Ischemic Stroke-A Retrospective Study. **2023**, 48, 101515
- 18 Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation. 14, 576-598
- 17 Acupuncture decreases risk of stroke among patients with atrial fibrillation: A nationwide investigation. **2022**, 101, e31889
- 16 Use of Diltiazem in Chronic Rate Control for Atrial Fibrillation: A Prospective Case-Control Study. **2023**, 12, 22
- 15 Enhanced neutrophil extracellular traps formation in AF patients with dilated left atrium.
- 14 Social App to Improve Warfarin Therapy in Post-MHVR Chinese Patients: A Randomized Controlled Trial. **2023**, 2023, 1-10
- 13 Efficacy and Safety of Catheter Ablation for Atrial Fibrillation in Patients with History of Cancer.
- 12 miR-135 protects against atrial fibrillation by suppressing intracellular calcium-mediated NLRP3 inflammasome activation.
- 11 Log-Spectral Matching GAN: PPG-based Atrial Fibrillation Detection can be Enhanced by GAN-based Data Augmentation with Integration of Spectral Loss. **2023**, 1-10
- 10 Clinical significance of the rivaroxabanâdronedarone interaction: insights from physiologically based pharmacokinetic modelling.
- 9 Cost-Effectiveness of Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation in Hong Kong. **2023**, 36, 51-57
- 8 Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands.
- 7 Inappropriate Combined Antiplatelet and Anticoagulant Therapy in Older Patients with Atrial Fibrillation: Trend over Time (2009â18). **2023**, 40, 273-283
- 6 Impact of left atrial appendage closure in patients on anticoagulation for atrial fibrillation and recurrent or chronic gastrointestinal bleeding. **2023**,
- 5 Percutaneous left atrial appendage closure: beyond the classic indications. **2023**, 9, 70-77
- 4 Family Physician Prescribing Practices and Perspectives on Shared Decision-Making Regarding the Use of Oral Anticoagulants for Stroke Prevention in Patients 75 Years or Older With Atrial Fibrillation. **2023**, 14, 215013192311640
- 3 Left atrial appendage occlusion in an older population cohort.
- 2 Explainable detection of atrial fibrillation using deep convolutional neural network with UCMFB.

1 Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer. **2023**,
9,

o